Drug, bio-affecting and body treating compositions patents - Monitor Patents
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents



USPTO Class 514  |  Browse by Industry: Previous - Next | All     monitor keywords
06/2011 | Recent  |  14:  | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan |  | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn |  | 2008 | 2007 |

Drug, bio-affecting and body treating compositions June invention type 06/11

Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application.
  
06/30/2011 > patent applications in patent subcategories. invention type

20110160118 - Methods and compositions for treating oral and esophageal lesions: The invention features methods and compositions for treating or preventing lesions of the upper alimentary canal, particularly oral aphthous or mucositis lesions. Trefoil peptides are administered in effective concentrations either alone or in combination with different therapeutic agents.... Agent:

20110160120 - Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders: The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as... Agent: Synergy Pharmaceuticals Inc.

20110160119 - Anti-inflammatory compounds and uses thereof: The present invention provides anti-inflammatory compounds, pharmaceutical compositions thereof, and methods of use thereof for treating inflammatory disorders. The present invention also provides methods of identifying anti-inflammatory compounds and methods of inhibiting NF-κB-dependent target gene expression in a cell.... Agent: Yale University

20110160121 - Unacylated ghrelin and analogs as therapeutic agents for vascular remodeling in diabetic patients and treatment of cardiovascular disease: The present invention relates to a method for treating a cardiovascular disease, for increasing the number of circulating angiogenic cells (CAC) and/or improving the function of CAC and a method for improving vascular remodeling and/or neovascularisation. The method comprises administering to the subject a therapeutically effective amount of unacylated ghrelin... Agent: Alize Pharma Sas

20110160122 - Polypeptides having antimicrobial activity and polynucleotides encoding same: The present invention relates to isolated polypeptides having antimicrobial activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides.... Agent: Novozymes Adenium Biotech A/s

20110160123 - Targeting the efflux systems of mycobacterium tuberculosis: Provided herein are methods of reducing drug resistance in Mycobacterium tuberculosis (Mtb). The methods comprise contacting the Mtb with an agent, wherein the agent inhibits the activity of an efflux complex. Also provided are methods of treating Mtb in a subject. The methods comprise administering to the subject an agent... Agent: The Uab Research Foundation

20110160124 - Antimicrobial protein compositions and production therefor from marine bacteria: Several bacterial species were isolated from marine segment obtained from seabed sediment at depths exceeding 1700 feet. At least four of the bacteria produced a compound that showed antibacterial activity against one or more multiple-drug-resistant (MDR) bacteria isolated from hospitals and clinics. One isolate, SJCH-12, exhibited a broad range of... Agent: St. Joseph's Children's Hospital

20110160125 - Method and culture medium for enhanced detection of mycobacterium: The present invention relates to an improved culture medium and method for the enhanced growth and detection of Mycobacterium growth. The invention further relates to an improved mycobacterial reagent system or kit that can be used for the enhanced growth and detection of Mycobacterium.... Agent: Biomerieux, Inc.

20110160126 - Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders: Methods for treatment of diseases, including human immunideficiency virus infection, are provided. The disease are treated by administering conjugates containing as a ligand a chemokine receptor targeting agents, such as a chemokine, and a targeted agent, such as a toxin.... Agent:

20110160127 - Prodrugs of neuraminidase inhibitors: A new class of neuramidase inhibitor prodrugs is provided characterized by a prodrug moiety of a carboxyl group modified to form a carbonyl ethoxy amino acid, a carbonyl ethoxy dipeptide or a carbonyl ethoxy tripeptide, a guanidine group modified to form a carbonyl ethoxy amino acid, a carbonyl ethoxy dipeptide,... Agent: Tsrl, Inc.

20110160128 - Corin for treating obesity and diabetes: Provided herein are methods of inhibiting agouti or agouti-related protein (AGRP) in a cell or in an individual in need thereof, comprising administering to the cell or the individual an effective amount of an agent that induces corin expression, activity or a combination thereof in the cell or individual. The... Agent:

20110160129 - Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device: Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other... Agent: Incube Labs, LLC

20110160130 - Cancer treatment method: Invented is a method of treating cancer and pre-cancerous syndromes in a mammal, including a human, in need thereof which comprises the administration of a therapeutically effective amount of a combination of a non-peptide TPO receptor agonist or a peptide TPO mimetic and a cell cycle signalling inhibitor compound to... Agent:

20110160131 - Growth factor-mimicking peptides and uses thereof: The present invention relates to a growth factor-mimicking peptide having an activity of the growth factor, and a composition and a method for improving skin conditions or for treating a wound using the same. The growth factor-mimicking peptides of this invention have identical functions or actions to natural-occurring human growth... Agent: Caregen Co., Ltd.

20110160132 - Lymphangiogenesis-promoting agents: Described herein is the discovery that HGFs activate the growth and migration of lymphatic endothelial cells and thereby promote lymphangiogenesis. The present invention is based on this finding, and provides lymphangiogenesis-promoting agents comprising as active ingredients HGFs, or proteins or compounds functionally equivalent thereto. Based on the finding described above,... Agent: Osaka University

20110160134 - Device and method for making solid beads: A method of making solid beads is disclosed, said method comprising: (i) providing a microfluidic device comprising a carrier fluid conduit and a functional fluid conduit which meet at a junction region; (ii) providing a laminar flow of a functional fluid comprising a solvent and a solute along the functional... Agent: Q Chip Limited

20110160133 - Method for inhibiting inflammation and pre-inflammatory cytokine/chemokine expression using a ghrelin analogue: The present invention provides a method of ameliorating inflammation, inhibiting proinflammatory cytokine and/or chemokine expression and treating various diseases and/or conditions incidental to the onset of inflammation, in a subject in need of treatment for such conditions, by administering select analogues of native hGhrelin.... Agent:

20110160135 - Suppression of neuroendocrine diseases: The present invention relates to a method for suppressing neuroendocrine disease. The therapy employs use of a non-cytotoxic protease, which is targeted to a neuroendocrine tumour cell, preferably via a somatostatin or cortistatin receptor, a GHRH receptor, a ghrelin receptor, a bombesin receptor, a urotensin receptor a melanin-concentrating hormone receptor... Agent: Syntaxin Limited

20110160136 - Polyphenols for the treatment of cartilage disorders: Compositions and methods for maintenance of cartilage health or prevention, alleviation and/or treatment of cartilage disorders are presented. The present invention also provides the manufacture of a nutritional product, a supplement or a medicament for promoting cartilage growth or for the maintenance of cartilage health and methods regarding same. In... Agent: Nestec S.a.

20110160137 - Composition containing collagen peptide for improving skin care: The present invention relates to an oral composition for improving the beauty of the skin, which exhibits the effects of reducing skin wrinkles and inhibiting wrinkle formation. The composition contains a collagen peptide and at least one selected from the group consisting of elastin protein, hyaluronic acid and vitamin C.... Agent: Amorepacific Corporation

20110160138 - Composition for improving brain function and method for improving brain function: The present invention provides a composition which may be ingested orally in a small dose for the purpose of improving brain function, and a method for improving brain function. The present invention is a composition for improving brain function, the composition comprising, as an active ingredient, X-Met-His-Gln-Pro-His-Gln-Pro-Leu-Pro-Pro-Thr-Val-Met-Phe-Pro-Pro-Gln-Ser-Val-Leu (SEQ ID NO:... Agent:

20110160139 - Composition for improving brain function and method for improving brain function: The present invention provides a composition which may be ingested orally in a small dose for the purpose of improving brain function, and a method for improving brain function. The present invention is a composition for improving brain function, comprising, as an active ingredient, X-Val-Arg-Gly-Pro-Phe-Pro-Ile-Ile-Val (SEQ ID NO: 5), wherein... Agent:

20110160140 - Composition for improving brain function and method for improving brain function: The present invention provides a composition which may be ingested orally in a small dose for the purpose of improving brain function, and a method for improving brain function. The present invention is a composition for improving brain function, the composition comprising, as an active ingredient, Xaa-Pro-Pro (wherein Xaa represents... Agent:

20110160141 - Neurotrophic peptides: The present invention relates to a neurotrophic peptide having an amino acid sequence of VGDGGLFEKKL (SEQ ID NO:1), EDQQVHFTPTEG (SEQ ID NO:2) or IPENEADGMPATV (SEQ ID NO:3), and comprising an adamantyl group at the C- and/or N-terminal end.... Agent:

20110160142 - Alpha b-crystallin as a therapy for inflammation: The invention provides methods for treating inflammatory diseases by administering to the subject an effective amount of an agent that provides alpha B-crystallin activity, where the dose is effective to suppress or prevent initiation, progression, or relapses of disease, including the progression of established disease. In some embodiments, the methods... Agent:

20110160144 - Topical acyl glutathione formulations: Topical compositions to prevent and to treat skin aging comprise an effective amount of S-acyl glutathione derivative and a carrier. Methods for preventing and treating skin aging comprise applying a composition containing S-acyl glutathione derivative in a dermatologically acceptable carrier to skin tissue. The acyl group is a saturated or... Agent:

20110160143 - Topical acyl glutathione psoriasis compositions: Topical compositions to treat inflammatory skin conditions such as psoriasis comprise an effective amount of S-acyl glutathione derivative and a carrier. Methods for treating inflammatory skin conditions such as psoriasis comprise applying a composition containing S-acyl glutathione derivative in a dermatologically acceptable carrier to skin tissue. The acyl group is... Agent:

20110160145 - Treatment of fine wrinkles with clostridia neurotoxins: Methods of using clostridial toxins and other biological agents to thin skin and control fine wrinkles in humans are provided. In preferred embodiments the methods provide beneficial effects in humans.... Agent:

20110160146 - Conjungation of small molecules to octaarginine transporters for overcoming multi-drug resistance: Many cancer therapeutic agents elicit resistance that renders them ineffective and often produces cross resistance to other drugs. One of the most common mechanisms of resistance involves P-glycoprotein (Pgp) mediated drug efflux. Here we provide compositions and methods that restore the efficacy of a therapeutic agent reduced by resistance by... Agent: National Institute Of Health (nih)

20110160147 - Novel dual targeting antitumoral conjugates: The present invention relates to dual-targeting cytotoxic compounds of formula (I) and to their preparation. The described compounds are endowed with tumour specific action, incorporating three functional units: a tumour recognition moiety and a tumour selective enzymatic substrate sequence connected together by means of a spacer. These conjugates are designed... Agent: Sigma-tau Industrie Farmaceutiche Riunite S.p.a.

20110160148 - Novel diverse lead compound autotaxin inhibitors: Classes of compounds that exhibit effective inhibition of autotaxin enzymes are provided. Such classes include naphthalenesulfones, phenylsulfones, and certain peptides with unnatural amino acids and exhibit reactivity with autotaxin to ultimately reduce the size of the reactive sites thereon to prevent conversion of lysophosphatidyl choline to lysophophatidic acid. Furthermore, such... Agent: The University Of Memphis Research Foundation

20110160149 - Pharmaceutical composition for a hepatitis c viral protease inhibitor: Disclosed is a pharmaceutical composition of a hepatitis C viral protease inhibitor which is suitable for oral administration via a liquid- or semi-solid-filled capsule and methods of using this composition for inhibiting the replication of the hepatitis C virus (HCV) and for the treatment of an HCV infection. The liquid-... Agent: Boehringer Ingelheim International Gmbh

20110160150 - Thiol-containing compounds for the removal of elements from tissues and formulations therefor: where R1 comprises benzene, pyridine, pyridin-4-one, naphthalene, anthracene, phenanthrene or alkyl groups, R2 comprises hydrogen, alkyls, aryls, a carboxyl group, carboxylate esters, organic groups or biological groups, R3 comprises alkyls, aryls, a carboxyl group, carboxylate esters, organic groups or biological groups, X comprises hydrogen, lithium, sodium, potassium, rubidium, cesium, francium,... Agent:

20110160151 - Novel acetates of 2-deoxy monosaccharides with anticancer activity: Novel compounds and methods of using the same to inhibit glycolysis and treat cancer and other diseases are provided herein.... Agent:

20110160152 - Extracts of aquilaria hulls and use thereof in the treatment of cancer: The invention discloses an ethyl acetate layer of methanol extract of Aquilaria hulls for killing cancer cells and treating/preventing cancers and its uses. The extracts of Aquilaria hulls has an significant amount of cucurbitacins and these cucurbitacins are effective in killing cancer cells and treating/preventing cancers.... Agent: Taipei Medical University

20110160153 - Methods and compositions for treating blood circulation disorders: Methods for preparing improved Panax Notoginseng saponin fraction from a Sanchi extract and its use in pharmaceutical compositions for treating or preventing a blood circulation disorder.... Agent:

20110160154 - Substituted piperazines: Disclosed herein are substituted piperazine late Na+ channel modulators of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Auspex Pharmaceuticals, Inc.

20110160155 - Composition and use of a long-acting oral bioadhesive endoparasiticide gel based on doramectin: The present invention relates to a bioadhesive endoparasiticidal gel composition comprising doramectin, having a high degree of adhesion to equine oral mucosa and having a sweet flavor greatly facilitating the dosing thereof, methods for the preparation thereof and methods for treating a condition comprising administering said composition.... Agent: Agrovet Market S.a.

20110160156 - Pharmaceutical composition for the eradication of helicobacter pylori and preparation method thereof: The present invention relates to a pharmaceutical composition and its preparation method for the eradication of Helicobacter pylorif in the forms of effervescent tablet, suspension or powder. The pharmaceutical composition comprises an effective dose of β-lactam antibiotic, an effective dose of macrolide antibiotic, an effective dose of antacid such as... Agent: Synmosa Biopharma Corporation

20110160157 - Methods of treating an inflammatory-related disease: The invention relates to pharmaceutical compositions and methods of treating inflammatory-related diseases associated with pro-inflammatory cytokine expression and/or reduced expression of anti-inflammatory cytokines. The method typically comprises administration of one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, such as, Meisoindigo and NATURA in an amount less... Agent: Natrogen Therapeutics International, Inc.

20110160286 - Allele-specific rna interference: Human diseases caused by dominant, gain-of-function mutations develop in heterozygotes bearing one mutant and one wild-type copy of a gene. Because the wild-type gene often performs important functions, whereas the mutant gene is toxic, any therapeutic strategy must selectively inhibit the mutant while retaining wild-type gene expression. The present invention... Agent: University Of Massachusetts

20110160280 - Cancer-related genes, cdca5, epha7, stk31 and wdhd1: The invention features methods for detecting cancers, especially lung cancer and/or esophageal cancer, using over-expressed gene; CDCA5, EPHA7, STK31 or WDHD1 compared the normal organs. Also disclosed are methods of identifying compounds for treating and preventing cancers, based on the over-expression or the biological activity of CDCA5, EPHA7, STK31 or... Agent: Oncotherapy Science, Inc.

20110160285 - Identification of mirna profiles that are diagnostic of hypertrophic cardiomyopathy: Disclosed herein are a collection of miRNAs and genes whose expression is altered in hypertrophic cardiomyopathy. Accordingly, these miRNAs and genes, singly or in combination, are useful as molecular markers for diagnosis or prognosis of hypertrophic cardiomyopathy. The miRNAs and genes disclosed can also be therapeutic targets for cardiac hypertrophy.... Agent: Dharmacon, Inc.

20110160278 - Methods for selectively modulating survivin apoptosis pathways: The present invention, based on the discovery of a new biological phenomena, provides methods and compositions for use in identifying agents that modulate the phosphorylation of survivin, the interaction between survivin and p34cdc2-cyclin B1 kinase complex, and the interaction between survivin and caspase-9. Related methods and compositions can be used... Agent:

20110160279 - Methods for treatment and prevention of ototoxicity by sirna: The present invention relates to methods for reducing and/or preventing ototoxicity caused by an ototoxic agent, noise or head and/or neck radiation. It is also directed to a method for preventing or reducing generation of reactive oxygen species in the inner ear of a patient. The methods of the present... Agent: Board Of Trustees Of Southern Illinois University

20110160277 - Modulation of 11 beta-hydroxysteriod dehydrogenase 1 expression for the treatment of ocular diseases: The invention relates to siNA compositions and methods for the treatment of eye conditions wherein the siNA compound capable of inhibiting the expression of 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD1).... Agent: Sylentis S.a.u.

20110160283 - Modulation of cd40 expression: Disclosed herein are antisense compounds and methods for decreasing CD40. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to CD40 include hyperproliferative disorders, graft versus host disease (GVHD), graft rejection, asthma, airway hyperresponsiveness, chronic obstructive pulmonary disease (COPD), multiple sclerosis (MS), systemic lupus... Agent: Isis Pharmaceuticals, Inc.

20110160282 - Nucleic-acid pharmaceutical composition for cancer therapy: The present invention provides at least one siRNA (small interfering RNA) which inhibits the expression of Mcl-1 within the cell, and which is selected from siRNA having SEQ. ID. NO. 1 sense sequence and SEQ. ID. NO. 2 antisense sequence, siRNA having SEQ. ID. NO. 3 sense sequence and SEQ.... Agent: Snu R&db Foundation

20110160288 - Oip5 as a target gene for cancer therapy and diagnosis: The present invention relates to the roles played by OIP5 genes in lung and/or esophageal cancer carcinogenesis and features a method for treating and/or preventing lung and/or esophageal cancer by administering a double-stranded molecule against the OIP5 genes or a composition, vector or cell containing such a double-stranded molecule and... Agent: Oncotherapy Science, Inc.

20110160287 - Potentiator of activity of anti-cancer agent and use thereof, and biomarker for prediction of prognosis in cancer patient and use thereof: Disclosed is a means for improving the clinical outcomes of cancer therapy. Specifically disclosed is an activity potentiator comprising a compound capable of inhibiting the expression of RFP (RET finger protein) gene or the activity of RFP as an active ingredient. The activity of an anti-cancer agent having an oxidative... Agent: National University Corporation Nagoya University

20110160281 - Rna interference mediated inhibition of vascular cell adhesion molecule (vcam) gene expression using short interfering nucleic acid (sina): This invention relates to compounds, compositions, and methods useful for modulating vascular cell adhesion molecule gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of vascular cell adhesion... Agent: Sirna Therapeutics, Inc.

20110160284 - Supercoiled minicircle dna for gene therapy applications: The present invention relates to nucleic acid molecule compositions comprising minivectors encoding a nucleic acid sequence and methods of gene therapy using minivectors encoding a nucleic acid sequence.... Agent: Baylor College Of Medicine

20110160289 - Compositions and methods for enhanced sensitivity and specificity of nucleic acid synthesis: The present invention relates to nucleic acid inhibitors, compositions and method for enhancing synthesis of nucleic acid molecules. In a preferred aspect, the invention relates to inhibition or control of nucleic acid synthesis, sequencing or amplification. Specifically, the present invention discloses nucleic acids having affinity for polypeptides with polymerase activity... Agent: Life Technologies Corporation

20110160291 - Oligonucleotide compositions and their use to induce apoptosis: The present invention provides novel synthetic oligonucleotide sequences (hereinafter sequence) of 3 to 9 bases in length comprising one or more non-DNA bases wherein the bases are nebularine, hypoxanthine, or uracil, or combinations of nebularine, hypoxanthine and uracil bases. These sequences optionally further comprise one or more guanine bases or... Agent: Bioniche Life Sciences Inc.

20110160293 - Prmt1 for target genes of cancer therapy and diagnosis: Objective methods for diagnosing a predisposition to developing cancer, particularly bladder cancer, gastric cancer, colorectal cancer, breast cancer, esophageal cancer, lung cancer, lymphoma, pancreatic cancer and testicular cancer, are described herein. In one embodiment, the diagnostic method involves determining an expression level of PRMT1 gene. The present invention further provides... Agent: Oncotherapy Science, Inc.

20110160292 - Regulation of integrin surface expression: Disclosed are methods and compositions for preventing and treating conditions associated with platelet aggregation, comprising administering a therapeutically effective amount of a composition that modifies the interaction of DNAJC10 with αIIbβ3 in a megakaryocyte, thereby altering the expression of αIIbβ3 on the surface of the megakaryocyte.... Agent:

20110160290 - Use of extracellular rna to measure disease: Stable, extracellular microRNAs and methods for isolating and identifying such microRNAs from a body fluid are provided. The extracellular microRNAs isolated from a bodily fluid of a subject can be used to measure disease and provide sensitive, efficient, and non invasive methods for the detection of disease, including cancer. The... Agent:

20110160158 - Methods of treatment of bipolar disorder: A method of treating an individual diagnosed with bipolar disorder, comprises determining the number of manic episodes and/or depressive episodes experienced by an individual exhibiting one or more symptoms of bipolar disorder (e.g., bipolar disorder I); and if the number of manic episodes and/or the number of depressive episodes is... Agent: Repligen Corporation

20110160159 - Treatment of cancer: Provided are methods relating to compositions that include a CDP-topoisomerase inhibitor, e.g., a CDP-camptothecin or camptothecin derivative conjugate, e.g., CRLX101.... Agent:

20110160160 - Methods for heat shock protein dependent cancer treatment: The present invention provides a method of treating an Hsp70 dependent cancer, including: providing at least one Hsp70 dependent cancer cell; contacting the at least one cell with a sub-effective concentration of a dihydropyrimidinone compound; and contacting the at least one cell with a sub-effective concentration of a proteasome inhibitor,... Agent: The Research Foundation Of State University Of New York

20110160161 - Concentrated therapeutic phospholipid compositions: The invention relates to concentrated therapeutic phospholipid compositions; methods for treating or preventing diseases associated with cardiovascular disease, metabolic syndrome, inflammation and diseases associated therewith, neurodevelopmental diseases, and neurodegenerative diseases, comprising administering an effective amount of a concentrated therapeutic phospholipid composition.... Agent: Acasti Pharma, Inc.

20110160162 - Prodrugs of a2b adenosine receptor antagonists: Disclosed are prodrugs of A2B adenosine receptor antagonists, and their use in treating mammals for various disease states.... Agent: Gilead Sciences, Inc.

20110160163 - Inhibitors of p38: The present invention relates to inhibitors of p38, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli. The invention also relates to inhibitors of ZAP70. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of... Agent: Vertex Pharmaceuticals Incorporated

20110160164 - Compounds for nonsense suppression and methods for their use: The present invention relates to methods, compounds, and compositions for treating or preventing diseases associated with nonsense mutations in an mRNA by administering the compounds or compositions of the present invention. More particularly, the present invention relates to methods, compounds, and compositions for suppressing premature translation termination associated with a... Agent: Ptc Therapeutics, Inc

20110160165 - 7-pyrazolyl tetracycline compounds and methods of use thereof: e

20110160166 - Therapeutic composition for the treatment and prevention of athlete's foot and fungal infections of the nail and surrounding tissues: Methods and topical pharmaceutical formulations are provided for the treatment of athlete's foot (tinea pedis) and nail fungus (onychomycosis). The invention involves an anhydrous composition containing a therapeutically effective amount of salicylic acid. Repeated applications of the resulting formula over a 4-12 week period resolve most infections without the use... Agent:

20110160169 - Method for producing high sapogenin content composition: A method for producing a high sapogenin content composition, including: allowing a strong acid aqueous solution having a concentration of 0.01 mol/L to 4 mol/L to act on a saponin-containing plant, so as to perform hydrolysis treatment; neutralizing a liquid obtained by the hydrolysis treatment; filtering the liquid so as... Agent: Lion Corporation

20110160168 - Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols: A formulation for drug delivery, providing enhanced modulation of solubility, stability, absorption, metabolism, and/or pharmacokinetic profile of a lipophilic therapeutic agent by formulation with sterols and/or sterol esters, resulting in higher bioavailability of a therapeutic agent administered to a subject in need of such therapeutic agent. The formulation contains a... Agent: Differential Drug Development Associates, LLC

20110160167 - Steroid derivatives acting as glucocorticosteroid receptor agonists: The present invention provides compounds of formula (I) wherein n, p, R1, R2, X1, X2, X3, R3a, R3b, R4, R5 and R6 are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy.... Agent: Astrazeneca Ab

20110160170 - Compositions and methods of inducing endoplasmic reticulum stress response: The present invention provides methods of inducing cell cycle arrest and/or cell growth inhibition, with the methods comprising administering to the cells an effective dose of the compounds of the present invention.... Agent:

20110160172 - Fluoroquinolone derivatives for ophthalmic applications: The present invention relates to fluoroquinolone derivatives having enhanced ocular penetration characteristics and/or antimicrobial activity, and to compositions comprising such derivatives. The derivatives and compositions are particularly well suited for treating ophthalmic bacterial infections. The present invention more particularly relates to the discovery that a 2-methyl substitution on a diazabicyclo... Agent: Alcon Research, Ltd.

20110160171 - Treatment of congestion using steroids and adrenergics: A decongestant composition is provided comprising: (a) a safe and effective amount of an adrenergic compound; (b) a safe and effective amount of a steroid; and (c) a pharmaceutically-acceptable carrier. Methods of treating congestion in a human or animal subject are also provided comprising administering to the subject a composition... Agent:

20110160174 - Method of treating disorder related to high cholesterol concentration: d

20110160173 - Method of treating human skin and a skin care composition for use in such a method: One aspect of the invention concerns a cosmetic method of treating human skin by delivering an estrogenic component to said skin. The method comprises applying to the skin a composition containing: (i) at least 5 μg/g of an estrogenic component selected from the group consisting of substances represented by the... Agent: Pantarhei Bioscience B.v.

20110160175 - 18,21-didesoxymacbecin derivatives for the treatment of cancer: The present invention relates to macbecin analogues that are useful, e.g. in the treatment of cancer, B-cell malignancies, malaria, fungal infection, diseases of the central nervous system and neurodegenerative diseases, diseases dependent on angiogenesis, autoimmune diseases and/or as a prophylactic pre-treatment for cancer. The present invention also provides methods for... Agent:

20110160177 - Novel carbapenem derivatives: e

20110160178 - Heterosubstituted n-thiolated beta-lactam compounds and methods of use:

20110160179 - Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes: The present invention provides novel substituted amino-azetidines that are useful as cannabinoid receptor antagonists/inverse agonists and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, dyslipidemias, cardiovascular disorders, hepatic disorders, and a combination thereof.... Agent: Jenrin Discovery

20110160180 - Cannabinoid receptor ligands: Compounds of Formulae (I), or pharmaceutically acceptable salts thereof: wherein R1, R2 and Y are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.... Agent: Astrazeneca Ab

20110160182 - Pyrazine compounds as phosphodiesterase 10 inhibitors: Pyrazine compounds, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.... Agent: Amgen Inc.

20110160181 - Substituted pyrazoline compounds, their preparation and use as medicaments: The present invention relates to substituted pyrazoline compounds, methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals.... Agent: Laboratorios Del Dr. Esteve, S.a.

20110160176 - Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor: The invention relates to compounds of the formula (I) wherein n is 0, 1 or 2; G is CH2 or CHR3; R1 is H, C,-C6-alkyl, C,-C6-alkyl substituted by C3-C6-cycloalkyl, C1-C6-hydroxyalkyl, fluorinated C,-C6-alkyl, C3-C6-cycloalkyl, fluorinated C3-C6-cycloalkyl, C3-C6 alkenyl, fluorinated C3-C6-alkenyl, formyl, acetyl or propionyl; R2, R3 and R4 are, independently of... Agent: Abbott Gmbh & Co. Kg

20110160183 - Inhibitors of akt activity: The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in... Agent: Merck & Co., Inc.

20110160184 - Dibenzothiazepine derivatives and use thereof: Compounds the following formula: wherein Z is as described in the specification, pharmaceutically acceptable salts thereof, compositions comprising the same, and methods of treating bipolar disorder, an anxiety disorder, a mood disorder or schizophrenia or other psychotic disorder with said compounds.... Agent: Astrazeneca Ab

20110160185 - Pyrrolopyrimidine derivatives as jak3 inhibitors: Pyrrolopyrimidine derivatives of Formula (I) that are useful as JAK3 kinase inhibitors.... Agent:

20110160186 - Methods of treating cyp2d6 alternative metabolizers: The invention provides various methods comprising the administration of a CYP2D6 bioactive drug covalently bound to a water-soluble oligomer. Metabolism of CYP2D6 bioactive drug conjugates is diverted from CYP2D6 to alternative pathways, and the conjugates may therefore be utilized to alleviate the problems associated with interpopulation variation resulting from the... Agent: Nektar Therapeutics

20110160187 - 3-aryl-5,6-disubstituted pyridazines: The present invention provides compounds of Formula (I) or (II) salt form or prodrug thereof, wherein variables are defined herein, that are modulators of metalloproteases such as matrix metalloproteases (MMPs) and ADAMs. The compounds or compositions described herein can be used to treat diseases associated with metalloprotease activity including, for... Agent: Neurogen Corporation

20110160188 - Paramyxovirus family inhibitors and methods of use thereof: Embodiments of the present disclosure include methods for identifying a compound or compounds useful as therapeutic agents in the treatment of paramyxovirus infections, compounds for the treatment of measles, and high throughput screening methods for identifying compounds capable of inhibiting the proliferation of a paramyxovirus.... Agent:

20110160190 - Carboline derivatives useful in the inhibition of angiogenesis: In accordance with the present invention, compounds that inhibit the expression of VEGF post-transcriptionally have been identified, and methods for their use provided. In one aspect of the invention, compounds useful in the inhibition of VEGF production, in the treatment of solid tumor cancer, and in reducing plasma and/or tumor... Agent: Ptc Therapeutics, Inc.

20110160189 - Compound that can inhibit ubc13-uev interactions, pharmaceutical compositions and therapeutic uses:

20110160192 - Biaryl amino acids and their use in dna binding oligomers: Compounds of formula (I): Z′-CO-A-B—NH-Z (I) wherein: Z is H or an amino protecting group; Z′ is OH, a protected or activated hydroxyl group or Cl; A is an optionally substituted C5-6 arylene group; and B is an optionally substituted C5-6 arylene group.... Agent: Spirogen Limited

20110160191 - New fused polycyclic compounds having a heterocyclic ring(s) and pharmaceutical use thereof: m

20110160193 - New benzothiazinone derivatives and their use as antibacterial agents:

20110160194 - Anti-inflammatory analgesic external preparation: An external preparation that effectively produces the anti-inflammatory analgesic effect of a non-steroidal anti-inflammatory analgesic agent, and reduces skin irritation on the application site of the preparation and has an excellent effect on pain associated with inflammation such as chronic rheumatoid arthritis, osteoarthritis, and also lumbago is provided. The external... Agent: Teikoku Seiyaku Co., Ltd

20110160195 - Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation: A method and solution for perioperatively inhibiting a variety of pain and inflammation processes during arthroscopic procedures. The solution preferably includes a vasoconstrictor that exhibits alpha-adrenergic activity and one or more additional pain and inflammation inhibitory agents at dilute concentration in a physiologic carrier, such as saline or lactated Ringer's... Agent: Omeros Corporation

20110160196 - Factor xa inhibitors: The present invention is directed to compounds represented by Formula (I) or a pharmaceutically acceptable salt, ester, or prodrug thereof which are inhibitors of Factor Xa. The present invention is also directed to intermediates used in making such compounds, pharmaceutical compositions containing such compounds, methods to prevent or treat certain... Agent: Millennium Pharmaceuticals, Inc.

20110160198 - Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof: The present invention is directed to substituted azoanthracene derivatives or pharmaceutically acceptable salts thereof that modulate the human GLP-1 receptor and that may be useful in the treatment of diseases, disorders, or conditions in which modulation of the human GLP-1 receptor is beneficial, such as diabetes mellitus type 2. The... Agent: High Point Pharmaceuticals, LLC

20110160197 - Substituted indoles and a method for the production and use thereof: The invention relates to novel substituted indoles, to the use thereof in the form of pharmacological composition substances and to use of said composition for producing medicinal preparations used for preventing and treating viral diseases, in particular caused by viruses of infectious hepatitis (HCV, HBV), human immune deficiency (HIV), atypical... Agent: Alla Chem, LLC

20110160199 - Aralkyl substituted piperidine or piperazine derivatives and their use for treating schizophrenia: The present invention discloses an aralkyl substituted piperidine or piperazine derivative and the use of the derivative in preparation of medicaments for treating schizophrenia and correlative psychoneuroses. It is shown by pharmacological tests that the derivative of the present invention has better antischizophrenic effect and less toxicity. Said derivative is... Agent: Shanghai Institute Of Pharmaceutical Industry

20110160200 - Nitroxyl progenitors for the treatment of pulmonary hypertension: The invention relates to methods of treating, preventing or delaying the onset or development of pulmonary hypertension using hydroxyl donors or pharmaceutically acceptable salts thereof. The invention further relates to methods of reducing mean pulmonary arterial pressure using hydroxyl donors or pharmaceutically acceptable salts thereof.... Agent: Cardioxyl Pharmaceuticals, Inc.

20110160201 - Compound with serotoninergic activity, process for preparing it and pharmaceutical composition comprising it: Compound of formula (I) in which R1, R2 and R3 are defined in the following description, and the pharmaceutically acceptable acid-addition or base-addition salts thereof. The invention also relates to a process and an intermediate for preparing it, and to a pharmaceutical composition comprising it. The invention also relates to... Agent: Aziende Chimi. Riun. Ang. Franc. A.c.r.a.f. S.p.a.

20110160202 - Pyrazine compounds as phosphodiesterase 10 inhibitors: Pyrazine compounds, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.... Agent: Amgen Inc.

20110160203 - Substituted pyrrolo-aminopyrimidine compounds: The present invention relates to substituted pyrrolo-aminopyrimidine compounds and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing substituted pyrrolo-aminopyrimidine compounds and methods of treating cell proliferative disorders, such as cancer, by administering these compounds and pharmaceutical compositions to subjects in need thereof.... Agent: Arqule, Inc.

20110160205 - Novel 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40: The present invention relates to novel 1-benzyl-3-hydroxymethylindazole derivatives according to formula (I) described in the claims, and to a pharmaceutical composition comprising them, together with a pharmaceutically acceptable vehicle. In addition, the present invention relates to the use of 1-benzyl-3-hydroxymethylindazole derivatives for the preparation of a pharmaceutical composition that is... Agent: Aziende Chim. Riun. Ang. Franc. A.c.r.a.f. S.p.a.

20110160204 - Pyridopyrazines and derivatives thereof as alk and c-met inhibitors: e

20110160206 - Tri-substituted pyrimidine compounds and their use as pde10 inhibitors: The present invention provides a tri-substituted pyrimidine compound having an excellent PDE10 inhibitory activity. The present invention relates to a tri-substituted pyrimidine compound represented by the following formula [I0] or a pharmaceutically acceptable salt thereof, a method for preparing the same, and use of said compound for PDE10 inhibitor, and... Agent:

20110160208 - Diaryl-substituted five-membered heterocycle derivative: e

20110160207 - Heterocyclic amide compounds useful as kinase inhibitors:

20110160210 - Control of intraocular pressure using alk5 modulation agents: An ophthalmic pharmaceutical composition useful in the treatment of glaucoma and control of intraocular pressure comprising an effective amount of a selective modulator of ALK5 receptor activity is disclosed. Also disclosed is a method of treating glaucoma and controlling intraocular pressure comprising applying a therapeutically effective amount of a pharmaceutical... Agent: Alcon, Inc.

20110160209 - Substituted pyridazine carboxamide compounds as kinase inhibitor compounds: Pyridazine derivatives have unexpected drug properties as inhibitors of protein kinases and are useful in treating disorders related to abnormal protein kinase activities such as cancer.... Agent:

20110160211 - Cyclopentylacrylamide derivative: (wherein R1 and R2 are each independently a hydrogen atom, a halogen atom, an amino group, a hydroxyl group, a hydroxyamino group, a nitro group, a cyano group, a sulfamoyl group, a C1 to C6 alkyl group, a C1 to C6 alkoxy group, a C1 to C6 alkylsulfanyl group, a... Agent:

20110160212 - Certain dipeptidyl peptidase inhibitors: Provided are certain dipeptidyl peptidase inhibitors, pharmaceutical compositions thereof, and methods of use therefor.... Agent:

20110160213 - Pharmaceutical compositions for the treatment of inflammatory and allergic disorders: The present invention relates to the pharmaceutical compositions, more particularly to the pharmaceutical compositions comprising novel phosphodiesterase type 4 (PDE4) inhibitors, and their use in treating allergic and inflammatory disorders.... Agent: Glenmark Pharmaceuticals, S.a.

20110160214 - Compositions and methods for eye whitening: The invention provides compositions and methods for whitening of eyes. The provided compositions and methods utilize low concentrations of selective α-2 adrenergic receptor agonists. The compositions preferably include brimonidine.... Agent:

20110160215 - Substituted triazolo-pyrazine compounds: The present invention relates to substituted triazolo-pyrazine compounds and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing substituted triazolo-pyrazine compounds and methods of treating cell proliferative disorders, such as cancer, by administering these compounds and pharmaceutical compositions to subjects in need thereof.... Agent: Arqule, Inc.

20110160216 - Thymidylate synthase haplotype is associated with tumor recurrence in stage ii and stage iii colon cancer patients: The invention provides compositions and methods for determining the likelihood of tumor recurrence following treatment with 5-FU based adjuvant therapy for Stage II or Stage III colon cancer patients. After determining if a patient is less likely to experience tumor recurrence once treated, the invention also provides methods for treating... Agent: University Of Southem California

20110160218 - Compositions comprising macrocyclic lactone compounds and spirodioxepinoindoles: The present invention provides formulations which may comprise macrocyclic lactones and at least one spirodioxepinoindole derivative or a spirooxepinoindole derivative for combating parasites in birds and mammals. The invention also provides for an improved method for eradicating, controlling and preventing parasite infestation in birds and mammals.... Agent:

20110160217 - Deuterium enriched analogues of tadalafil as pde5 inhibitors: The present invention relates to derivatives of tadalafil, substituted with fluorine on the methylene carbon atom situated between the oxygens of the benzodioxol ring, and optionally further substituted with deuterium atoms in place of normally abundant hydrogen, and 13C in place of normally abundant 12C. These compounds are selective PDE5... Agent: Concert Pharmaceuticals Inc.

20110160219 - Inhibitors of phosphodiesterase type 5a for treating or preventing muscle disease or the symptoms thereof in a patient: Disclosed are pharmaceutical compositions and methods for treating or preventing muscle diseases or the symptoms thereof. The compositions typically include and the methods typically utilize phosphodiesterase type 5A inhibitors.... Agent: University Of Iowa Research Foundation

20110160220 - Crystalline form of 6-[(4s)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine: The present disclosure generally relates to a crystalline form of 6-[(4S)-2-methyl-4-(naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine. The present disclosure also generally relates to pharmaceutical compositions comprising the crystalline form, as well of methods of using a crystalline form in the treatment of depression and other conditions and methods for obtaining such crystalline form.... Agent: Bristol-myers Squibb Company And Albany Molecular Research, Inc.

20110160222 - Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders: Aryl 119 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control.... Agent: Metabolex, Inc.

20110160221 - Pyrimidyl cyclopentanes as akt protein kinase inhibitors: The present invention provides compounds of Formula I, including tautomers, resolved enantiomers, diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.... Agent: Genentech, Inc.

20110160223 - Nmda receptor antagonists for the treatment of neuropsychiatric disorders: Provided are pharmaceutical compositions and methods of treatment or prophylaxis of certain neuropsychiatric conditions, in particular mood disorders. The compounds are of the general Formula I-V as described herein.... Agent:

20110160224 - Aripiprazole complex formulation and method: An aripiprazole formulation is provided which includes the antipsychotic agent aripiprazole in the form of an inclusion complex in a β-cyclodextrin, preferably, sulfobutyl ether β-cyclodextrin (SBECD), which in the form of an injectable produces reversible generally minimal to mild irritation at the intramuscular injection site. A method for minimizing or... Agent: Bristol-myers Squibb Company

20110160225 - Compositions and methods of use for treating or preventing lipid related disorders: Disclosed herein are novel compositions and methods for treating or preventing a variety of disorders and conditions associated with lipid metabolism. The methods generally include administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising one or more fibric acid or statin derivative compositions... Agent: Ironwood Pharmaceuticals, Inc.

20110160226 - Substituted triazolo-pyrimidine compounds: The present invention relates to substituted triazolo-pyrimidine compounds and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing substituted triazolo-pyrimidine compounds and methods of treating cell proliferative disorders, such as cancer, by administering these compounds and pharmaceutical compositions to subjects in need thereof.... Agent: Arqule, Inc.

20110160227 - Prolyl hydroxylase inhibitors: e

20110160230 - Ceramic matrix for incorporating controlled release drugs, a tablet, method for obtaining the ceramic matrix and method for producing a tablet: The present invention refers to a ceramic nanosystem constructed for releasing medications in a controlled manner, in the treatment of human beings and animals presenting an organic deficiency which requires the application of said medications. The present invention further refers to the method for preparing said nanosystem, in the form... Agent: Instituto Presbiteriano Mackenzie

20110160229 - Ahcy hydrolase inhibitors for treatment of hyper homocysteinemia: The present invention is directed to AHCY inhibitors of formula (I): which are useful in the treatment of diseases characterized by high homocysteine levels, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the... Agent:

20110160228 - Dihydro-iso-ca-4 and analogues: potent cytotoxics, inhibitors of tubulin polymerization: The present invention relates to compounds of formula (I) below in which: —R1 and R3 represent, independently of one another, a methoxy group optionally substituted by one or more fluorine atoms, —R2 and R4 represent, independently of one another, a hydrogen atom or a methoxy group optionally substituted by one... Agent: Centre National De La Recherche Scienrifique (cnrs)

20110160232 - Certain chemical entities and therapeutic uses thereof: Certain chemical entities that modulate PI3 kinase activity, and chemical entities, pharmaceutical compositions, and methods of treatments of diseases and conditions associated with PB kinase activity are described.... Agent:

20110160231 - Dihydroorotate dehydrogenase as antifungal drug target and quinazolinone-based inhibitors thereof: A method of identifying an antifungal agent which targets a DHODH protein (alias PyrE, dihydroorotate dehydrogenase, EC: 1.3.99.11) of a fungus comprising contacting a candidate substance with a fungal DHODH protein and determining whether the candidate substance binds or modulates the DHODH protein, wherein binding or modulation indicates that the... Agent:

20110160233 - Anti-viral compounds: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using... Agent: Abbott Laboratories

20110160234 - Tricyclic compounds as modulators of tnf-alpha synthesis and as pde4 inhibitors: The present invention relates to chemical compounds of Formula (I) are as herein defined, pharmaceutical compositions, and methods of use in the treatment of conditions or disorders mediated by TNF-α or by PDE4, including but not limited to rheumatoid arthritis.... Agent: High Point Pharmaceuticals, LLC

20110160235 - Triazolyl tropane derivatives: This invention relates to novel triazolyl tropane derivatives, their acceptable acid addition salts, solvates, hydrates and polymorphs thereof. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by blocking or reducing the binding... Agent: Concert Pharmaceuticals, Inc.

20110160237 - Substituted heterocyclic compounds: The present invention relates to substituted heterocyclic compounds and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing substituted heterocyclic compounds and methods of treating cell proliferative disorders, such as cancer, by administering these compounds and pharmaceutical compositions to subjects in need thereof.... Agent: Arqule, Inc.

20110160236 - Treating vascular events with statins by inhibiting par-1 and par-4: The present invention relates to new methods for treating and/or preventing vascular events by inhibiting G-coupled Protease Activating Receptor (PAR)-1 and/or PAR-4 with the administration of statins. In one embodiment, individuals who are at risk for vascular events, but have cholesterol levels (e.g., total cholesterol or Low Density Lipoprotein) in... Agent:

20110160238 - Octahydroquinolizines for antidiabetic treatment: This invention relates to octahydroquinolizines for pharmaceutical use with the following formula: (I), X=H, F; R=Methyl, Ethyl, nPropyl, nButyl.... Agent: 55pharma Drug Discovery & Development Ag

20110160239 - Oral administration of peripherally-acting opioid antagonists: Peripherally-acting opioid antagonists can be orally administered to treat the side effects of opioid administration in convenient dosing schedules.... Agent:

20110160240 - Polymorphs and salts of a kinase inhibitor: The present invention relates to novel crystalline polymorphic salt forms of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid, processes for the preparation thereof, compositions thereof and their use in methods of treatment and prevention of conditions mediated by casein kinase (CK) and/or poly(ADP-ribose)polymerase (PARD).... Agent: Cylene Pharmaceuticals, Inc.

20110160241 - New peptidomimetic compounds: The present invention relates to new compounds of the formula (I), (II), or (III) wherein R1, R2, R3, R4, R5 and W are as defined herein, and pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, especially Aβ amyloid disease, such as observed in Alzheimer's disease,... Agent:

20110160242 - Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same: The present invention relates to a form 1 and form 2 polymorph of (−)-trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione. The present invention also relates to (−)-trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione compounds having a chiral purity greater than 99%, and methods of preparation of these compounds. The present invention also relates to pharmaceutical compositions comprising these (−)-trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione compounds. The present... Agent: Arqule, Inc.

20110160243 - Substituted tricyclic acid derivatives as s1p1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders: The present invention relates to certain substituted tricyclic acid derivatives of Formula (I) and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists of the S1P1 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the... Agent: Arena Pharmaceuticals ,inc.

20110160244 - Phenylpiperidine modulators of mu-opioid receptor: The present invention relates to new phenylpiperidine modulators of μ-opioid receptors, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Auspex Pharmaceuticals, Inc.

20110160245 - Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate: The invention relates to a method of treating Attention Deficit Disorder (ADD) and Attention Deficit/Hyperactivity Disorder (ADHD) and compositions for topical application of methylphenidate comprising methylphenidate in a flexible, finite system wherein said composition comprises about 10 to 30 wt % methylphenidate, about 30 to 50 wt % acrylic adhesive,... Agent: Noven Pharmaceuticals, Inc.

20110160246 - Neurodegenerative protein aggregation inhibition methods and compounds: Methods and compositions are provided for reducing aggregation of neurodegenerative proteins associated with neurotoxicity or other proteins. The compounds comprise a first domain or targeting element for binding to the target proteins linked to a second domain or recruiting element that binds to an aggregation inhibiting protein, e.g. a prolyl... Agent:

20110160247 - Aralkyl alcohol piperidine derivative and the use thereof as a medicament for treating depression: The present invention relates to an aralkyl alcohol piperidine derivative and use as antidepressant thereo. The said aralkyl alcohol piperidine derivative has a triple inhibition effect on the reuptaking of 5-HT, NA and DA. The derivative may be administered to the patient in need of such treatment in the form... Agent: Shanghai Institute Of Pharmaceutical Industry

20110160248 - Pyrazole compounds and uses thereof: wherein R1-R6, X, Y, and B have any of the values described herein, as well as salts of such compounds, compositions comprising such compounds, and therapeutic methods that comprise the administration of such compounds. The compounds are inhibitors of MAO-B enzyme function and are useful for improving cognitive function and... Agent:

20110160249 - 5-lipoxygenase-activating protein inhibitor: A pharmaceutically acceptable salt comprising 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxy-pyridin-3-yl)-benzyl]-5-(5-methyl-pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionate as the anion and a cation selected from Na+, K+, Li+, Ca2+, NH4+, the protonated form of dicyclohexylamine, the protonated form of N-methyl-D-glucamine, the protonated form of tris(hydroxymethyl)methylamine, the protonated form of arginine, and the protonated form of lysine is disclosed, along with formulations... Agent:

20110160250 - Crystalline forms of a factor xa inhibitor: The present invention provides crystalline forms of a mesylate salt of the compound 5-chloro-N-((1-(4-(2-oxopyridin-1(2H)-yl)phenyl)-1H-imidazol-4-yl)methyl)thiophene-2-carboxamide and pharmaceutical compositions and methods thereof.... Agent: Millennium Pharmaceuticals, Inc.

20110160251 - Animal ectoparasite control composition: The present invention provides an animal ectoparasite control composition containing an insecticidal component and an adipate, and a method of controlling an animal ectoparasite which comprises administering an effective amount of the animal ectoparasite control composition to an animal.... Agent:

20110160252 - Pharmaceutical compositions for treatment or prevention of hbv infection: Then, the present inventors revealed that the HBV replication-suppressing effect of PEG-IFN is enhanced in chimeric mice having a human liver infected with genotype C or A HBV when PEG-IFN is used in combination with the compound represented by formula (III) above. The present inventors also revealed that the HBV... Agent:

20110160253 - Deuterated tizanidine: This disclosure relates to novel benzothiadiazoles, their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an α2-adrenoceptor agonist.... Agent:

20110160254 - Combination of a bis-thiazolium salt or a precursor thereof and artemisinin or a derivative thereof for treating acute malaria: The present invention relates to a combination of antimalarial active ingredients, namely a bisthiazolium salt or a precursor thereof and artemisinin or derivatives thereof. The invention also relates to a pharmaceutical composition comprising such a combination and use thereof in the treatment and/or prevention of malaria.... Agent: Universite Montpellier Ii

20110160255 - Inhibitors of akt activity: Invented are novel hetero-pyrrole compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.... Agent:

20110160256 - Inhibitors of akt activity: Invented are novel hetero-pyrrole compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.... Agent:

20110160257 - Novel salts and polymorphs of desazadesferrothiocin polyether analogues as metal chelation agents: Disclosed herein are new salts and polymorphs of desazadesferrithiocin polyether (DADFT-PE) analogues, as well as pharmaceutical compositions comprising them and their application as metal chelation agents for the treatment of disease. Methods of chelation of iron and other metals in a human or animal subject are also provided for the... Agent: Ferrokin Biosciences, Inc.

20110160258 - Synergistic antifouling compositions comprising 4-bromo-2-(4-chlorophenyl)-5-(trifluoromethyl)-1h-pyrrole-3-carbonitrile: The present invention relates to antifouling compositions and particularly to compositions which are able to provide an improved protecting effect against fouling organisms. More particularly, the present invention relates to synergistic antifouling compositions comprising an amount of at least 3.5 wt %, based on the total weight of the dry... Agent:

20110160259 - Compounds and methods for inhibiting the interaction of bcl proteins with binding partners: One aspect of the present invention relates to heterocyclic compounds that bind to bcl proteins and inhibit Bcl function. Another aspect of the present invention relates to compositions comprising a heterocyclic compound of the invention. The present invention provides methods for treating and modulating disorders associated with hyperproliferation, such as... Agent: Infinity Discovery, Inc.

20110160260 - Method of treating a neurodegenerative disorder: The present invention provides a method of treating a neurodegenerative disorder in a patient, comprising administration to the patient a therapeutically effective amount of D-cycloserine and its derivatives.... Agent: T.l. & G.m. Chemical Company

20110160261 - Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents: The present invention provides for methods of using tert-butyl alcohol (TBA) co-solvent systems in the formulation and production of a pharmaceutical agent with low solubility. The present invention also provides for pharmaceutical compositions made using the novel co-solvent system. In one embodiment, the invention provides for a method of making... Agent: Us Worldmeds, LLC

20110160262 - Method of treating retinal vein occlusion: e

20110160263 - Small molecule inhibition of pdz-domain interaction: Novel compounds that have been found effective in inhibiting PDZ domain interactions, and particularly interactions of PDZ domains in MAGIs with the oncogenic (tumor suppressor) protein PTEN and interactions between the PDZ domain in the Dishevelled (Dvl) protein and other proteins such as the Frizzled (Fz) protein, have the general... Agent:

20110160264 - Orally administrable film dosage forms containing ondansetron: The invention relates to orally administrable, disintegrating film dosage forms which include ondansetron and methods of orally administering the film dosage forms.... Agent: Monosol Rx, LLC

20110160265 - Method of treating motor disorders with alpha-2b adrenergic receptor agonists: Disclosed herein is a method of treating motor disorders comprising administering to a subject in need of such treatment an alpha-2 receptor agonist lacking significant alpha-2A receptor activity.... Agent:

20110160266 - Novel anti-arrhythmia agent: It has been discovered that SKF-96365 prevents and reverses ectopic activity in myocyte cells, and that SKF-96365 is effective against all types of ectopic activity. Methods are provided using SKF-96365 and its derivatives to prevent and reverse electromechanical disorders of myocytes; these include methods of treatment and prevention of cardiac... Agent: The Uab Research Foundation

20110160268 - Compositions and methods for treating lung disorders: The present invention relates to methods of treating subjects with alveolar capillary membrane injury or methods of preventing alveolar capillary membrane injury in subjects, with the methods comprising administering to the subjects a therapeutically effective amount of ergothioneine and a pharmaceutically acceptable carrier. The invention also relates to methods of... Agent:

20110160267 - Method of treating diabetic retinopathy: e

20110160269 - Pyrrolin-2-ylamino compounds for combating animal pests: wherein * indicates the point of attachment to the remaining part of the compound; R5a, R5b, R5c, R5d, R5e and R5f are selected independently from one another from hydrogen, halogen, C1-C6-alkyl, C1-C6-alkoxy, C1-C6-alkylamino, di(C1-C6-alkyl)amino, C3-C6-cycloalkyl and Ar2, etc.; R6 and R7 are selected each independently from one another from hydrogen,... Agent: Basf Se

20110160270 - Deuterium-enriched sdx-101: The present application describes deuterium-enriched SDX-101, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Protia, LLC.

20110160271 - Ketorolac tromethamine compositions for treating or preventing ocular pain: The present invention provides an aqueous ophthalmic solution comprising an effective amount of ketorolac which comprises carboxymethyl cellulose in an aqueous solution wherein said concentration of carboxymethyl cellulose is selected to provide an increased absorption of ketorolac in the eye of a patient that is at least 130% greater than... Agent: Allergan, Inc.

20110160272 - Methods and compositions for use of angiogenesis inhibitors in the prevention and/or control of epilepsy: In accordance with some preferred embodiments, without limitation, the invention comprises methods and compositions for the prophylactic and/or antiepileptic administration of angiogenesis inhibitors in conjunction with seizures or traumatic insults to the brain, which administration may limit the extent of trauma-associated angiogenesis and/or decrease the likelihood that angiogenesis will give... Agent:

20110160273 - Co-crystals of duloxetine and cox-inhibitors for the treatment of pain: The present invention relates to co-crystals of duloxetine and co-crystal formers selected from COX-INHIBITORs, processes for preparation of the same and their uses as medicaments or in pharmaceutical formulations, more particularly for the treatment of pain.... Agent:

20110160274 - Fenofibrate formulation with enhanced oral bioavailability: The present invention provides a formulation of fenofibrate with enhanced oral bioavailability, simplicity of design and manufacture and absence of food effect. The formulation comprises fenofibrate dissolved in a lipophilic surfactant, with a hydrophilic surfactant optionally added. The formulation can be effectively used in the management and treatment of conditions... Agent: Panacea Biotec Limited

20110160275 - Synergistic antifouling compositions comprising 4-bromo-2-(4-chlorophenyl)-5-(trifluoromethyl)-1h-pyrrole-3-carbonitrile: The present invention relates to antifouling compositions and particularly to compositions which are able to provide an improved protecting effect against fouling organisms. More particularly, the present invention relates to synergistic antifouling compositions comprising an amount of at least 3.5 wt %, based on the total weight of the dry... Agent:

20110160276 - Curcumin derivatives: e

20110160294 - Compositions and methods for treating ischemia and ischemia-reperfusion injury:

20110160295 - Antitumor agent: An antitumor agent containing, in combination, at least one kind of antitumor agent selected from the group consisting of an antitumor agent that forms a cross-link with DNA and shows an antitumor effect, an antimetabolite antitumor agent and a taxane antitumor agent, and a histone deacetylase inhibitor. According to the... Agent: Astellas Pharma Inc.

20110160296 - Preparation of 6-oxa-8alpha-steroid estrogen analogues - a new group of unnatural estrogens and their use in medicine: The invention is related to the area of new 6-Oxa-8α-steroid estrogen analogues and the synthesis of these new biological active steroid estrogen analogues, namely, to the preparation of 6-oxa-8α-steroid estrogens and their use as estrogen receptor modulators. These new estrogen analogues are ligands for estrogen receptors and as such may... Agent: Topass Gmbh

20110160297 - Schweinfurthin analogues: The invention provides fluorescent schweinfurthin analogs of formula(I) which are useful as probes and for the treatment of cancer and other diseases.... Agent: University Of Iowa Research Foundation

20110160298 - Pharmaceutical composition for prevention and/or treatment of bone loss: A pharmaceutical composition for preventing and/or treating bone loss is disclosed. The pharmaceutical composition includes an effective amount of a licorice, black bean, Cnidi Fructus, and buckhorn.... Agent:

20110160299 - Composition and method: A companion pet diet meeting ordinary nutritional requirements for an aged pet and further comprising a sufficient amount of antioxidant or mixture thereof, to inhibit the deterioration of the mental capacity of an aged companion pet.... Agent: Hill's Pet Nutrition, Inc.

20110160300 - Renin inhibitors and methods of use thereof: Disclosed are aspartic protease inhibitors represented by the following Formula: wherein R1, R2, R3, R4, R5, R6, R7a, R7b and n are as defined herein, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods for treating an aspartic protease mediated disorder using the same.... Agent:

20110160301 - Ascorbate, vitamin k3 and hydroxytolans in the treatment of cancer: The combination of compounds of the hydroxytolan family with ascorbate plus naphthoquinone (Vitamin K3; VK3), or a quinone or semiquinone analogue of VK3, kill tumor cells, inhibit tumor growth and development, and treat cancer in subjects in need thereof.... Agent: Kent State University

20110160302 - Device and methods for treatment and prevention of tendon injuries: The present invention relates to treatment and prevention devices and regimens for tendon injury and damage. The invention further provides compositions comprising therapeutic agents and the use of such compositions in methods of treating disorders, injuries and conditions beneficially treated by these agents, particularly those relating to the management of... Agent:

20110160304 - Inhibitors of yeast filamentous growth and method of their manufacture: The invention broadly relates to the use of α, β-unsaturated fatty acids to inhibit the filamentous growth of fungi and yeasts and to a method for producing same. In particular the invention relates to the use of optionally substituted C8 to C15 α, β-unsaturated fatty acids or salts, esters or... Agent:

20110160303 - N-alkylcarbonyl-amino acid ester and n-alkylcarbonyl-amino lactone compounds and their use: The present invention generally relates to refreshing, soothing, and cooling compounds that affect sensory processes. More particularly, the present invention pertains to certain N-alkylcarbonyl-amino acid ester and N-alkylcarbonyl-amino lactone compounds as described herein; compositions and articles comprising such compounds; and methods of treatment, for example, methods of alleviating the discomforts... Agent: Edward Tak Wei

20110160305 - Oral delivery of therapeutic doses of glutathione: Nutritional supplements such as acetyl glutathione with malodor treated to remove the malodor associated with it. Acetyl glutathione, glutathione, esters of glutathione, derivatives of glutathione, and precursors of glutathione and other thiol compounds that may have a strong malodor based on their sulfur content. These compounds are treated with tartaric... Agent:

20110160306 - Use of alkanedicarboxylic acids and retinoids for treatment of rosacea and other inflammatory skin diseases: In order to make available another therapeutic possibility for rosacea the use of at least one α,ω-n-alkanedicarboxylic acid with 7 to 13 carbon atoms or its esters and at least one retinoid for producing a pharmaceutical preparation is proposed. The suggested formulation is also effective in treatment of other inflammatory... Agent:

20110160307 - Compositions and methods for treating hemorrhagic conditions: A method of treating a hemorrhagic condition in a subject in need thereof, comprising administering a composition comprising a therapeutically effective amount of Dencichine, a co-solvent, a dispersion supporter, and optionally a cryoprotectant. Compositions and formulations comprising a solid dispersion composition of Dencichine and methods for preparation of same are... Agent:

20110160308 - Use of monoamine oxidase inhibitors to treat outer retina disorders: Compositions and methods for treating disorders of the outer retina with compounds that inhibit monoamine oxidase are disclosed.... Agent: Alcon Research, Ltd.

20110160309 - Interleukin-1 and tumor necrosis factor-alpha modulators; syntheses of such modulators and methods of using such modulators: Described herein are chemical compounds and pharmaceutical compositions, including novel chemical compounds and pharmaceutical compositions thereof, useful in the treatment of various diseases and disease states. Also described are methods of synthesizing natural products and novel, structurally-related chemical compounds. More particularly, disclosed are new analogs of and processes for the... Agent: Nereus Pharmaceuticals, Inc.

20110160310 - Tcb based hydrophilic polyurethane dispersions: The present invention relates to a polyurethaneurea dispersion including a polyurethaneurea which is terminated with at least one polyethylene oxide- and polypropylene oxide-based copolymer unit, and includes a polycarbonate polyol-based unit of formula (I)... Agent: Bayer Materialscience Ag

20110160311 - Sweetness enhancers, compositions thereof, and methods for use: Disclosed herein are sweetener compositions comprising at least one sweetener and at least one sweetness enhancer chosen from terpenes (such as sesquiterpenes, diterpenes, and triterpenes), flavonoids, amino acids, proteins, polyols, other known natural sweeteners (such as cinnamaldehydes, selligueians, hematoxylins), secodammarane glycosides, and analogues thereof, wherein the at least one sweetness... Agent: The Coca-cola Company

20110160312 - Cosmetic transparent gel preparation and gelling agent: A cosmetic transparent gel preparation that has high levels of transparency and hardness and favorable usability, as well as a gelling agent that is ideal for use in the cosmetic transparent gel preparation. The cosmetic transparent gel preparation contains an esterification reaction product obtained by reacting glycerol with a dibasic... Agent: The Nisshin Oillio Group, Ltd.

  
06/23/2011 > patent applications in patent subcategories. invention type

20110152168 - Antiadhesive carbohydrates: Provided is a pharmaceutical or dietetic product, which serves for reducing and/or blocking the adhesion of pathogenic substances and organisms to eucaryontic cells, in particular mammal cells. Said preparation contains at least one carbohydrate having an uronic acid unit on one of the ends thereof. 10 to 100% of the... Agent: N.v. Nutricia

20110152167 - Biodegradable block polymers for drug delivery, and methods related thereto: A biodegradable block copolymer is disclosed, comprising a hydrophilic block derived from a polyether alcohol; and a hydrophobic block comprising a first repeat unit derived by ring opening polymerization of a first cyclic carbonyl monomer initiated by the polyether alcohol, the first repeat unit comprising a side chain moiety comprising... Agent:

20110152166 - Method of modulation of protein phosphorylation-dependent conformational transitions with low molecular weight compounds: The present patent application discloses a method of identifying or validating a compound that modulates the phosphorylation-dependent activity of a target protein or protein complex, where the target protein or protein complex activity is regulated by phosphorylation, as well as the use of identified compounds for the production of a... Agent:

20110152169 - Sparc anti-inflammatory activity and uses thereof: The invention provides methods of treating a mammal afflicted with an inflammatory disease, such as peritonitis, peritoneal adhesions or endometriosis, comprising the administration, intraperitoneal or otherwise, of a therapeutically effective amount of a SPARC polypeptide or a SPARC polypeptide-encoding isolated polynucleotide and a pharmacologic carrier.... Agent:

20110152170 - Use of procalcitonin (pct) in risk stratification and prognosis of patients with a primary, non-infectious disease: Subject of the present invention are assays and in vitro methods for the in vitro diagnosis, prognosis and risk stratification of a patient having a primary, non-infectious disease, whereby the level of Procalcitonin (PCT) in a sample of a body fluid of the patient is indicative for the risk of... Agent: B.r.a.h.m.s. Gmbh

20110152171 - Histamine binding protein: The invention relates to histamine binding proteins. The invention also relates to the use of such histamine binding proteins in the treatment and prevention of diseases.... Agent:

20110152174 - Inhibition of secretion from non-neuronal cells: The present invention relates to treatment of disease by inhibition of cellular secretory processes, to agents and compositions therefor, and to manufacture of those agents and compositions. The present invention relates particularly, to treatment of disease dependent upon the exocytotic activity of endocrine cells, exocrine cells, inflammatory cells, cells of... Agent: Syntaxin Limited

20110152172 - Methods of treating pulmonary diseases and disorders by modulating calcium/calmodulin dependent protein kinase ii activity: Disclosed are methods of treating or preventing a pulmonary disease or disorder in a subject, the methods comprising administering an effective amount of an compound that inhibits Calmodulin Kinase II (CaMKII) activity, either directly or indirectly, thereby treating or preventing the pulmonary disease or disorder in the subject.... Agent: University Of Iowa Research Foundation

20110152173 - Tnf-a antagonist multi-target binding proteins: This disclosure provides a multi-target fusion protein composed of a TNF-α antagonist domain and another binding domain antagonistic for a heterologous target, such as IL6, RANKL, IL7, IL17A/F, TWEAK, CSF2, IGF1, IGF2 or BLyS/APRIL, or agonistic for a heterologous target, such as IL10. The multi-specific fusion protein may also include... Agent: Emergent Product Development Seattle ,llc

20110152175 - Dendrimeric compounds comprising amino acids, hyperbranched core compound, process for preparation of dendrimeric compounds comprising amino acids and hyperbranched core compound, and use thereof: The invention provides dendrimeric compounds of the formula 1 comprising amino acids, wherein n is an integer of 1-4, T is an alkylidene —(CH2)2CONH(CH2)2- group, R2 is an —NH2 group or a moiety of a primary organic amine, and P is an amino acid and/or peptide moiety, wherein at least... Agent: Instytut Chemii Organicznej Polska Akademia Nauk

20110152176 - Agr-mediated inhibition and dispersal of biofilms: The present invention involves the use of activators of bacterial agr quoroum-sensing systems to block, inhibit or reverse biofilm formation. The biofilm may be located on an industrial or medical surface, or may be located in a subject, such as in a wound or infected organ, or on an in-dwelling... Agent: University Of Iowa Research Foundation

20110152177 - Functional feed composition: A feed composition comprising conventional feed ingredients, peptidoglycan and nucleotides is described. The feed composition can be used to prevent or reduce infectious diseases, and prevent symptoms related to an infectious disease in an animal. There is also provided a method for feeding of fish by providing this feed composition... Agent:

20110152178 - Prophylactic or therapeutic agent for influenza virus infection: (wherein R1 represents a linear or branched acyl group having 14 to 24 carbon atoms; R2 represents OH, NH2, NR3R4, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted aryloxy group, or a substituted or unsubstituted aralkyloxy group; and R3 and R4 independently represent a substituted or unsubstituted alkyl... Agent: Keio University

20110152179 - Method of treating hiv in drug resistant non plasma viral reservoirs with monomeric dapta: Residual HIV-1 replication reemerges after intensive therapy from location or locations in the body called the drug resistant non-plasma viral reservoir. Methods are disclosed of treating HIV by inhibiting or blocking this reemergence with various monomeric therapeutic peptide compositions including monomeric DAPTA prepared in least 80% trifluoroethanol, with vigorous shaking... Agent:

20110152180 - Bioactive pentapeptides from rice bran and use thereof: In general, the invention relates to novel bioactive pentapeptides from heat stabilized defatted rice bran having anti-cancer, anti-obesity, anti-Alzheimer and other health-promoting activities proteins. The bioactive pentapeptides can be incorporated into pharmaceutical, nutraceuticals and food compositions having at least the bioactive pentapeptide as an active ingredient.... Agent: Board Of Trustees Of The University Of Arkansas

20110152181 - Oxyntomodulin peptide analogue: The present invention provides Oxyntomodulin peptide analogues useful in the treatment of diabetes and/or obesity.... Agent: Eli Lilly And Company

20110152183 - Derivatised hybrid peptides of amylin and salmon calcitonin: Described are derivatives of hybrid peptides and pharmaceutical compositions comprising such, wherein said hybrid peptides comprise the C-terminal end of the human amylin peptide sequence, the middle portion of the salmon calcitonin peptide sequence and the N-terminal end of the human amylin peptide sequence, and wherein an albumin binding moiety... Agent: Novo Nordisk A/s

20110152182 - Oxyntomodulin peptide analogue: The present invention provides an Oxyntomodulin peptide analogue useful in the treatment of diabetes and/or obesity.... Agent: Eli Lilly And Company

20110152184 - Nutritional composition for improving muscle function and daily activity: (c) a lipid fraction comprising at least a ω-3 polyunsaturated fatty acid selected from the group of eicosapentaenoic acid, docosahexaenoic acid, eicosatetraenoic acid and docosapentaenoic acid for improving the muscle function in a mammal, for improving daily activity, for improving physical performance, for providing a better prognosis in terms of... Agent: N.v. Nutricia

20110152185 - Pharmaceutical compositions comprising glp-1 peptides or extendin-4 and a basal insulin peptide: Pharmaceutical composition for parenteral administration comprising a basal insulin peptide and an insulinotropic GLP-1 peptide comprising at least 6 zinc atoms per 6 insulin molecules.... Agent: Novo Nordisk A/s

20110152186 - Glucagon-like-peptide-2 (glp-2) analogues: GLP-2 analogues are disclosed which comprise one of more substitutions as compared to [hGly2]GLP-2 and which improved biological activity in vivo and/or improved chemical stability, e.g., as assessed in in vitro stability assays. More particularly, preferred GLP-2 analogues disclosed herein comprise substitutions at one or more of positions 8, 16,... Agent: Zealand Pharma A/s

20110152187 - Insulin-like growth factor fusion proteins: This disclosure relates to insulin-like growth factor fusion polypeptides; nucleic acid molecules encoding said polypeptides and methods of treatment that use said polypeptides.... Agent: Asterion Limited

20110152188 - Pharmaceutical compositions of igf/i proteins: The present invention relates to a pharmaceutical composition, comprising an Insulin-like growth factor I (IGF-I) protein as active pharmaceutical ingredient (API), a tonicity agent and a buffer. This composition may be administered as injection or infusion and is especially useful for the treatment, prevention and/or delay of progression of neurodegenerative... Agent:

20110152189 - Methods for the inhibition of scarring: The invention provides new methods of treatment using TGF-β3 to inhibit scarring in humans, and TGF-β3 for new uses in the inhibition of scarring in humans. In a first incidence of treatment each centimetre of wound margin, or each centimetre of a site at which a wound is to be... Agent: Renovo Limited

20110152190 - Erodible polymers for injection: A composition for administration of a beneficial agent, contains a solvent mixture including a hydrophobic solvent and a hydrophilic solvent; a bioerodible polymer; and a beneficial agent. The polymer and the beneficial agent are dissolved. The composition has a low viscosity, allowing for easy injection through standard hypodermic needles.... Agent:

20110152191 - Natriuretic polypeptides with unique pharmacologic profiles: This document provides natriuretic polypeptides. For example, this document provides polypeptides having a natriuretic activity. In some cases, a polypeptide provided herein can have natriuretic activities without inducing excessive hypotension. This document also provides methods and materials for inducing natriuretic activities within a mammal.... Agent: National Institutes Of Health (nih)

20110152192 - Compositions and methods for the treatment of angiogenesis-related eye diseases: The invention generally relates to compositions and methods of treatment and/or prevention of angiogenesis-related eye diseases using low doses of rhodostomin variants, and in particular, low doses of a fusion protein comprising a rhodostomin variant, wherein the rhodostomin variant is conjugated with a variant of Human Serum Albumin (HSA) where... Agent:

20110152193 - Inhibitors of human plasmin derived from the kunitz domains: This invention provides: novel proteins, which are homologous to the first Kunitz domain (K1) of lipoprotein-associated coagulation inhibitor (LACI), and which are capable of inhibiting plasmin; uses of such novel proteins in therapeutic, diagnostic, and clinical methods; and polynucleotides that encode such novel proteins.... Agent: Dyax Corp.

20110152194 - Chimeric natriuretic polypeptides and methods for inhibiting cardiac remodeling: Materials and methods related to chimeric polypeptides containing the amino acid sequence of CNP and the C-terminal sequence of DNP. The polypeptides are natriuretic and diuretic, GFR enhancing, cardiac unloading, renin inhibiting and less hypotensive when compared to BNP. The polypeptides also inhibit cardiac fibroblast proliferation.... Agent: Mayo Foundation For Medical Education And Research

20110152195 - Post irradiation shelf-stable dual paste direct injectable bone cement precursor systems and methods of making same: The present invention relates to a bone cement precursor system that is presented in the form of two shelf-stable pastes which have been terminally sterilized and are held in separate containers during product transport and storage. When the product is used during surgery, these pastes inject to a site of... Agent: Howmedica Osteonics Corp.

20110152196 - Isolated extracellular matrix material including subserous fascia: Described are purified extracellular matrix materials isolated from the abdominal wall of animals and including the subserous fascia layer of the abdominal wall. Such medical materials can find use in treating damaged tissue and in certain aspects in providing tissue support for the repair of hernias. Related methods of manufacture... Agent:

20110152197 - Analgesic effects of peptide toxin apetx2: The invention relates to the use of the peptide toxin APETx2 that blocks the ASIC3 cationic channels and that is derived from the Anthopleura elegantissima sea anemone, and to the use of the analogs and derivatives thereof as a drug, particularly as an analgesic pain associated with the activation of... Agent: Universite Nice Sophia Antipolis

20110152198 - Pharmaceutical compositions containing botulinum toxin: This invention relates to the use of a composition comprising a polysaccharide and a botulinum toxin for reducing a skin wrinkle. In some embodiments, the polysaccharide comprises disaccharides. In some embodiments, the average molecular weight of a disaccharide unit of the polysaccharide is between about 345 D and about 1,000... Agent: Allergan, Inc.

20110152199 - Cdca1 peptide and pharmaceutical agent comprising the same: i

20110152200 - Methods and compositions for inhibition of bcl6 repression: The invention is directed to a compound that binds to a BCL6 lateral groove and prevents binding of a corepressor to the lateral groove. The present invention is further directed to methods for blocking corepressor binding to a BCL6 lateral groove, methods for inhibiting BCL6 repression in a mammalian cell,... Agent:

20110152201 - Emulsion preconcentrates containing cyclosporin or a macrolide: This invention provides an emulsion, e.g., microemulsion, pre-concentrate comprising a difficultly soluble active agent and a carrier medium. The active agent may, e.g., be a cyclosporin or a macrolide.... Agent:

20110152202 - Development of c-reactive protein mutant with improved therapeutic benefit in immune thrombocytopenia and lupus nephritis: The present invention relates to the use of a mutant CRP molecule in which tyrosine 175 is replaced by leucine (Y175L CRP) or the leucine 176 is replaced by glutamic acid (L176E CRP) for the treatment of various disease states and conditions associated with SLE, including lupus of the skin... Agent:

20110152203 - Transfection agent: A transfection agent is provided that has lower toxicity and can be applied in the clinical setting. The transfection agent comprises a peptide surfactant.... Agent:

20110152204 - Treatment of obesity or diabetes with bile acid sequestrants: Provided herein are methods of treating obesity and diabetes with labile bile acid sequestrants. An effective amount of a labile bile acid sequestrant may be orally administered to an obese or diabetic individual. A labile bile acid sequestrant provided herein may have a low affinity in the colon or rectum... Agent: Satiogen Pharmaceuticals, Inc.

20110152205 - Application of puerarin in the preparation of p2x3 mediated drugs for pain/nervous system diseases: The invention relates to the new usage of puerarin in the field of pharmaceutical products, in other words, it relates to the application of puerarin in the preparation of drugs for P2X3 mediated pain/nervous system diseases. The experiment shows that puerarin can inhibit pain-related behavioral responses, subsequently immunohistochemical analysis, in... Agent: Nanchang University

20110152206 - Therapeutic combinations for use in neoplasia: The invention features compositions and methods that are useful for the treatment of neoplasia (e.g., breast cancer) by increasing DNA damage and reducing base excision repair (BER).... Agent: University Of Florida Research Foundation, Inc.

20110152207 - Use of vitamin d glycosides and sulfates for treatment of disease: Disclosed are methods of treating vitamin D-sensitive diseases without inducing severe forms of hypercalcemia. The methods comprise administering biologically inert vitamin D prodrugs. The vitamin D prodrugs have a vitamin D-drug moiety and a pro moiety, wherein the pro moiety is selected from the group consisting of a glycone moiety... Agent:

20110152209 - Core 2 glcnac-t inhibitors: The present invention relates to the use of known and novel compounds as inhibitors of UDP-GlcNAc:Galβ1,3GalNAc-R (GlcNAc to GalNAc) β1,6-N-acetylglucosaminyl transferase (core 2 β1,6 N-acetylaminotransferase, core 2 GlcNAc-T-EC 2.4.1.102). Such inhibitors have applications in therapy for diseases associated with raised activity of core 2 GlcNAc-T, in particular inflammatory diseases, atherosclerosis,... Agent: Btg International Limited

20110152208 - Use of compounds extracted from momordica charantia l. in the manufacture of medicaments for prevention and treatment of diabetes and obesity: The present invention disclosed a medical use of cucurbitane triterpenoids represented by the following formula and isolated from Momordica charantia L. of Cucurbitaceae family in the preparation of medications for prevention and treatment of diabetes and obesity. The above cucurbitane triterpenoids may be acted as a glucose uptake stimulator, an... Agent: The Garvan Institute Of Medical Research, Australia

20110152210 - Polyphenol compounds for inhibiting proteasome and uses thereof: Synthetic polyphenolic compounds of formula (I), their modes of synthesis, and pharmaceutical compositions thereof are provided herein. Use of the compounds and compositions described herein for inhibiting proteasomal activity and for treating cancer is also provided.... Agent: Wayne State University

20110152211 - Methods and formulations for reducing amphotericin b treatment side effects: A method of ameliorating amphotericin treatment side effects in a mammal that comprises administering a therapeutically effective amount of a formulation that comprises a polyene active ingredient that includes amphotericin B, wherein the amphotericin B compound is present, in terms of polyene content, in an amount greater than 90%, and... Agent: University Of Mississippi

20110152212 - Aqueous formulations: A method of preparing an aqueous formulation of an active material and such a formulation per se are described, wherein the active material has a very low solubility in water. The method may involve contacting active material in solid form with an optionally cross-linked water soluble polymer. The water soluble... Agent:

20110152354 - Bispecific oligonucleotide for the treatment of cns malignancies: CNS malignancy is treated in a subject suffering from a CNS malignancy by administering to the subject an antisense oligonucleotide having a sequence of bases that is complementary to portions of both the gene encoding IGFBP-2 and the gene encoding IGFBP-5, and which is of sufficient length to act as... Agent: The University Of British Columbia

20110152358 - Compositions and methods for diagnosis and treatment of pancreatic ductal cancer: The present invention includes compositions and methods for diagnosing and treating pancreatic cancer. These compositions and methods are based on the finding that 14-3-3σ protein is secreted from pancreatic cancer cells and is therefore a specific biomarker protein.... Agent:

20110152349 - Compositions and methods for inhibiting expression of il-18 genes: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a IL-18 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA or nucleic acid molecules or vectors encoding the same together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the... Agent:

20110152350 - Compositions and methods for inhibiting expression of xbp-1 gene: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting X-Box Protein 1 (XBP-1), and methods of using the dsRNA to inhibit expression of XBP-1.... Agent:

20110152353 - Double-stranded polynucleotide: It is intended to provide a double-stranded polynucleotide that is resistant to RNase and has RNA interference effect, etc. The present invention provides a double-stranded polynucleotide comprising sense and antisense strands comprising polynucleotides comprising a nucleotide unit of DNAs and 2′-O-methyl RNAs alternately combined.... Agent: Daiichi Sankyo Company, Limited

20110152345 - Ebi3, dlx5, nptx1 and cdkn3 for target genes of lung cancer therapy and diagnosis: The present invention relates to methods for treating or preventing lung cancer by administering a double-stranded molecule against one or more of EBI3, DLX5, NPTX1, CDKN3 or EF-I delta genes or compositions, vectors or cells containing such a double-stranded molecule. The present invention also features methods for diagnosing lung cancer,... Agent: Oncotherapy Science, Inc.

20110152344 - Inhibition of filovirus entry into cells and uses thereof: The present invention discloses method to treat infections caused by filovirus. Such a method comprises blocking the PI3 kinase pathway or the calcium-associated pathway at the gene or protein level. Also disclosed herein are the compounds useful in the treatment of filoviral infection.... Agent:

20110152355 - Method for predicting and detecting tumor metastasis: The invention provides a method of determining the prognosis of cancer in a subject. The method comprises (a) obtaining a sample from the subject, (b) analyzing the sample for the expression level of a carboxypeptidase E (CPE) splice variant, and (c) correlating the expression level in the sample with the... Agent: Human Services

20110152347 - Methods and compositions for controlling efficacy of rna silencing: Based at least in part on an understanding of the mechanisms by which small RNAs (e.g., naturally-occurring miRNAs) mediate RNA silencing in plants, rules have been established for determining, for example, the degree of complementarity required between an RNAi-mediating agent and its target, i.e., whether mismatches are tolerated, the number... Agent: University Of Massachusetts

20110152348 - Methods for treating androgen receptor dependent disorders including cancers: The invention provides the combination use of antisense oligomers targeting androgen receptor mRNA and androgen receptor binding inhibitors that reduce androgen receptor activity for the treatment of androgen receptor related medical disorders, such as cancers, particularly prostate cancers and breast cancers.... Agent: Enzon Pharmaceuticals, Inc.

20110152357 - Micro-rna-based compositions and methods for the diagnosis, prognosis and treatment of multiple myeloma: Methods for assessing a pathological condition in a subject includes measuring an expression profile of one or more markers where a difference is indicative of multiple myeloma (MM) or a predisposition to MM. The present invention provides novel methods and compositions for the diagnosis, prognosis and treatment of MM. The... Agent: The Ohio State University

20110152351 - Modulation of smrt expression: Disclosed herein are compounds and methods for decreasing SMRT and treating metabolic and/or cardiovascular diseases in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to SMRT include obesity, diabetes, dyslipidemia, and hypothyroidism.... Agent: Isis Pharmaceuticals, Inc.

20110152356 - Novel rnai therapeutic for treatment of hepatitis c infection: Small interfering RNAs (siRNAs) or small hairpin RNA (shRNAs) and compositions comprising same are provided that specifically target human cyclophilin A (CyPA) to effectively inhibit Hepatitis C(HCV) infection in a cell. Such siRNA and shRNAs may have a length of from about 19 to about 29 contiguous nucleotides corresponding to... Agent: Florida State University Research Foundation

20110152352 - Smad proteins control drosha-mediated mirna maturation: The invention, in some aspects, relates to compositions and methods useful for modulating expression of miRNAs that are regulated by the TGF-β/BMP signaling pathway. In some aspects, the invention relates, to oligonucleotides comprising a CAGRN-motif that modulate expression of miRNAs that are regulated by TGF-β/BMP signaling pathway. The invention, in... Agent: Tufts University

20110152346 - Use of oligonucleotides with modified bases in hybridization of nucleic acids: The invention is concerned with the use of oligonucleotide analogs that contain specifically modified DNA bases to be used in hybridization of nucleic acids, polymerase chain reaction (PCR) and siRNA-mediated gene silencing (RNAi).... Agent: Baltic Technology Development Ltd.

20110152359 - Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising threreof: Provided are soluble neutral active Hyaluronidase Glycoproteins (sHASEGP's), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active... Agent:

20110152213 - Riboswitches, methods for their use, and compositions for use with riboswitches: It has been discovered that certain natural mRNAs serve as metabolite-sensitive genetic switches wherein the RNA directly binds a small organic molecule. This binding process changes the conformation of the mRNA, which causes a change in gene expression by a variety of different mechanisms. Modified versions of these natural “riboswitches”... Agent: Yale University

20110152215 - Riboswitches, methods for their use, and compositions for use with riboswitches: It has been discovered that certain natural mRNAs serve as metabolite-sensitive genetic switches wherein the RNA directly binds a small organic molecule. This binding process changes the conformation of the mRNA, which causes a change in gene expression by a variety of different mechanisms. Modified versions of these natural “riboswitches”... Agent: Yale University

20110152214 - Silk polymer-based adenosine release: therapeutic potential for epilepsy: This invention relates to sustained release formulations comprising silk fibroin biopolymer and adenosine, that provide for sustained, focal release of adenosine at therapeutic levels for the treatment of epilepsy and/or the prevention of epileptogenesis. An embodiment provides for a silk-based, adeno sine-releasing implant that alleviates seizures or prevents epileptogenesis. Another... Agent: Trustees Of Tufts College

20110152216 - Anaesthetic composition: A stable anaesthetic composition is described which is particularly suitable for use in cats and dogs. The composition comprises an aqueous solution of an anaesthetically effective amount of a water soluble cyclodextrin or a cyclodextrin derivative complex of alfaxalone and a buffer, excluding phosphate buffer pH 7.0, 0.1M mixed as... Agent: Jurox Pty. Ltd.

20110152217 - Polymorphs of (s)-3-aminomethyl-7-(3-hydroxy-propoxy)-3h-benzo[c][1,2]oxaborol-1-ol: This invention provides, among other things, polymorphs of the hydrochloride salt of (S)-3-aminomethyl-7-(3-hydroxy-propoxy)-3H-benzo[c][1,2]oxaborol-1-ol.... Agent: Glaxosmithkline LLC

20110152218 - Crystalline phospholipid, method for its production and use in treating damaged tissue: The present invention provides phospholipid in a crystalline form, a method for its preparation, compositions comprising it and its use in the treatment of damaged tissue.... Agent:

20110152219 - Use of enhancers, possibly associated to riboflavin, as well as corresponding ophthalmic compositions for corneal cross-linking in the treatment of the keratoconus or of other corneal ectasic disorders: The use of enhancers with possibly riboflavin, as well as the corresponding compositions for the treatment of keratoconus or other ectasic corneal disorders by the method of corneal cross-linking.... Agent: Sooft Italia Spa

20110152220 - Methods of diagnosing, preventing and treating bone mass diseases: The present invention provides methods and therapeutic agents for lowering or increasing serum serotonin levels in a patient in order to increase or decrease bone mass, respectively. In preferred embodiments, the patient is known to have, or to be at risk for, a low bone mass disease such as osteoporosis... Agent:

20110152221 - Pak1 agonists and methods of use: The present invention is directed to Pak1 agonists and methods of use.... Agent: The Board Of Trustees Of The University Of Illinois

20110152223 - Therapeutic agent for anca-related vasculitis: Disclosed is an agent for preventing/treating ANCA-related vasculitis and/or preventing the recurrence of ANCA-related vasculitis. Also disclosed is a therapeutic method using the agent. Specifically disclosed is a pharmaceutical composition comprising at least one member selected from the group consisting of eicosapentaenoic acid, a pharmaceutically acceptable salt thereof and an... Agent:

20110152222 - Use of 2,5-dihydroxybenzene derivatives for the treatment of arthritis and pain: The present invention relates to the use of a compound of Formula (I′″) or pharmaceutically acceptable salt or solvate, isomer or prodrug thereof in the manufacturing of a medicament for the treatment and/or prophylaxis of arthritis and pain.... Agent:

20110152224 - Myeloperoxidase, a risk indicator for cardiovascular disease: Diagnostic tests for characterizing an individual's risk of developing or having a cardiovascular disease. In one embodiment the present diagnostic test comprises determining the level of myeloperoxidase (MPO) activity in a bodily sample obtained from the individual or test subject. In another embodiment, the diagnostic test comprises determining the level... Agent: The Cleveland Clinic Foundation

20110152225 - Ppar-gamma agonists for the induction of cationic antimicrobial peptide expression as immunoprotective stimulants: Rosiglitazone, 5-ASA or structurally analogous Compounds according to the general formula (I): or Compounds according to the general formula (Ia): For the induction of CAMP expression in tissues having PPAR-gamma receptors. Such tissues include epithelia or mucosae tissue having PPAR-gamma receptors and of particular interest is CAMP expression in the... Agent:

20110152227 - Deuterium labelled derivatives of 3-(2-hydroxy-5-methyphenyl)-n,n-diisopropyl-3-phenylpropylamine and methods of use thereof: This invention relates to novel derivatives of tolterodine, 5-hydroxymethyl tolterodine, fesoterodine and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by muscarinic receptor antagonists.... Agent: Concert Pharmaceuticals Inc.

20110152226 - Development of new selective estrogen receptor modulators: The present disclosure concerns a new class of selective estrogen receptor modulators (SERMs). The disclosure also includes the identification of a previously unknown membrane associated estrogen receptor. Methods for making and using the disclosed SERMs are disclosed, including pharmaceutical formulations of the disclosed novel compounds in useful compositions.... Agent: The Regents Of The University Of California

20110152228 - Sprayable pharmaceutical compositions comprising a corticoid and an oily phase: Anhydrous sprayable pharamecutical/dermatological compositions containing, as active pharmaceutical agent, a corticoid, preferably clobetasol propionate, and an oily phase, are formulated in a physiologically acceptable medium, and are useful for the treatment of a variety of conditions and afflictions, notably psoriasis.... Agent: Galderma, S.a.

20110152229 - Betulinic acid derivatives as anti-hiv agents: h

20110152230 - Photoactive metal nitrosyls for blood pressure regulation and cancer therapy: Disclosed are nitric oxide delivery agents and methods of their use, more specifically to photoactive compounds, which are able to perform targeted delivery of nitric oxide in vitro and in vivo and are useful for medicinal applications including, but not limited, to blood pressure regulation and cancer treatment.... Agent: The Regent Of The University Of California

20110152231 - Methylsulfonylmethane (msm) for treatment of drug resistant microorganisms: Embodiments of the invention relate generally to the use of compositions comprising methylsulfonylmethane (MSM), and one or more therapeutic agents, for the treatment of drug-sensitive and drug resistant microorganisms. In several embodiments, such compositions are effective in treating drug resistant infectious diseases, for example, MRSA.... Agent:

20110152233 - Pyrrolidine compounds: b

20110152239 - 10a-azalide compound having 4-membered ring structure: The present invention relates to a process for preparing compositions of high concentrations of omega-3 fatty acids from krill. Furthermore, the invention relates to a composition comprising high concentrations of omega-3 fatty acids, and a lipid fraction from krill comprising high amounts of the fatty acids with chain length C14... Agent: Meiji Seika Kaisha, Ltd.

20110152237 - Chemical compounds: Disclosed are compounds of Formula III. Also disclosed are salts of the compounds, pharmaceutical composition comprising the compounds or salts, and methods for treating HCV infection by administration of the compounds or salts.... Agent:

20110152238 - Pharmaceutical compounds: s

20110152241 - Novel compounds as receptor modulators with therapeutic utility: The present invention relates to novel cyclic amine and cycloalkyl derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.... Agent: Allergan, Inc.

20110152240 - Pyrazolopyrimidines and related heterocycles as ck2 inhibitors: The invention provides compounds that inhibit protein kinase CK2 activity (CK2 activity), and compositions containing such compounds. These compounds and compositions are useful for treating proliferative disorders such as cancer, as well as other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and have the following general formula:... Agent: Cylene Pharmaceuticals, Inc.

20110152235 - Aminopyrimidine kinase inhibitors: Disclosed are compounds, pharmaceutical compositions containing those compounds, and uses of the compounds and compositions as modulators of casein kinase 1 (e.g., CK1γ), casein kinase 2 (CK2), Pim 1, Pim2, Pim3, the TGFβ pathway, the Wnt pathway, the JAK/STAT pathway, and/or the mTOR pathway. Uses are also disclosed for the... Agent: Jasco Pharmaceuticals, LLC

20110152236 - Azetidine polysubstituted compounds, preparation thereof, and therapeutic application thereof: The invention relates to compounds of the formula (I) where: R is a (C1-C6)alkyl group, a halo(C1-C6)alkyl group; R1 is a hydrogen atom; R2 is a heteroaromatic group or a heteroaromatic(C1-C4)alkyl group, said groups being optionally substituted; R3 and R4 represent independently from each other an optionally substituted phenyl group;... Agent: Sanofi-aventis

20110152234 - Novel compounds: The invention relates to thiophene carboxamides of formula (I), wherein A, R1, R2, R3, n and X are as defined in the specification, processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy.... Agent:

20110152232 - Sulfonamide compounds and uses thereof: Compounds that modulate GHS-R are described, for examples compounds formula (I)... Agent:

20110152242 - 2,3-substituted fused pyrimidin -4 (3h)-ones as vr1 antagonists: A compound of formula (I), wherein W is formula (1); A is a benzene ring, a fÊve-membered heteroaromatic ring containing 1, 2 or 3 heteroatoms independently chosen from O, N and S, providing that no more than one O or S atom is present, or a six-membered heteroaromatic ring containing... Agent:

20110152243 - Novel thienopyrrole compounds: c

20110152244 - Pyrrolopyrimidine compounds and their uses: The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity... Agent: Astex Therapeutics Ltd.

20110152245 - Substituted benzamides: Compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds can be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease,... Agent:

20110152246 - Novel inhibitors of hepatitis c virus replication: The embodiments provide compounds of the general Formulae I, II, III, IV, or V as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving... Agent: Intermune, Inc.

20110152247 - Benzoxazepine compounds, their preparation and use: wherein R1 and R2 are as defined in the specification; or a stereoisomer, a geometric isomer, a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate, or a polymorph thereof; a process for its preparation; and a pharmaceutical composition including an effective amount of the compound. The compounds are useful in the... Agent:

20110152248 - Bridgehead amine ring-fused indoles and indolines: e

20110152249 - Evaluating central nervous system: Evaluating hemodynamic parameters in the cortex can be used as an objective test for CNS activity, e.g., pain.... Agent: The Brigham And Women's Hospital, Inc.

20110152250 - Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor and uses thereof: a

20110152251 - Compounds for modulating tlr2: The present invention is directed to methods, kits, and uses of inhibitors of LCMV mediated NF-κB activation to treat viral infections and inflammatory conditions.... Agent: University Of Massachusetts

20110152252 - Shiga toxin b-subunit/chemotherapeutics conjugates: The present invention relates to the use of a Shiga toxin B-subunit moiety as carrier for therapeutic agents, for example, anti-cancer agents such as anti-cancer agents that require intracellular uptake to exert their anti-cancer effects. In particular, the present invention provides conjugates comprising a Shiga toxin moiety covalently linked to... Agent: Centre National De La Recherche Scientifique (cnrs)

20110152253 - Spiroaminodihydrothiazine derivatives: A compound represented by the general formula (I): or a pharmaceutically acceptable salt thereof, has an Aβ production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by Aβ and typified by Alzheimer-type dementia.... Agent: Eisai R&d Management Co., Ltd

20110152254 - Sirtuin modulating compounds: Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases,... Agent: Sirtris Pharmaceuticals, Inc.

20110152255 - Therapeutic compounds: Compounds comprising formula (I) or a pharmaceutically acceptable salt thereof, are disclosed, wherein J, B, Y, and A are as described in claims 1-13. Methods, compositions, and medicaments related thereto are also disclosed, for treating baldness, glaucoma or inflammatory bowel diseases.... Agent:

20110152256 - 1,2,4-triazolo[4,3-c]pyrimidin-3-one and pyrazolo[4,3-e]-1,2,4-triazolo[4,3-c]pyrimidin-3-one compounds for use as adenosine a2a receptor antagonists: Compounds of the Formula I wherein R1 and R2 together with the carbon atoms to which they are bonded optionally form a further heteroaromatic ring of the formula (II) as well as pharmaceutically acceptable salts, solvates, esters and prodrugs thereof are adenosine A2a receptor antagonists and, therefore, are useful in... Agent:

20110152257 - Ethynyl compounds useful for treatment of cns disorders: or to a pharmaceutically acceptable salt or acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof. Compounds of formula I are positive allosteric modulators (PAM) of the metabotropic glutamate receptor subtype 5 (mGluR5) and they are therefore useful for the treatment... Agent:

20110152258 - Compounds and methods for kinase modulation, and indications therefor: Compounds and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof are active on at least one Raf protein kinase. In certain aspects and embodiments,... Agent:

20110152259 - Nitrogen-containing heterocyclic compounds and methods of use thereof: m

20110152260 - Indazole derivatives as modulators of interleukin-1 receptor-associated kinase: The present invention relates to modulators of IRAK kinases of formula (I) and provides compositions comprising such modulators, as well as methods therewith for treating IRAK-mediated or IRAK-associated conditions or diseases.... Agent: Biogen Idec Ma Inc.

20110152261 - Organic compounds: There are described cyclohexyl amide derivatives useful as corticotropin releasing (CRF1) receptor antagonists.... Agent:

20110152262 - Novel compounds: wherein R1 is 2-indanyl, R2 is 1-methylpropyl, R3 is a group selected from 2,6-dimethyl-3-pyridyl or 4,6-dimethyl-3-pyridyl, R4 represents methyl and R5 represents hydrogen or methyl or, R4 and R5 together with the nitrogen atom to which they are attached represent morpholino and pharmaceutically acceptable derivatives thereof are described, as are... Agent: Glaxo Group Limited

20110152263 - Composition and method for inhibiting norovirus infection: A composition for use in inhibiting the binding of a Norovirus to the histo-blood group antigen on the surface of epithelia. The composition contains a therapeutically effective amount of a binding-inhibiting compound selected from Compounds 1 through 15, and at least one diluent, carrier or excipient. The Compounds competitively bind... Agent:

20110152264 - Method and composition for treating ocular hypertension and glaucoma: The present invention relates to an ophthalmic aqueous composition containing PGF2α analogues for treating ocular hypertension and glaucoma, to a method for treating ocular hypertension and glaucoma by administering said composition to a subject in need of such treatment, and to a method for increasing aqueous solubility and stability of... Agent: Asahi Glass Co., Ltd.

20110152265 - Carboxamide compounds and their use as calpain inhibitors v: in which R1, R2, R3 R4, R5, m and n have the meanings mentioned in the claims and the description, the tautomers thereof, the hydrates thereof and the pharmaceutically suitable salts thereof. Of these compounds those are preferred wherein R1 is optionally substituted phenyl-C1-C2-alkyl or hetaryl-C1-C2-alkyl, R2 is optionally substituted... Agent: Abbott Laboratories

20110152266 - Co-crystal compound of rivaroxaban and malonic acid: The present invention relates to a novel cocrystal compound of 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide (rivaroxaban) and malonic acid, to processes for its preparation, to medicaments comprising this compound and to their use for controlling diseases.... Agent: Bayer Schering Pharma Ag

20110152267 - Compositions and methods for treating hyperproliferative disorders: A method of treating a hyperproliferative disorder in a subject in need of such treatment, comprising administering to said subject, in combination, a treatment effective amount of: (a) a ceramide-increasing retinoid such as fenretinide or a pharmaceutically acceptable salt thereof; and (b) at least one (and in certain embodiments at... Agent: Texas Tech University System

20110152268 - Novel pharmaceutical composition for treating nociceptive pain: The present invention relates to a pharmaceutical composition for treating nociceptive pain, containing a morpholine derivative or a pharmaceutically acceptable salt thereof, as an active ingredient. The present invention is useful in providing an excellent pharmaceutical composition for treating nociceptive pain. In addition, the present invention is particularly useful in... Agent: Astellas Pharma Inc.

20110152269 - Process for treating animal habitats: This invention deals with a process for treating and sanitizing animal habitats. In addition to sanitizing the habitat the production of ammonia and odor from fecal matter and urine is inhibited or terminated. In the process an animal habitat is cleaned and subsequently treated with trichloromelamine (TCM). The TCM may... Agent: H&s Chemical Company, Inc.

20110152275 - Agent for maintenance of induced remission: Disclosed is a method for maintaining induced remission of an immune disease, which can alleviate or reduce any serious side effect and the burdens exerted on a patient suffering from the same. The method comprises carrying out the remission induction for an immune disease by the use of a biological... Agent:

20110152271 - Compositions and methods for ophthalmic delivery of nasal decongestants: The invention provides compositions and methods for treating nasal congestion through ophthalmic delivery. The provided compositions and methods utilize low concentrations of selective α-2 adrenergic receptor agonists. The compositions preferably include brimonidine.... Agent:

20110152273 - Fused heteroaromatic pyrrolidinones: and pharmaceutically acceptable salts thereof, wherein G, L1, L2, R1, R2, R3, and R4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, pharmaceutical compositions containing them, and their use for treating disorders, diseases, and conditions involving the immune system... Agent: Takeda Pharmaceutical Company Limited

20110152277 - Heterocyclic compounds and their uses: Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE),... Agent:

20110152279 - Macrocyclic indole derivatives useful as hepatitis c virus inhibitors: Inhibitors of HCV replication of formula (I) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein Y, R1, R2, R4 and n have the meaning defined in the claims. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use in HCV... Agent: Tibotec Pharmaceuticals

20110152274 - Preparations and methods for ameliorating or reducing presbyopia: This application relates to the use of one or more parasympathomimetic drugs in combination with one or more alpha agonists to create optically beneficial miosis to, for example, temporarily treat presbyopia. The invention provides a pharmaceutical preparation comprising a therapeutically effective amount of one or more parasympathomimetic drugs or cholinesterase... Agent:

20110152276 - Substituted pyrrolo[2,3-d]pyrimidines as antifolates: R4, R5, R6, R7, R8, and R9 independently are H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, acyl, —C(O)-alkyl, —C(O)-alkenyl, or —C(O)-alkynyl; as well as pharmaceutically acceptable esters, amides, salts, solvates, and prodrugs thereof. The compounds are useful in pharmaceutical compositions and in methods of treating multiple conditions,... Agent: Chelsea Thereapeutics, Inc.

20110152270 - Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts: Crystalline salts of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine, compositions thereof, methods for their preparation, and methods for their use are disclosed.... Agent: Metabolex, Inc.

20110152278 - Synthesis and anti-proliferative effect of benzimidazole derivatives: This invention provides for compounds, compositions, and methods that involve anti-proliferative and anti-neoplastic activity in cancer cells. In particular, a series of benzimidazole, purine, imidazopyridine, and imidazopyrizine compounds having selected substitution patterns are disclosed, and the activity of various subject compounds is demonstrated.... Agent: Spelman College

20110152272 - Treatment of incontinence: The present invention relates to the use of agonists of 5-HT2C receptors for the treatment of urinary incontinence, preferably mixed incontinence or stress urinary incontinence. The invention also relates to the use of antagonists of 5-HT2C receptors for the treatment of urine retention. The present invention also relates to a... Agent: Pfizer Inc

20110152280 - Novel ergoline analogs: Provided herein are novel ergoline derivatives and pharmaceutical compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing... Agent: Map Pharmaceuticals, Inc.

20110152281 - Compounds and method for treatment of cancer: The invention relates to a compound of Formula (I) and/or a pharmaceutically-acceptable salt, hydrate, solvate, tautomer, optical isomer, E-isomer, Z-isomer, or combination thereof, wherein X is selected from S or O; R5 is selected from a substituted or unsubstituted aromatic group, a substituted or unsubstituted heteroaromatic group, or (Formula II)... Agent: Critical Outcome Technologies, Inc.

20110152282 - Hedgehog pathway modulators: The invention provides a method, compounds and compositions for modulating the activity of the hedgehog signaling pathway. In particular, the invention provides a method for inhibiting aberrant growth states resulting from phenotypes such as Ptc loss-of-function, hedgehog gain-of-function, smoothened gain-of-function or GIi gain-of-function, comprising contacting a cell with a sufficient... Agent: Irm LLC

20110152283 - Crystalline pimobendan, process for the preparation thereof, pharmaceutical composition and use: The invention relates to a pharmaceutical composition containing pimobendan as an active ingredient. The invention also relates to a crystalline form of pimobendan, as well as to a combination of said crystalline form with at least one other therapeutically active ingredient. Moreover, the invention relates to uses of said crystalline... Agent: Eurovet Animal Health B.v.

20110152284 - Sigma ligands for neuronal regeneration and functional recovery: The invention discloses methods and compositions useful for facilitating neuronal regeneration and functional recovery in neurodegenerative diseases. The methods and compositions utilize ligands for the sigma receptor, wherein the ligand is preferable AGY-94806, or salts or solvates thereof. These molecules can be delivered alone or in combination with agents which... Agent:

20110152285 - Pyrrole antifungal agents: The invention provides compounds of formula (I), and pharmaceutically and agriculturally acceptable salts thereof; wherein: R1, R2, R3, R4, R5, R6, A1, L1 and n are as defined herein. These compounds and their pharmaceutically acceptable salts are useful in prevention or treatment of a fungal disease. Compounds of formula (I),... Agent:

20110152286 - Piperazine-substituted benzothiophenes for treatment of mental disorders: The present invention provides a heterocyclic compound represented by the general formula (1): The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety.... Agent: Otsuka Pharmaceutical Co., Ltd.

20110152287 - Substituted benzothiazole and benzoxazole derivatives useful as inhibitors of dpp-1: The present invention is directed to substituted benzothiazole and benzoxazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by DPP-1.... Agent:

20110152288 - Methods of treating vasomotor symptoms: The present invention relates to methods for treating, preventing or controlling vasomotor symptoms such as hot flashes comprising administering specific norepinephrine/serotonin reuptake inhibitors.... Agent:

20110152289 - Dimeric derivatives of artemisinin and application in anti-cancer therapy: The present invention relates to dimeric derivatives of 10-trifluoromethylated artemisinin of formula (I) below: Formula (I) and the pharmaceutically acceptable salts thereof, and also to the preparation method thereof and to the uses thereof, especially in the treatment of cancer.... Agent: Universite Paris-sud

20110152290 - Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals: wherein A, Y, Z, R3 to R6, R20 to R22 and R50 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. Specifically, they are inhibitors of the endothelial differentiation gene receptor 2 (Edg-2, EDG2), which is activated by lysophosphatidic acid (LPA) and is also termed as... Agent: Sanofi-aventis

20110152291 - Novel aromatic compounds and their use in medical applications: Pharmaceutical compositions comprising at least one compound of the formulas (Ia) or (Ib) and a pharmaceutically acceptable carrier wherein the symbols have the following meaning —X- is e.g. and Y being e.g. or the pharmaceutically acceptable salts can be applied to modulate the in-vitro and in-vivo binding processes mediated by... Agent: Revotar Biopharmaceuticals Ag

20110152293 - Arylvinylazacycloalkane compounds and methods of preparation and use thereof: Novel vinylazacycloalkane compounds of Formula (I) are disclosed. The compounds are ligands of various nAChRs. The compounds and their pharmaceutically acceptable salts can be used to prepare pharmaceutical compositions and/or medicaments intended to prevent or treat disorders associated with dysfunction of nAChRs, especially within the central nervous system or the... Agent: Targacept, Inc.

20110152295 - Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase: Heteroaromatic compounds of structural formula I are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, such as atherosclerosis;... Agent:

20110152292 - Salts comprising a pyrimidinecarboxylic acid derivative for cosmetic use: The invention relates to novel compounds which comprise, as cationic or as anionic component, a pyrimidinecarboxylic acid derivative, in particular a derivative of ectoin or hydroxyectoin, to a process for the preparation thereof, and to the use thereof as ionic liquid or to the use thereof in pharmaceutical, cosmetic and... Agent: Merck Patent Gesellschaft

20110152294 - Use of osmolytes obtained from extremophilic bacteria for the production of inhalable medicaments for the prophylaxis and treatment of pulmonary and cardiovascular diseases and an inhalation device comprising osmolyte as active agent component: e

20110152296 - Heterocyclic compounds and their uses: Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE),... Agent: Amgen Inc.

20110152297 - Quinazoline derivatives as tyrosine kinase inhibitors: wherein each of R1, R2, R3, R4 and m are as defined in the description; processes for their preparation; pharmaceutical compositions containing them and their use in the manufacture of a medicament for providing an anti-proliferative effect. The quinazoline derivatives of Formula I are expected to be useful in the... Agent: Astra Zeneca Ab Corporation

20110152298 - Imidazo [2,1-b] quinazolin-2-one derivatives and their use as platelet anti-aggregative agents: This invention relates to the discovery of substituted analogues of the selective platelet lowering agent anagrelide with reduced potential for cardiovascular side-effects which should lead to improved patient compliance and safety in the treatment of myeloproliferative diseases. More specifically, the present invention relates to certain imidazoquinazoline derivatives which have the... Agent: Shire LLC

20110152299 - Substituted benzamide analogs as mglur5 negative allosteric modulators and methods of making and using the same: Disclosed are negative allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for... Agent:

20110152300 - 2-aldoximino-5-fluoropyrimidine derivatives: This present disclosure is related to the field of 2-aldoximino-5-fluoropyrimidines and their derivatives and to the use of these compounds as fungicides.... Agent: Dow Agrosciences LLC

20110152301 - Compounds that inhibit hiv particle formation: The present invention describes novel methods of identifying compounds which inhibit HIV particle formation and Rev-dependent HIV production. The present invention also provides methods and compounds for inhibiting HIV particle formation and or treating patients infected with HIV.... Agent: University Of Virginia Patent Foundation

20110152303 - Chemical compounds: Novel diarylpyrimidine derivatives and pharmaceutically acceptable salts, solvates or hydrates thereof, designed to inhibit HIV reverse transcriptase, are provided, and a pharmaceutical composition containing the same, especially an anti-HIV agent. More specifically, novel diarylpyrimidine derivatives that are derivatives of the HIV reverse transcriptase inhibitor TMC278 of formula (1a) are provided,... Agent: Glaxosmithkline LLC

20110152302 - Novel dicyclanil-based shelf stable aqueous suspension and non-aqueous solution pour-on and spray-on formulations useful for the prevention and treatment of insect infestation in animals: This invention relates to topically active compositions, including pour-on and spray-on formulations, comprising insect growth regulator (IGR) insecticides prepared as aqueous suspension formulations, or as non-aqueous solution formulations, and to the methods of making these formulations, and to methods of using these formulations for the treatment and/or prevention of insect... Agent:

20110152304 - Spiroazaindoles: The present invention relates to spiroazaindole compounds useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.... Agent: Merck Sharp & Dohme Corp.

20110152305 - Films and particles: Described herein are compounds and processes that can be used to prepare polymer-based films, particles, gels and related compositions, and processes for delivery of agents, and other uses.... Agent: The Trustees Of The Boston University

20110152306 - Aza-bridged ring-fused indoles and indolines: s

20110152307 - Ophthalmic composition comprising ascomycin: This invention relates to topical ophthalmic compositions comprising an ascomycin e.g. for the treatment of inflammatory diseases such as blepharitis.... Agent:

20110152308 - Aza-ring fused indole and indoline derivatives: i

20110152309 - Pharmaceutical, food or beverage having inhibitory activity on serotonin transporter: There is provided a pharmaceutical agent, food, or beverage for treating or preventing a disease or condition that can be ameliorated by inhibiting serotonin reuptake, comprising a clinically-effective amount of (1S,3S)-1-methyl-1,2,3,4-tetrahydro-β-carboline-3-carboxylic acid.... Agent: Suntory Holdings Limited

20110152310 - Tricyclic triazole compounds that modulate hsp90 activity: The present invention relates to substituted tricyclic triazole compounds and compositions comprising substituted tricyclic triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need... Agent: Synta Pharmaceuticals Corp.

20110152312 - Antiparisitic dihydroazole compounds and compositions comprising same: e

20110152311 - Novel crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt: The present invention relates to novel crystalline forms of sodium salt of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide (e.g., NXL-104) thereof. The present invention relates to compositions comprising a crystalline form of sodium salt of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide (e.g., NXL-104) alone or in combination with an antibacterial agent (e.g., ceftaroline fosamil). Processes for the preparation of the... Agent:

20110152313 - Synthesis of ageladine a and analogs thereof: The invention describes a one pot process for synthesizing a compound of structure (I), or a tautomer thereof. A compound of structure (II), or a tautomer thereof, and an aldehyde of structure RdCHO are condensed to form a condensation product. The resulting condensation product is then oxidized in the same... Agent: Macquarie University

20110152314 - Use of tenatoprazole for the treatment of gastroesophageal reflux disease: The invention relates to a novel therapeutic application of tenatoprazole. Tenatoprazole and the salts thereof can be used in the production of a medicament for the treatment of atypical and esophageal symptoms of gastroesophageal reflux, gastrorrhagia and dyspepsia.... Agent: Mitsubishi Pharma Corporation

20110152315 - Compounds for the treatment of metabolic diseases: There is provided novel compounds capable of modulating the G-protein-coupled receptor GPR40, compositions comprising the compounds, and methods for their use for controlling insulin levels in vivo and for the treatment of conditions such as type I1 diabetes, hypertension, ketoacidosis, obesity, glucose intolerance, and hypercholesterolemia and related disorders associated with... Agent: Syddansk Universitet

20110152316 - 3,4-substituted piperidine derivatives as renin inhibitors: The present invention relates to 3,4-substituted piperidinyl-based renin inhibitor compounds bearing at 4-position Isoqumolone and having the Formula (I): The invention further relates to pharmaceutical compositions containing said compounds, as well as their use in treating cardiovascular events and renal insufficiency.... Agent:

20110152317 - Prevennting the occurrence of obesity: Administration of autophagy inhibitor (e.g. 400 mg chloroquine daily) prevents occurrence of obesity and insulin resistance in human subject on prolonged high-fat diet.... Agent: Duke University

20110152318 - Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist and pharmaceutical compositions containing the same: This present invention relates to novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor (Vanilloid Receptor 1; VR1; TRPV1) antagonist; and a pharmaceutical composition containing the same. The present invention provides a pharmaceutical composition for preventing or treating a disease such as pain, migraine, arthralgia, neuralgia, neuropathies,... Agent: Amorepacific Corporation

20110152319 - Method to predict response to pharmacological chaperone treatment of diseases: The present invention provides methods to determine whether a patient with a lysosomal storage disorder will benefit from treatment with a specific pharmacological chaperone. The present invention exemplifies an in vitro method for determining α-galactosidase A responsiveness to a pharmacological chaperone such as 1-deoxygalactonojirimycin in a cell line expressing a... Agent: Amicus Therapeutics, Inc.

20110152320 - Pyrrole derivatives, their preparation and their therapeutic application: e

20110152321 - Bicyclic derivatives useful as inhibitors of dpp-1: The present invention is directed to novel bicyclic derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by DPP-1.... Agent:

20110152322 - Aminopropenoates as fungicides: The present invention relates to aminopropenoate derivatives, the process of their preparation, intermediate compounds, their use as fungicide active agents, particularly in the form of fungicide compositions, and methods for the control of phytopathogenic fungi, notably of plants and in material protection, using these compounds or compositions.... Agent: Bayer Cropscience Ag

20110152323 - Histone deacetylase inhibitors and uses thereof: The present invention discloses a group of histone deacetylase inhibitors and use thereof. The histone deacetylase inhibitors are useful in the treatment of malignant tumors and the diseases associated with differentiation and proliferation. The histone deacetylase inhibitors are the compounds represented by the following formula or salts thereof:... Agent: Shanghai Institute Of Pharmaceutical Industry

20110152324 - Therapeutic agents useful for treating pain: wherein Ar1, Ar2, V, X, R3, R4, and m are as disclosed herein or a pharmaceutically acceptable salt thereof (a “Cyclo(hetero)alkenyl Compound”); compositions comprising an effective amount of a Cyclo(hetero)alkenyl Compound; and methods for treating or preventing, e.g., pain, UI, an ulcer, IBD, or IBS in an animal, comprising administering... Agent: Purdue Pharma L.p.

20110152325 - Carboxamide compounds and their use as calpain inhibitors iv: in which R1, R2, R3 R4, R5, m and n have the meanings mentioned in the claims and the description, the tautomers thereof, the hydrates thereof and the pharmaceutically suitable salts thereof. Of these compounds those are preferred wherein R1 is optionally substituted phenyl-C1-C2-alkyl or hetaryl-C1-C2-alkyl, R2 is optionally substituted... Agent: Abbott Laboratories

20110152326 - Substituted aryloxoethyl cyclopropanecarboxamide compounds as vr1 receptor antagonists: This invention provides a compound of the formula (I): (I) These compounds are useful for the treatment of disease conditions caused by overactivation of the VR1 receptor, such as pain, or the like in mammalian. This invention also provides a pharmaceutical composition comprising the above compound.... Agent:

20110152327 - Pre-mixed, ready-to-use pharmaceutical compositions: Provided herein are ready-to-use premixed pharmaceutical compositions of nicardipine or a pharmaceutically acceptable salt and methods for use in treating cardiovascular and cerebrovascular conditions.... Agent: Ekr Therapeutics, Inc.

20110152328 - Combination therapy for glaucoma: Disclosed herein is method of treating glaucoma or ocular hypertension comprising administering a prostaglandin agonist and a second therapeutically active agent to a mammal in need thereof, wherein said second therapeutically active agent is selected from: β-Blockers, Adrenergic Agonists, non-selective adrenergic agonists, α2-selective adrenergic agonists, Carbonic Anhydrase Inhibitors, Cholinergic Agonists,... Agent:

20110152329 - Use of epothilone derivatives for the treatment of hyperparathyroidism: s

20110152330 - Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation: This invention relates to novel indane acetic acid derivatives which are useful in the treatment of diseases such as diabetes, obesity, hyperlipidemia, and atherosclerotic diseases. The invention also relates to intermediates useful in preparation of indane acetic derivatives and to methods of preparation.... Agent:

20110152331 - Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation: This invention relates to novel indane acetic acid derivatives which are useful in the treatment of diseases such as diabetes, obesity, hyperlipidemia, and atherosclerotic diseases. The invention also relates to intermediates useful in preparation of indane acetic derivatives and to methods of preparation.... Agent:

20110152333 - 3-cyanopyrrolidinyl-phenyl-oxazolidinones as antibacterial agents: The invention provides new oxazolidinone compounds of formula (I) wherein R1, R2 and R3 have different meanings. Preparative processes, pharmaceutical compositions, and uses thereof in the treatment of bacterial infections are also provided.... Agent: Ferrer Internacional, S.a.

20110152332 - Pesticidal heterocyclic compounds: e

20110152334 - Mglu2 agonists: The present invention provides novel mGlu2 agonists useful in the treatment of bipolar disorder, schizophrenia, depression, and generalized anxiety disorder.... Agent: Eli Lilly And Company

20110152335 - Allantoin-containing skin cream: An allantoin-containing skin cream composition can comprise allantoin and at least one anionic or nonionic emulsifier that is substantially hydrophilic and is soluble in water. The pH of the composition is in a range of from about 3.0 to about 6.0; preferably, the pH of the composition is from about... Agent: Alwyn Company, Inc.

20110152336 - Combination therapy with parp inhibitors: The present invention describes benzimidazole derivatives of Formula (I) which constitute potent PARP inhibitors in combination with radiotherapy or in combination with other chemotherapeutic agents.... Agent: Abbott Laboratories

20110152337 - 2,4,5-trisubstituted imidazoles and their use as anti-microbial agents: The present invention provides therapeutically effective 2,4,5-trisubstituted imidazole compounds, methods of preparing the same, and compositions comprising the compounds alone or in combination with other agents. The present invention further provides for the use of the compounds as anti-microbial agents. The anti-microbial properties of the compounds include anti-bacterial and/or anti-fungal... Agent: Lorus Therapeutics Inc.

20110152338 - Cycloalkane[b]indole antagonists of prostaglandin d2 receptors: Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the compounds described herein that are antagonists of PGD2 receptors. Also described herein are methods of using such antagonists of PGD2 receptors, alone and in combination with other compounds, for treating... Agent: Amira Pharmaceuticals, Inc.

20110152339 - Fluorescent regulators of rassf1a expression and human cancer cell proliferation: The invention provides methods for the treatment of cancer in a subject comprising administering a dansyl-carbazole compound.... Agent:

20110152340 - Methods for identifying subjects with an increased likelihood of responding to dpp-iv inhibitors: The invention provides novel in vitro diagnostic methods for identifying subjects or patients who may have an increased likelihood of responding to DPP-IV inhibitor therapy. The invention also provides novel polynucleotides associated with increased responsiveness of a patient to DPP-IV inhibition. Polynucleotide fragments which comprise at least one polymorphic locus,... Agent: Bristol-myers Squibb Company

20110152341 - Cleavage of b-amyloid precursor protein: Methods and means for the identification of meprin-α and meprin-β as novel β-secretases and antagonists thereof for use in the treatment of amyloidosis.... Agent: Probiodrug Ag

20110152342 - Stabilized pharmaceutical composition: (in the formula (1), A represents CH2, CHF or CF2; and R1 represents a secondary amino group which may have a substituent), and the following components blended with the derivative: (1) a sugar alcohol; (2) calcium carbonate, sodium citrate or sodium sulfate; and (3) a neutral low melting point oily... Agent:

20110152343 - Protease inhibitors and broad-spectrum antiviral: Caspace inhibition provides inhibition of viral infection across a wide collection of caspaces and viruses. Caspace inhibition, the prevention of the formation of active caspaces, can be achieved either through gene therapy, protein binding an inhibition, or through small molecule administration. Examples for small molecule inhibition allow the formation of... Agent: Functional Genetics, Inc.

20110152360 - Liquid pharmaceutical formulations of docetaxel: There is provided a liquid pharmaceutical formulation for parenteral administration comprising: docetaxel or a pharmaceutically acceptable salt thereof; one or more glycols; and a pharmaceutically acceptable nonaqueous solvent system; wherein the formulation has a pH meter reading in the range of from 2.5 to 7.... Agent: Hospira Australia Pty Ltd.

20110152361 - Novel epigallocatechin gallate tetramer and vascular endothelial function improving agent containing the same: e

20110152362 - Methods of treating epileptogenesis and epilepsy: wherein phenyl is substituted at X with one to five halogen atoms selected from the group consisting of fluorine, chlorine, bromine and iodine; and, R1, R2, R3, R4, R5 and R6 are independently selected from the group consisting of hydrogen and C1-C4 alkyl; wherein C1-C4 alkyl is optionally substituted with... Agent:

20110152363 - Organically chelated mineral compositions and methods thereof: Embodiments of the invention relate to a method of making a mineral product. The method includes contacting a carboxylic acid and an inorganic mineral compound sufficient to form a solution, reacting the solution over a period of time sufficient to provide a mineral chelated compound, transferring the mineral chelated compound... Agent: Ralco Nutrition, Inc.

20110152364 - Compositions for repelling fluid and uses thereof: wherein R1, R2, R3, R5, R6, R8 and R9 are independently linear or branched, substituted or unsubstituted, saturated or unsaturated, C3-C22 alkyl or alkenyl groups, R4 is a linear or branched, substituted or unsubstituted, saturated or unsaturated, C3-C22 alkylene or alkenylene moiety, and R7 is a linear or branched, substituted... Agent:

20110152365 - Disinfectant formulations that remain liquid at low temperature: e

20110152366 - N-alkylcarbonyl-amino acid ester compounds and their use for skin irritation, itch, and pain: The present invention generally relates to refreshing, soothing, and cooling compounds that affect sensory processes. More particularly, the present invention pertains to certain N-alkylcarbonyl-D-Ala-esters compounds as described herein; compositions and articles comprising such compounds; and methods of treatment, for example, methods of reducing skin irritation, itch, and/or pain.... Agent:

20110152367 - Process for the preparation of fesoterodine with low impurities content: Disclosed is a process for the preparation of (R)-2-(3-diisopropylamino-1-phenylpropyl)-4-(hydroxymethyl)-phenol isobutyrate (Fesoterodine) or a pharmaceutically acceptable salt thereof having a low content of impurities such as tolterodine and tolterodine isobutyrate.... Agent: Dipharma Francis S.r.l.

20110152368 - Perhydrolase providing improved peracid stability: An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a Thermotoga maritima acetyl xylan esterase gene was modified using error-prone PCR and site-directed mutagenesis to create an enzyme catalyst characterized by an increase in... Agent:

20110152369 - Perhydrolase providing improved peracid stability: An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a Thermotoga maritima acetyl xylan esterase gene was modified using error-prone PCR and site-directed mutagenesis to create an enzyme catalyst characterized by an increase in... Agent:

20110152370 - Perhydrolase providing improved peracid stability: An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a Thermotoga maritima acetyl xylan esterase gene was modified using error-prone PCR and site-directed mutagenesis to create an enzyme catalyst characterized by an increase in... Agent:

20110152371 - Antioxidant extract from fruit skins: The application generally relates to methods of inhibition of oxidation of polyunsaturated fatty acid—(PUFA) and/or lipid-containing foods and nutraceutical products. The application provides natural and consumer friendly method for preventing the oxidation or rancidity development of PUFA and/or lipids by incorporation of apple skin extracts as natural antioxidant in emulsions,... Agent:

20110152372 - Anhydrous petroleum jelly/elastomer-free depigmenting compositions comprising a solubilized phenolic compound and a retinoid: The present invention relates to a novel depigmenting composition especially for topical application, comprising as pharmaceutical active agents a dissolved phenolic derivative and a retinoid, in the form of an anhydrous composition free of petroleum jelly and free of elastomer, to the process for preparing it and to its use... Agent: Galderma Research & Development

20110152373 - Hair growth promoting agent containing 15,15-difluoroprostaglandin f2alpha derivative as active ingredient: The present invention provides a new pharmaceutical application of a 15,15-difluoroprostaglandin F2α derivative. As a result of intensive studies in order to find a new pharmaceutical application of a 15,15-difluoroprostaglandin F2α derivative, it was found that, in a European Phase III clinical trial for tafluprost, one of the 15,15-difluoroprostaglandin F2α... Agent: Santan Pharmaceutical Co., Ltd.

20110152374 - Biphenyloxyacetic acid derivatives for the treatment of respiratory disease: The invention relates to substituted phenoxyacetic acids as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.... Agent:

20110152375 - Method of reducing the methane gas level and of increasing the total gas yield in animal feed: The present invention relates to the use of at least one porous metal-organic framework material (MOF) comprising at least one first and, if appropriate, one second organic compound, where at least the first organic compound binds coordinatively to at least one metal ion in an at least partly bidentate manner,... Agent: Basf Se

20110152376 - 7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)- cyclopentyl]-n-ethyl-hept-5-enamide (bimatoprost) in crystalline form ii, methods for preparation, and methods for use thereof: The present invention provides a new crystalline form of bimatoprost, designated as crystalline form II. This new crystalline form is the most stable form known to date of bimatoprost. Moreover, it has been found that bimatoprost crystalline form II is readily prepared from crystalline form I.... Agent: Allergan, Inc.

20110152377 - External preparation comprising fatty acid salt or benzoic acid salt of basic pharmacologically active component, and method for production thereof: It has been demanded to develop a formulation for a novel external preparation having excellent transdermal absorption of a basic pharmacologically active component contained therein. It is found that the lipid solubility (logP values) of a basic pharmacologically active component and an organic acid (particularly a fatty acid) contribute significantly... Agent:

20110152378 - Disinfectant formulations suitable for use at low temperature:

20110152379 - Composition for control of aging and/or extension of life, containing dapsone as active ingredient: The present invention relates to a composition for controlling aging and/or extending lifespan. More specifically, the present invention relates to a composition containing dapsone as an effective component for controlling aging and/or extending lifespan, in which when applying the composition according to the present invention to an object, the effect... Agent:

20110152380 - Paediatric compositions for treating multiple sclerosis: The present invention relates to pharmaceutical compositions comprising a 2-amino-2-[2-(4-C2-20-alkyl-phenyl)ethyl]propane-1,3-diol compound or a pharmaceutically acceptable salt thereof, and to the use thereof for treating, preventing or delaying the progression of multiple sclerosis in a pediatric patient or a patient suffering from a specific condition.... Agent:

20110152381 - 3-keto-n-propargyl-1-aminoindan: The subject invention provides a pharmaceutical composition containing N-propargyl-1(R)-aminoindan or a pharmaceutically acceptable salt thereof, and a compound of 3-keto-N-propargyl-1-aminoindan or a salt thereof.... Agent:

20110152382 - Composition of molecular elements for phosphorylase kinase inhibition: Symmetrical curcuminoids molecular compounds that have been found to have anti-injury activity. It has been shown to benefit burns, injured and inflamed skin and mucous membrane and photodamaged skin. The improvement is mediated via inhibition of phosphorylase kinase activity. Phosphorylase kinase is released within 5 minutes following injury. Blocking the... Agent:

20110152383 - Compositions comprising benzyl alcohol derivatives and further antimicrobial active compounds: m

20110152384 - Mild leave-on skin care compositions: This invention relates to a composition that is mild to the skin containing a cosmetically acceptable oil; water; a cosmetically acceptable emulsifier having an HLB of from about 1 to about 25; and a preservative comprising an organic acid selected from the group consisting of benzoic acid, p-anisic acid, sorbic... Agent:

20110152385 - Nucleic acids and methods for detecting turfgrass pathogenic fungi: The present invention relates to the use of at least one nucleic acid comprising or consisting of: (i) CATCGAT-GAAGAACGCWGCRAAHTGCGATAMGTARTGYGAATTGCAGRATTCAGTGARTCATCGAAWYTTTGAACG-CAYMTTGCRC (SEQ ID NO: 1), wherein: R represents A or G Y represents C or T M represents A or C W represents A or T H represents A or C or... Agent:

  
06/16/2011 > patent applications in patent subcategories. invention type

20110143991 - Peptides for activation and inhibition of delta-pkc: Peptides able to inhibit or activate the translocation or function of δPKC are identified. Administration of the peptides for protection or enhancement of cell damage due to ischemia is described. Therapeutic methods to reduce damage to cells or to enhance damage to cells due to ischemia are also described, as... Agent: The Board Of Trustees Of The Leland Stanford Junior University

20110143993 - Endothelial basement membrane targeting peptide ligands: Peptides that selectively bind to antigens exposed in vascular disease or dysfunction have been identified by biopanning a phage library. The ligands are useful when attached to a substrate to be in contact with endothelial surfaces, especially those where drug delivery is utilized, such as following angioplasty, with release from... Agent: Massachusetts Institutes Of Technology

20110143992 - Methods and compositions related to ghs-r antagonists: Disclosed herein are methods and compositions related to GHS-R antagonists.... Agent:

20110143994 - Compositions and methods for treatment of autoimmune and allergic diseases: The present invention provides improved methods and compositions for treating and preventing autoimmune and allergic diseases. More specifically the invention relates to new immuno-modulating complexes which are fusion proteins comprising mutant subunits of bacterial endotoxins, a peptide capable of binding to a specific cellular receptor, and one or more epitopes... Agent:

20110143995 - Novel anti-allergic agents: The present invention discloses novel complex molecules useful as anti-allergic agents. These complex molecules include in particular, peptidic or peptidomimetic molecules, having a first segment which is competent for cell penetration and a second segment which is able to reduce or abolish mast cell degranulation, and in particular to reduce... Agent: Ramot At Tel-aviv University Ltd.

20110143996 - Antimicrobial kinocidin compositions and methods of use: The present invention provides novel kinocidin peptides comprising a C-terminal portion of a kinocidin, wherein the C-terminal portion encompasses an α-helical secondary structure and further displays antimicrobial activity. The kinocidin peptides of the invention are derived from and correspond to a C-terminal portion of a kinocidin that includes a γκo... Agent: Los Angeles Biomedical Research Institute At Harbor-ucla Medical Center

20110144000 - Antimicrobial polypeptide: A molecule has a first isolated peptide as shown in SEQ ID NO: 1 or part thereof or a peptide having at least 78% homology to SEQ ID NO:1 conjugated to a second peptide. The second peptide is an amphipatic peptide with an alpha-helical structure or a linear cationic peptide... Agent:

20110143999 - Fowlicidins and methods of its use: Antimicrobial peptides and methods for their use are provided. The peptides are optimized, truncated versions of chicken cathelicidins (“fowlicidins”).... Agent: The Board Of Regents For Oklahoma State University

20110144001 - Highly bridged peptides from actinomadura namibiensis: t

20110143998 - Identification and use of peptide inhibitors of protein synthesis: The present invention discloses compositions of peptide inhibitors of protein synthesis, and methods of identifying peptide inhibitors that are capable of inhibiting protein synthesis through an interaction at a stem-loop H18 in 16S rRNA of a 30S ribosomal subunit. Screening methods for peptides are disclosed, in addition to methods of... Agent: The Board Of Trustees Of The University Of Illinois

20110143997 - Phage receptor binding proteins for antibacterial therapy and other novel uses: The subject invention relates in part to novel uses of bacteriophage tail spike proteins (TSPs). Some preferred uses are therapeutic uses in animals, such as chickens, against pathogenic bacteria, such as Salmonella. Fragments of the TSPs can also be used according to the subject invention, particularly protein fragments comprising the... Agent: National Research Council Of Canada

20110144002 - Use of amps for treatment of uti/cystitis: The present invention relates to methods for treating urinary tract infections, such as cystitis, with antimicrobial polypeptides polypeptides.... Agent: Novozymes A/s

20110144003 - Maintenance therapy regime/regimen for the treatment of acne: A novel maintenance therapy regime/regimen for the treatment of acne related diseases includes administering an oral antibiotic with a topical fixed-dose combination of a retinoid, such as adapalene, and an anti-bacterial agent, such as benzoyl peroxide.... Agent: Galderma Research & Development

20110144004 - Ricin-like toxin variants for treatment of cancer, viral or parasitic infections: The present invention provides a protein having an A chain of a ricin-like toxin, a B chain of a ricin-like toxin and a heterologous linker amino acid sequence, linking the A and B chains. The linker sequence contains a cleavage recognition site for a disease specific protease such as a... Agent: Twinstrand Therapeutics Inc.

20110144005 - Novel cyclic peptides: e

20110144007 - Glucose-dependent insulinotropic polypeptide analogues: There is provided a novel series of analogues of glucose-dependent insulinotropic polypeptide compounds, pharmaceutical compositions containing said compounds, and the use of said compounds as GIP-receptor agonists or antagonists for treatment of GIP-receptor mediated conditions, such as non-insulin dependent diabetes mellitus and obesity.... Agent:

20110144006 - Protein composition: The invention relates to a protein composition which upon ingestion by a healthy person with a normal fasting insulin level between 3.0-8.0 μU/L increases the insulin level to at most 20.0 μU/L. The invention may be in the shape of a powder, capsules, pellets, tablets, effervescent tablets or food products... Agent: Igelosa Life Science Ab

20110144008 - Peptide agonists of glp-1 activity: Novel peptide agonists of GLP-1 activity useful for lowering blood glucose levels. The novel peptides comprise variants of the GLP-1 or the exendin-4 polypeptide sequence and are pharmacologically active and stable. These peptides are useful in the treatment of diseases that benefit from regulation of excess levels of blood glucose... Agent:

20110144009 - Brown adipocyte progenitors in human skeletal muscle: Brown adipose tissue (“BAT”) progenitor cells and methods for identifying BAT progenitor cells in a population of cells are provided. Methods are also provided for inducing differentiation of BAT progenitor cells into differentiated brown adipocytes, inducing expression or increased activity levels of BAT uncoupling protein-1 (“UCP1”), and for identifying agents... Agent:

20110144010 - Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier: The present invention relates to a solid or semi-solid pharmaceutical composition that includes a polypeptide drug, at least one polar organic solvent, at least one surfactant, at least one hydrophilic component and which composition is spontaneously dispersible.... Agent: Novo Nordisk A/s

20110144011 - Cellular activation insulin therapy: Diabetic and other patients are treated using an aggressive form of Pulsed Insulin Therapy in which a pre-treatment blood sugar level in the patient of at least 250-300 mg/dL, and the patient is treated with at least first and second cycles, each cycle comprising (1) pulsing a recombinant human insulin... Agent:

20110144012 - Shortened glucagon-like peptide 1(sglp-1) preparation method and application: This present invention a peptide consisting of 26 amino acids. The sequence is as follows: His-X1-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu. In comparison with the present GLP-1 and its similar compound, the shortened glucagon-like peptide 1(sGLP-1) in this invention has the following prominent advantages: 1. After reconstruction, the shortened peptide chain has stronger simulation to... Agent: Dalian D.n. Bio-engineering Co., Ltd.

20110144013 - Vegf-d mutants and their use: The present invention is a VEGF-D protein, containing one or more amino acid mutations at the dimer interface, and their use in therapy, particularly in the promotion of angiogenesis.... Agent:

20110144014 - Cytokine receptor modulators and uses thereof: The present invention relates to cytokine receptor-binding compounds, such as non-competitive VEGF receptor, IL-1 receptor, IL-4 receptor, or IGF-1 receptor-binding peptides and petidomimetic antagonists, and therapeutic uses of such compounds. The compounds of the present invention may be used in the treatment of cytokine-associated diseases such as proliferative disorders (for... Agent: Centre Hospitalier Universitaire Sainte-justine

20110144015 - Methods for treating muscle diseases and disorders: The invention relates to methods of treating diseases and disorders of the muscle tissues in a vertebrate by the administration of compounds which bind the p185erbB2 receptor. These compounds are found to cause increased differentiation and survival of cardiac, skeletal and smooth muscle.... Agent:

20110144016 - Methods and compositions for treating cancer: Methods and compositions for treating cancer are described herein. More particularly, the methods for treating cancer comprise administering a 17α-hydroxylase/C17,20-lyase inhibitor, such as abiraterone acetate (i.e., 3β-acetoxy-17-(3-pyridyl) androsta-5,16-diene), in combination with at least one additional therapeutic agent such as an anti-cancer agent or a steroid. Furthermore, disclosed are compositions comprising... Agent:

20110144017 - Protein conjugates and methods for their preparation: Reductive amination of peptide-derived aldehydes with anilines or heteroarylamines containing a property-modifying group provides new, hydrolytically stable protein conjugates, suitable for therapy.... Agent: Novo Nordisk Health Care Ag

20110144018 - Agent for prophylaxis of reflex sympathetic dystrophy after cerebral apoplexy: The present invention is intended to provide a novel pharmaceutical agent having an excellent preventive effect on post-stroke RSD. The present invention provides an agent for preventing the onset of post-stroke RSD, comprising natural calcitonin or a calcitonin derivative as an active ingredient. The present invention is also intended to... Agent:

20110144019 - Method of treating chronic heart failure: The present disclosure relates to methods for treating human subjects afflicted with chronic heart failure. The methods described herein employ administration of relaxin.... Agent:

20110144020 - Treatment of infections and other disorders: Microbial infections including anthrax infection, and gastrointestinal disorders, are treated or prevented by administration of an actin-sequestering peptide including amino acid sequence LKKTET, such as Thymosin β4, an isoform of Thymosin β4, oxidized Thymosin β4, or Tβ4 sulfoxide.... Agent: Regenerx Biopharmaceuticals, Inc.

20110144021 - Therapeutic proteins from latex: The invention refers to compositions that comprise the protein preparation, obtained from the latex of Hevea brasiliensis, in a low concentration. Additionally, the invention refers to the use of the protein preparation or the composition described herein, for the preparation of a medicine to treat chronic inflammatory diseases, and to... Agent:

20110144022 - Anti-angiogenic peptide: The invention relates to an anti-angiogenic peptide corresponding to a fragment of angiostatin molecule, pharmaceutical compositions containing it and the use thereof in the preventive or therapeutic treatment of diseases involving angiogenesis.... Agent: Istituto Nazionale Per La Ricerca Sul Cancro

20110144023 - Nano cancer barrier device (ncbd) to immobilize and inhibit the division of metastic cancer stem cells: The present invention provides methods, compositions, and kits wherein nanomaterials are used for inhibiting cancer stem cell division, colony formation, spheroid formation and self-renewal. The present invention also provides methods, compositions, and kits wherein nanomaterials are used for treating cancer, coating tumors, and inhibiting metastasis. The present invention also provides... Agent: The University Of Hong Kong

20110144024 - Prevention and treatment of radiation injury: The invention relates to the field of radiation injury. More particularly, this invention relates to the protection against/prevention of and treatment of diseases caused by ionizing radiation by the use of thrombomodulin.... Agent: Paion Deutschland Gmbh

20110144025 - Methods of reducing hemorrhage due to surgical procedure: The invention concerns glycosylated proteins having human factor VIII activity. In a preferred embodiment, the protein is glycosylated with oligosaccharides that include an alpha-(2,6)-linked sialic acid and a bisecting GlcNAc linked to a core beta-mannose.... Agent: Bayer Healthcare LLC

20110144026 - Method of treating low blood pressure: A method for treating a patient suffering from one of septic shock, acute kidney injury, severe hypotension, cardiac arrest, and refractory hypotension, but not from myocardial infarction, is provided. The method includes administering a therapeutically effective dose of Angiotensin II, or Ang II, to the patient.... Agent:

20110144027 - Pharmaceutical compositions for promoting wound healing: The present invention relates to pharmaceutical compositions and methods for promoting wound healing. The invention also relates to methods of making pharmaceutical compositions disclosed herein. Pharmaceutical compositions are disclosed comprising an effective amount of a 2-alkoxyadenosine or 2-aralkoxyadenosine, about 10% to about 70% w/w propylene glycol and a thickening agent.... Agent:

20110144028 - Modulating cellular electrophysiology: The present invention relates to compositions, apparatus, and methods for improving the viability of cells, including, but not limited to, nonexcitable cells, and tissues expressing exogenous polynucleotides that encode membrane proteins that regulate that flow of ions across the cell membrane. The viability of the cells and tissues may be... Agent:

20110144029 - Model systems and materials for the study and treatment of neurodegenerative diseases: The present invention provides models for studying the development of, and/or pathologies associated with neurodegenerative diseases, and agents that can modulate such development and/or pathologies.... Agent: Board Of Regents, The University Of Texas System

20110144030 - Conjugate of hyaluronic acid for cosmetic treatment and preparation method: This invention discloses a new conjugate compound that comprises at least one HA oligomer derivatised through one thiolated linker, whereby it binds to at least one metal nanoparticle, such as, for example, a gold nanoparticle. Moreover, it discloses methods of obtaining it, as well as the use thereof in a... Agent:

20110144031 - Pharmaceutical composition for inducing damages of endothelial cells and treating tumor and method for treating tumor by using the same: The present invention relates to a pharmaceutical composition for inducing damages of endothelial cells, a pharmaceutical composition for treating a tumor, and a method for treating a tumor by using the same. In addition, the pharmaceutical compositions for inducing damages of endothelial cells comprises: an effective amount of Concanavalin A... Agent: National Cheng Kung University

20110144032 - Biological applications of steroid binding domains: A polypeptide comprising an androgen binding region, the androgen binding region capable of binding to an androgen at a sufficient affinity or avidity such that upon administration of the polypeptide to a mammalian subject the level of biologically available androgen is decreased.... Agent:

20110144033 - Proteasome inhibitors and methods of using the same: The present invention provides boronic acid compounds, boronic esters, and compositions thereof that can modulate apoptosis such as by inhibition of proteasome activity. The compounds and compositions can be used in methods of inducing apoptosis and treating diseases such as cancer and other disorders associated directly of indirectly with proteasome... Agent: Cephalon, Inc.

20110144034 - Inhibition of tumor metastases using protein kinase c (pkc) inhibitors: Described are methods for reducing tumor metastasis in an animal by administering an inhibitor of a protein kinase C (PKC) isozyme.... Agent: The Board Of Trustees Of The Leland Stanford Junior University

20110144035 - Methods and compositions for treating conditions of the eye: Provided are methods and compositions for the photodynamic therapy (PDT) of ocular conditions characterized by the presence of unwanted choroidal neovasculature, for example, neovascular age-related macular degeneration. The selectivity and sensitivity of the PDT method can be enhanced by combining the PDT with an anti-angiogenesis factor, for example, angiostatin or... Agent:

20110144036 - Hip/pap polypeptide composition for use in liver regeneration and for the prevention of liver failure: This invention is based on the experimental finding that HIP/PAP has mitogenic and antiapoptotic effects in vitro on hepatocytes in primary culture. Moreover, HIP/PAP is a mitogenic and anti-apoptotic molecule for hepatocytcs, in vivo, during liver failure and liver regeneration. The present invention is also based on the experimental finding... Agent: Universite Rene Descartes

20110144037 - Substrates and inhibitors of antiplasmin cleaving enzyme and fibroblast activation protein and methods of use: The presently disclosed and claimed inventive concepts include inhibitors of antiplasmin cleaving enzyme (APCE) and fibroblast activation protein alpha (FAP) which can be used in various therapies related to disorders of fibrin and α2-antiplasmin and abnormal cell proliferation. The presently disclosed and claimed inventive concepts also include substrates of APCE... Agent:

20110144038 - Human cd154-binding synthetic peptide and uses thereof: The invention refers to a synthetic peptide comprising an amino acid sequence of seven residues in length, preferably flanked by 2 cysteine residues at both ends, which is capable of specifically recognizing human CD154 and blocking CD40:CD154 interaction, thereby inhibiting the biological effects depending on such interaction. The peptide of... Agent:

20110144040 - Acteoside and acteoside-rich plant extracts for increasing athletic performance in humans: The present invention relates to increasing the athletic performance of humans using acteoside. This may be in the form of a pure compound, or plant extracts containing at least 10% acteoside by weight. Application of this invention provides increased strength, muscle power, endurance, muscle protein content, and reduced fatigue.... Agent: Mn Intellectual Property Corp, LLC

20110144039 - Antioxidative and hepatoprotective compositions containing diaryheptanoids from alnus japonica: The present invention relates to antioxidative and hepatoprotective compositions, and more particularly to antioxidative and hepatoprotective compositions comprising diarylheptanoid compounds from Alnus japonica. The diarylheptanoid compounds from Alnus japonica include a compound selected from the group consisting of alusenone 1a, alusenone 1b, hirsutenone, hirsutanonol, oregonin, alnuside A, alnuside B, rubranoside... Agent: Rnl Bio Co., Ltd.

20110144041 - Methods for treating inflammatory bowel disease: A method is described for treating inflammatory bowel disease in a subject in need thereof. The method comprises administering a formulation comprising at least one ganglioside to the subject, wherein the formulation comprises at least about 50% GD3 by weight of total ganglioside content.... Agent: Mti Meta Tech Inc.

20110144042 - Novel polysaccharides with antithrombotic activity comprising at least one covalent bond with biotin or a biotin derivative: The present invention relates to novel synthetic polysaccharides with antithrombotic activity exhibiting at least one covalent bond with biotin or a biotin derivative and to a process employing avidin or streptavidin which makes it possible to neutralize these polysaccharides.... Agent: Sanofi-aventis

20110144044 - Composition and method for increasing post workout recovery: The composition of a dietary supplement is provided for increasing post workout recovery, increasing replenishment and regaining energy following exercise. A method for achieving the same is also provided. The present composition comprises branched chain amino acids, caffeine and a source of carbohydrates including waxy maize. The dietary supplement may... Agent: Allmax Nutrition Inc.

20110144043 - Stat modulators: The present invention is directed to methods, kits and compositions for modulating the activity of Stat molecules (e.g., Stat1, Stat3 and Stat5). The compounds of the invention are useful for treating and/or preventing disorders characterized by Stat dysregulation, such as hyperproliferative disorders. Further, the compounds of the present invention are... Agent: Dana-farber Cancer Institute

20110144046 - Anthelmintic compositions: An anthelmintic composition comprising two or more active agents, each agent being selected from a separate anthelmintically active family, the families being a macrocyclic lactone (ML), levamisole or its equivalent and a benzimidazole, in a suitable carrier, which includes at least one effective protective agent, which stabilises the chemical and... Agent:

20110144045 - Use of fumagillin and the derivatives thereof to increase the bioavailability of the macrocyclic lactones: A method for increasing the bioavailability of antiparasitic active ingredients, and therefore to potentiate the effects thereof, including combining antiparasitic active ingredients with an adjuvant, wherein, the antiparasitic active ingredients are capable of being recognized and binding to cellular transporters in order to be transported out of cells without being... Agent: Institut National De La Recherche Agronomique

20110144047 - Combined method for predicting the response to an anti-cancer therapy: The invention provides methods for predicting the response to a topoisomerase Ilα inhibitor therapy in an individual having cancer, wherein the methods comprise the steps of determining TIMP-I DNA aberration/TIMP-1 protein aberration in combination with determining DNA aberration in TOP2A/HER2 amplicon on chromosome 17q21 including TOP2A and HER2 or aberrations... Agent: Dako Denmark A/s

20110144048 - Novel uses of neuraminidase inhibitors in infectious diseasess: The present invention relates to methods of decreasing the infectivity, morbidity and rate of mortality, in treating diseases associated with a variety of pathogenic organisms, specifically diseases involving one or more pathogens that require neuraminidase as a virulence factor. In addition, the present invention uses biology based therapy to treat... Agent:

20110144183 - Oligonucleotides for treating inflammation and neoplastic cell proliferation: There is provided oligonucleotides directed against the CCR3 receptor and the common beta sub-unit of IL-3, IL-5 and GM-CSF receptors. The oligonucleotides are useful to inhibit general inflammation, including inflammation associated with asthma, COPD, allergy, Cystic fibrosis (CF), hypereosinophilia and neoplastic cell proliferation such as cancer.... Agent:

20110144184 - Preventing or treating viral infection using an inhibitor of the lsd1 protein, a mao inhibitor or an inhibitor of lsd1 and a mao inhibitor: An embodiment of the invention provides preventing or treating a viral infection of a host, comprising administering to the host an effective amount of an inhibitor of the protein LSD1 and/or a monoamine oxidase inhibitor. Another embodiment of the invention provides preventing or treating reactivation of a virus after latency... Agent: The United States Of America, As Rep. By The Secretary, Dept Of Hhs

20110144182 - Treatment of surgical adhesions: Connexin modulation for the treatment of surgical adhesions, and associated methods, compositions, and articles.... Agent:

20110144187 - Aptamer inhibition of thrombus formation: Boronic acid-modified DNA-based aptamers can be selected to recognize fibrinogen through binding at a glycosylation site and thus are useful for probing the effect of glycosylation pattern changes on the ability for fibrinogen to mediate blood coagulation. In addition, the aptamers of the disclosure also have anticoagulation effects due to... Agent:

20110144185 - Rna antagonists targeting hsp27: The present invention relates to oligomer compounds (oligomers), which target Hsp27 mRNA in a cell, leading to reduced expression of Hsp27. Reduction of Hsp27 expression is beneficial for the treatment of certain medical disorders, such as cancer. The invention provides therapeutic compositions comprising oligomers and methods for modulating the expression... Agent: Santaris Pharma A/s

20110144186 - Ssx-2 peptides presented by hla class ii molecules: The invention describes HLA class II binding peptides encoded by the SSX-2 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating thereto. The peptides stimulate the activity and proliferation of CD4+ T lymphocytes. Methods and products also are provided for diagnosing and treating conditions characterized... Agent: Ludwig Institute For Cancer Research Ltd.

20110144049 - Treating cardiac arrhythmias, heart failure, peripheral artery disease and stroke with cyclopentyl-triazolo-pyrimidine or derivative thereof: The present invention relates to new methods for treating and/or preventing cardiac arrhythmias, heart failure, stroke and/or peripheral artery disease by administering a composition comprising triazolopyrimidine, or derivative or metabolite thereof. In particular, the present invention relates to methods for treating cardiac arrhythmias, heart failure, stroke and/or peripheral artery disease... Agent:

20110144050 - Salts of hiv inhibitor compounds: The invention is related to salts of anti-viral compounds, compositions containing such salts, and therapeutic methods that include the administration of such salts, as well as to processes and intermediates useful for preparing such salts.... Agent: Gilead Sciences, Inc.

20110144051 - Compositions and methods for treatment of mitochondrial diseases: Compounds, compositions, and methods are provided for treatment of disorders related to mitochondrial dysfunction. The methods comprise administering to a mammal a composition containing pyrimidien nucleotide precursors in amounts sufficient to treat symptoms resulting from mitochondrial respiratory chain deficiencies.... Agent: Wellstat Therapeutics Corporation

20110144052 - Niacin prodrugs and deuterated versions thereof: The invention relates to prodrugs of niacin and their use in pharmaceutical composition and therapeutic treatment of disease.... Agent: Concert Pharmaceuticals, Inc.

20110144053 - Process for obtaining purified pterostilbene and methods of use thereof: The present invention relates to a process of extraction and purification of a stilbenoid, pterostilbene, from botanical sources. The process involves obtaining pterostilbene having high degree of purity and the present invention also relates to pure form of pterostilbene obtained. The invention also relates to complexing the pterostilbene with carriers... Agent:

20110144054 - Polyol and polyether iron oxide complexes as pharmacological and/or mri contrast agents: Pharmacological compositions, and methods for administration, of the type employing an iron oxide complex with a polyol or polyether. The methods of administration may comprise parenteral administration of an effective dose of the complex formulated in a biocompatible liquid delivered at a rate of from about 1 mL/sec to less... Agent: Amag Pharmaceuticals, Inc.

20110144055 - Health care: The use of a pharmaceutical regimen to deter in an individual, as the individual ages, the development of a cardiovascular disease (CVD) or Alzheimer's disease or to treat an individual who has CVD or Alzheimer's, the individual ingesting on a daily basis a regimen comprising pharmaceutically effective amounts of magnesium... Agent:

20110144057 - Antagonists of the vanilloid receptor subtype 1 (vr1) and use thereof: e

20110144058 - Insecticidal compositions:

20110144056 - Pyrazole derivatives useful as inhibitors of faah: The present invention is directed to certain imidazole derivatives which are useful as inhibitors of Fatty Acid Amide Hydrolase (FAAH). The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including... Agent:

20110144059 - Prodrugs of 2,4-pyrimidinediamine compounds and their uses: The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds, salts and hydrates of the prodrugs, compositions comprising the prodrugs, intermediates and methods for synthesizing the prodrugs and methods of using the prodrugs in a variety of applications.... Agent: Rigel Pharmaceuticals, Inc.

20110144060 - Substituted pyrazinone melanin concentrating hormone receptor-1 antagonists and methods: Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression or... Agent: Bristol-myers Squibb Company

20110144061 - Nanoparticle/dispersant complex, nanoparticle dispersion liquid, and nanoparticle/matrix-material complex: Provided are a nanoparticle/dispersant complex having excellent dispersibility and long-term stability in a dispersion medium, a production method therefor, and a nanoparticle dispersion liquid and a nanoparticle/matrix-material complex which are colorless and transparent even at high concentrations. In the nanoparticle/dispersant complex, a nanoparticle is covered with a dispersant containing a... Agent: Canon Kabushiki Kaisha

20110144062 - Dermatological anti-wrinkle agent: o

20110144063 - Glycerophospholipids for the improvement of cognitive functions: The invention described herein provides a preparation comprising a non-mammalian derived mixture of serine glycerophospholipid conjugates with a specific content and specific conjugation patterns of LA, linolenic acid (alpha-linolenic acid, gamma-linolenic acid) DHA and EPA which depend on utilizing different sources of lipids, and uses of such preparations.... Agent:

20110144064 - Inhibitors of kynurenine aminotransferase and uses therefor: Provided herein are methods of decreasing a level of kynurenic acid in a cell and of treating a pathophysiological condition in a subject associated with an increase in kynurenic acid in a subject. In these methods the inhibitory action of dicarboxylic acids or derivatives or analogs thereof are effective to... Agent:

20110144065 - Selective high-affinity polydentate ligands and methods of making such: This invention provides novel polydentate selective high affinity ligands (SHALs) that can be used in a variety of applications in a manner analogous to the use of antibodies. SHALs typically comprise a multiplicity of ligands that each bind different region son the target molecule. The ligands are joined directly or... Agent:

20110144068 - 3,4-diarylpyrazoles as protein kinase inhibitors: 3,4-diarylpyrazole derivatives of formula (I) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer.... Agent: Nerviano Medical Sciences S.r.l.

20110144067 - N-acyloxysulfonamide and n-hydroxy-n-acylsulfonamide derivatives: The invention provides certain N-acyloxysulfonamide and N-hydroxy-N-acylsulfonamide derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the invention provides methods of using such compounds or pharmaceutical compositions for treating, preventing, or delaying the onset and/or develop of a disease... Agent:

20110144066 - Small molecule inhibitors of the pleckstrin homology domain and methods for using same: Pleckstrin homology domain binding compounds, pharmaceutical compositions including such compounds, and methods for their use are described herein.... Agent: Arizona Board Of Regents On Behalf Of The University Of Arizona

20110144069 - Compounds for treating viral infections: The invention relates to compounds, pharmaceutical compositions and methods useful for treating viral infection.... Agent: Myriad Genetics, Incorporated

20110144070 - Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors: Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols are useful as inhibitors of the phosphodiesterase 4 (PDE4) enzyme.... Agent: Chiesi Farmaceutici S.p.a.

20110144071 - Crystalline active ingredient microparticles, method for producing the same and use thereof in drugs: A method for producing highly crystalline and stable microparticles of an active substance with a very narrow size distribution. The microparticles being crystallized out of a suspension made of primary particles of the active substance, a solution of the active substance, a non-solvent for the active substance and inert formed... Agent: Jesalis Pharma Gmbh

20110144072 - Antiglucocorticoid therapy for the prevention of neurological damage in premature infants: This invention pertains to the discovery that agents which inhibit the binding of cortisol to its receptors can be used in methods for preventing neurological damage associated with glucocorticoid therapy in ventilator-dependent low birth weight preterm infants. Mifepristone, a potent glucocorticoid receptor antagonist, can be used in these methods.... Agent: Corcept Therapeutics, Inc.

20110144073 - Glucocorticoids attached to nitrate esters via an aromatic linker in position 21 and their use in ophthalmology: The invention relates to nitrooxy derivatives of fluocinolone acetonide, triamcinolone acetonide, betamethasone and beclomethasone, methods for their preparation, pharmaceutical compositions containing these compounds, and methods of using these compounds and compositions for treating diabetic macular edema, diabetic retinopathy, macular degeneration, age-related macular degeneration and other diseases of retina and macula... Agent: Nicox S.a.

20110144074 - Caspase inhibitors and uses thereof: wherein Z is oxygen or sulfur; R1 is hydrogen, —CHN2, R, CH2OR, CH2SR, or —CH2Y; between R3 and R4 represents a single or double bond; Y is an electronegative leaving group; R2 is CO2H, CH2CO2H, or esters, amides or isosteres thereof; R3 is a group capable of fitting into... Agent: Vertex Pharmaceuticals Incorporated

20110144075 - Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors: Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols are useful as inhibitors of the phosphodiesterase 4 (PDE4) enzyme.... Agent: Chiesi Farmaceutici S.p.a.

20110144076 - Preterm delivery diagnostic assay: The present invention in one aspect relates generally to the identification, provision and use of a plurality of biomarkers to provide risk assessment of a woman for preterm delivery, and products and processes related thereto. In one aspect, a novel plurality of biomarkers as described herein is provided to determine... Agent:

20110144077 - Treatment of retinal degeneration: The use of a compound having a gon-4-ene nucleus, said nucleus having attached thereto, in the 13 position, a polycarbon-alkyl radical having 2 to about 16 carbon atoms, said compound containing at least 19 and up to 40 carbon atoms in its carbon-carbon skeleton, in the manufacture of a medicament... Agent:

20110144078 - Transition metal complexes of corroles for preventing cardiovascular diseases or disorders: Transition metal complexes of amphiphilic/bipolar corroles, optically active isomers or pharmaceutically acceptable salts thereof are useful for prevention of a cardiovascular disease or disorder in a subject susceptible to develop such a cardiovascular disease or disorder.... Agent: Technion Research And Development Foundation Ltd.

20110144079 - Antimicrobial system: The present invention relates to the use of ionic liquids as antimicrobial agents, and to the use of antimicrobial compositions comprising an ionic liquid, a film-enhancing composition and a viscosity controlling agent. The invention further relates to methods of disinfecting substrate surfaces, to substrates produced by such methods, and to... Agent:

20110144081 - Pyrrolidine derivatives: e

20110144082 - Compounds for the treatment of peripheral neuropathies:

20110144080 - Pyrazole derivatives as protein kinase modulators: The invention provides compounds of the formula: (I) having protein kinase B inhibiting activity: wherein A is a saturated hydrocarbon linker group containing from 1 to 7 carbon atoms, the linker group having a maximum chain length of 5 atoms extending between R1 and NR2R3 and a maximum chain length... Agent: The Institute Of Cancer Research Royal Cancer Hospital

20110144084 - 6 substituted 2- heterocyclylamino pyrazine compounds as chk-1 inhibitors: e

20110144085 - Triazolopyridine compounds as pim kinase inhibitors: Compounds of Formula (I), in which A, B, R1, R1a, R2, R3, R4, R5, R6, and R7 have the meanings given in the specification, are receptor tyrosine inhibitors useful in the treatment of immune cell-associated diseases and disorders, such as inflammatory and autoimmune diseases.... Agent: Array Biopharma Inc.

20110144083 - Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions: m

20110144086 - Inhibitors of the plasmodial surface anion channel as antimalarials: Disclosed are inhibitors of the plasmodial surface anion channel (PSAC) inhibitors and the use thereof in treating or preventing malaria in an animal such as a human, comprising administering an effective amount of an inhibitor or a combination of inhibitors. An example of such an inhibitor is a compound of... Agent: The United States Of America, As Represented By The Secretary, Dept Of Health And Human Service

20110144087 - Short acting benzothiazepine calcium channel blockers and uses thereof: The present invention relates to short-acting calcium channel blocking compounds and their use to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension in general, hypertension been.) fore, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow.... Agent: Milestone Pharmaceuticals Inc.

20110144089 - Method of treating schizophrenia and other disorders: e

20110144088 - Method of treating sleep disorders:

20110144090 - Compounds and methods of use thereof: Indole compounds are disclosed. Also disclosed are methods for using the compounds to treat human and animal disease, pharmaceutical compositions of the compounds, and kits including the compounds.... Agent:

20110144091 - Inhibitors of diacylglycerol acyltransferase: d

20110144092 - Substituted alkyl pyrimidin-4-one derivatives:

20110144094 - Heterocyclic tetracyclic tetrahydrofuran derivatives:

20110144093 - Method of treating organophosphorous poisoning: A method for treating organophosphorous poisoning (OP) comprising administering to a mammal at risk for OP poisoning an OP poisoning-inhibiting amount of galantamine.... Agent: The Gov. Of The US As Repr. By The Sec. Of The Army, U.s. Army Med. Resr. Inst. Of Chem. Defense

20110144095 - Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions: m

20110144096 - Treating various disorders using trkb agonists: Novel compounds and methods for activating the TrkB receptor are provided. The methods include administering in vivo or in vitro a therapeutically effective amount of a compound containing four six-membered rings and a substituted or unsubstituted C5 or C6 heteroaryl or hetero-cycloalkyl ring and pharmaceutically acceptable salts, prodrugs, and derivatives... Agent: Emory University

20110144097 - 2-amino-5,5-difluoro-5,6-dihydro-4h-[1,3]oxazin-4-yl)-phenyl]-amides: v

20110144098 - Amino oxazine derivatives:

20110144099 - Aryloxy and arylalkyleneoxy substituted imidazoquinolines: Imidazoquinoline compounds with an aryloxy or arylalkyleneoxy substituent at the 6, 7, 8, or 9-position, pharmaceutical compositions containing the compounds, intermediates, and methods of use of these compounds as immunomodulators, for modulating cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.... Agent: 3m Innovative Properties Company

20110144100 - Triazolopyridine compounds as pim kinase inhibitors: Compounds of Formula (I): I in which B, R1, R1a, R2, R3, R4, R5, R6, R7, R10 and R11 have the meanings given in the specification, are receptor tyrosine inhibitors useful in the treatment of diseases mediated by PIM-1 and/or PIM-2 and/or PIM-3 kinases.... Agent: Array Biopharma Inc.

20110144101 - Macrocyclic compounds useful as pharmaceuticals: The present invention provides methods for the use of compounds having formula (I) in the treatment of various disorders including inflammatory or autoimmune disorders, and disorders involving malignancy or increased angiogenesis, wherein R1-R11, t, X, Y, Z, and n are as defined herein.... Agent: Eisai Co., Ltd.

20110144102 - Calcimimetic compound for use in the treatment of epithelial injury: This invention relates generally to the field of medicine and, more specifically, to methods for treating epithelial injury, in particular, due to ischemia, hypoxia, trauma, chemolytics or radiation exposure.... Agent: Amgen Inc.

20110144103 - Pyrrole compounds that modulate hsp90 activity: The present invention relates to substituted pyrrole compounds and compositions comprising substituted pyrrole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to... Agent:

20110144104 - Pyrrolidinyl-alkyl-amide derivatives, their preparation, and their therapeutic application as ccr3 receptor ligands: e

20110144105 - Azaindole glucokinase activators:

20110144106 - Novel cyclopropane indolinone derivatives:

20110144107 - Compounds and compositions useful for the treatment of malaria: The invention provides a class of compounds of formula I, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent malaria.... Agent: Dana-farber Cancer Institute Inc.

20110144109 - Derivatives of 1--4-methylpiperazine, synthesis process and uses thereof: The present invention concerns pyrrole compounds, derivatives of 1-{[1,5-bis(4-chlorophenyl)-2-methyl-1H-pyrrol-3-yl]methyl}-4-methylpiperazine (BM212). The invention concerns the use of the described compounds as antitubercular agents having high activity and low toxicity and process to obtain intermediates and final compounds.... Agent:

20110144110 - Novel pyrrole inhibitors of s-nitrosoglutathione reductase as therapeutic agents: The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same.... Agent: N30 Pharmaceuticals, LLC

20110144108 - Substituted piperidine compounds and methods of their use: Novel 3,4-disubstituted-4-aryl-piperidine compounds are disclosed. Pharmaceutical compositions containing the 3,4-disubstituted-4-aryl-piperidine compounds and methods of their pharmaceutical uses are also disclosed. The compounds disclosed are useful, inter alia, as antagonists of opioid receptors.... Agent: Adolor Corporation

20110144111 - Pharmaceutical composition for preventing or treating diseases associated with beta-amyloid accumulation containing morpholin or piperazine based compounds having so3h or cooh as active ingredient: v

20110144112 - Apoptosis promoters: Disclosed are compounds which inhibit the activity of anti-apoptotic protein family members, compositions containing the compounds and uses of the compounds for preparing medicaments for treating diseases during which occurs expression one or more than one of an anti-apoptotic protein family member.... Agent:

20110144113 - Triazolotriazines as kinase inhibitors: The present invention is directed to [1,2,4]triazolo[4,3-b][1,2,4]triazines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.... Agent:

20110144114 - Substituted triazinone derivatives: e

20110144115 - Substituted 1-benzyl-cinnolin-4(1h)-one derivatives, preparation thereof, and therapeutic use thereof: The present invention is related to novel substituted 1-benzylcinnolin-4(1H)-one derivatives having affinity for cannabinoid CB2 receptors, their preparation and their therapeutic application.... Agent: Sanofi-aventis

20110144116 - Derivatives of (bridged piperazinyl)-1-alkanone and use thereof as p75 inhibitors: e

20110144117 - Pharmaceutical dosage form containing tetrahydrobiopterin: Pharmaceutical dosage form comprising tetrahydrobiopterin, or a metabolic precursor thereof, comprising an aqueous solution of tetrahydrobiopterin, or a metabolic precursor thereof, and an antioxidant in a dispensing container and a dosing means for the dosed dispensation of the aqueous solution, as well as the use of an antioxidant for stabilizing... Agent: Orpha Swiss Gmbh

20110144118 - Antiviral salts: This invention relates to antiviral agents, in particular to salts useful in the treatment of infections caused by Picornaviridae, such as human rhinovirus (HRV) and methods for their preparation. The invention also relates to the use of these salts in the treatment of picornavirus infections. The salts of this invention... Agent: Biota Scientific Management Pty Ltd

20110144119 - Oxazole derivatives useful as inhibitors of faah: The present invention is directed to certain oxazole derivatives which are useful as inhibitors of Fatty Acid Amide Hydrolase (FAAH). The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including... Agent:

20110144120 - Phenyl-alkyl piperazines having tnf-modulating activity, preparation method, and therapeutic use thereof: e

20110144121 - Bicyclic pyrazolo-heterocycles:

20110144122 - Derivatives of 2-oxoalkyl-1-piperazin-2-one, preparation method thereof and therapeutic use of same:

20110144123 - Thiazoles and oxazoles useful as modulators of atp-binding cassette transporters: The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.... Agent: Vertex Pharmaceuticals Incorporated

20110144124 - Compounds and compositions for use as modulators of tau aggregation and alleviation of tauopathies: This invention relates to the use of bis- and tris-dihydroxyaryl compounds as well as sulfonamides, heteroaryls, tricycloalkyl and their analogs and pharmaceutically acceptable salts, for modulating tau aggregation and alleviating tauopathies, such as Alzheimer's disease (AD), Pick's disease (PiD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and familial frontotemporal dementia/Parkinsonism... Agent:

20110144125 - Anti-arrhythmia agents, methods of their use, methods of their identification and kits therefore: The disclosure describes an animal model for simulating cardiac arrhythmia. Methods of discovering new anti-arrhythmia drugs using the model are described. Novel anti-arrhythmia agents are provided, as are pharmaceutical compositions made from the agents. Methods of inhibiting spontaneous mechanical activity in myocardially-derived biological systems, and methods of treating and preventing... Agent: The Uab Research Foundation

20110144127 - Agents for treatment of glaucomatous retinopathy and optic neuropathy: Agents that stimulate nuclear translocation of Nrf2 protein and the subsequent increases in gene products that detoxify and eliminate cytotoxic metabolites are provided in a method for treating glaucomatous retinopathy or optic neuropathy. The structurally diverse agents that act on the Nrf2/ARE pathway induce the expression of enzymes and proteins... Agent: Alcon Inc.

20110144126 - Compounds useful for inhibiting chk1: The present invention provides an aminopyrazole compound, or a pharmaceutically acceptable salt thereof or a solvate of the salt, that inhibits Chk1 and is useful in the treatment of cancer.... Agent:

20110144129 - 3-aminocyclopentanecarboxamides as chemokine receptor agonists: e

20110144128 - Heterocyclic carboxamide compounds as steroid nuclear receptors ligands: Heterocyclic carboxamide compounds are described herein as being useful in modulating the activity of steroid nuclear receptors. Pharmaceutical compositions containing the compounds, methods of using the compounds and processes for making the compounds are also described.... Agent: Exelixis, Inc.

20110144130 - Use of 5-(7-methoxy-3,3-dimethyl-2,3-dihydro-1-benzoxepin-5-yl)-3-methyl-penta-2,4-dienoic acid as a cosmetic: The invention relates to 5-(7-methoxy-3,3-dimethyl-2,3-dihydro-1-benzoxepin-5-yl)-3-methyl-penta-2,4-dienoic acid and its use in compositions, especially topical, cosmetic and/or personal care compositions, and compositions containing said compound.... Agent: Merck Patent Gesellschaft Mit Beschrankter Haftung

20110144131 - Substituted imidazo- and triazolopyrimidines, imidazo- and pyrazolopyrazines and imidazotriazines: The invention relates to substituted imidazo- and triazolopyrimidines, imidazo- and pyrazolopyrazines and imidazotriazines and processes for their preparation, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, in particular of hematological disorders, preferably of leukopenias and neutropenias.... Agent: Bayer Schering Pharma Aktiengeselleschaft

20110144132 - Substituted pyrimidin-4-one derivatives: e

20110144133 - Substituted pyrimidone derivatives:

20110144134 - Anti-inflammatory pyrazolopyrimndines: The present invention provides anti-inflammatory compounds useful in the treatment of diseases and conditions in which inflammation is involved in disease progression or the manifestation of symptoms of the disease or condition.... Agent: The Regents Of The University Of California

20110144135 - Compounds for modulating trpv3 function: The present application relates to compounds and methods for treating pain and other conditions related to TRPV3.... Agent: Hydra Biosciences, Inc.

20110144136 - Novel adenine derivatives: n is an integer having a value of 1 to 6; Het is a 6-membered saturated heterocycle containing one nitrogen atom wherein Het is attached to the —(CH2)n— moiety at any carbon atom of the heterocycle; R3 is hydrogen, C1-8alkyl, or C3-7cycloalkylC0-6alkyl; and salts thereof are inducers of human interferon.... Agent: Glaxosmithkline LLC

20110144137 - method for preventing or alleviating the noxious effects resulting from toxicant exposure: The present invention provides a method of using agents which can modulate TRPA1 function as counteragents to inhibit the physical effects of chemical irritants/toxicants when given prior to exposure or to lessen the physical effects when administered post exposure, and more specifically, to a method for counteracting the acute physical... Agent: Yale University

20110144138 - Substituted pyrimido isoquinoline derivatives: e

20110144139 - Hepsin inhibitors: Compositions and methods are provided for preventing or attenuating cancer progression or blocking metastasis in prostate cancer and other cancers (e.g., ovarian carcinoma, endometrial cancer, renal cell carcinoma) that are characterized by overexpression of the type II cell surface serine protease hepsin, based on the discovery of multiple disclosed compounds... Agent: Fred Hutchinson Cancer Research Center

20110144140 - Pyridinyl-pyrimidine derivatives useful as potassium channel modulating agents: This invention relates to novel pyridinyl-pyrimidine derivatives and their use as potassium channel modulating agents. Moreover the invention is directed to pharmaceutical compositions useful for the treatment or alleviation of diseases or disorders associated with the activity of potassium channels.... Agent:

20110144141 - Hair growth and/or regrowth compositions: The present disclosure relates to compositions containing certain pyrimidine compounds such as minoxidil and/or certain pyrimidine sulfate (inner salt) compounds such as minoxidil sulfate and especially compositions containing pyrimidine compounds in combination with an admixtures comprising at least one antioxidant, at least one organic acid and a select fatty acid... Agent: Mcneil-ppc, Inc.

20110144142 - Methods of reducing hair loss and/or facilitating hair growth and/or regrowth: The present disclosure relates to methods of retarding hair loss or facilitating hair growth and/or regrowth. More specifically, the present disclosure relates to methods of using the disclosed compositions to increase the rate of terminal hair growth and/or regrowth in a mammal.... Agent: Mcneil-ppc, Inc.

20110144143 - pharmaceutical composition containing ferulic acid and matrine compounds, the preparation and the use thereof: Preparation and usage of a pharmaceutical composition containing ferulic acid and matrine compounds are described. The ingredients ferulic acid and matrine compounds in this pharmaceutical composition have synergistic effects which can obviously improve the pharmacology effects of both the ferulic acid and matrine compounds. Moreover, the pharmaceutical composition can significantly... Agent: Qingdao Qiyuan Bio-technologies Co., Ltd.

20110144144 - Ibuprofen and narcotic analgesic compositions: Provided herein are compositions and methods of making compositions of ibuprofen in combination with a narcotic analgesic. Specifically provided is a pharmaceutical tablet composition comprising ibuprofen; a narcotic analgesic; colloidal silicon dioxide; a filler selected from the group consisting of microcrystalline cellulose and powdered cellulose; a disintegrant selected from the... Agent: Abbott Gmbh & Co. Kg

20110144145 - Methods for treating visceral fat conditions: Disclosed are methods and compositions for treating visceral fat conditions and/or metabolic syndrome using combinations of naltrexone and bupropion.... Agent: Orexigen Therapeutics, Inc.

20110144146 - Aminomethyl substituted bicyclic aromatic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor: s

20110144147 - Injectable pharmaceutical compositions of an anthracenedione derivative with anti-tumoral activity: Injectable pharmaceutical compositions containing 6,9-bis[(2-aminoethyl)amino]benzo[g]isoquinoline-5,10-dione dimaleate as active ingredient in the form of a lyophilised powder with a carrier selected from lactose and dextran, mixed with sodium chloride.... Agent:

20110144148 - Acetylcholinesterase dual inhibitors: which have a tacrine moiety connected to an heterocyclic moiety through a linker. Through careful selection of the substituents and the linker, the activity and selectivity towards acetylcholinesterase can be modulated. The compounds show potent AChE inhibition activities together with modifications in the β-amyloid aggregation properties by binding simultaneously to... Agent: Noscira, S.a.

20110144149 - Gemifloxacin process and polymorphs: The present invention provides a novel process for the preparation of gemifloxacin and its pharmaceutically acceptable acid addition salts in high yield. The present invention also relates to novel polymorphs of gemifloxacin free base and its hydrates to the processes for their preparation and to pharmaceutical compositions comprising them. The... Agent: Hetero Drugs Limited

20110144150 - Bridged bicyclic rho kinase inhibitor compounds, composition and use: The present invention is directed to synthetic bridged bicyclic compounds that are inhibitors of rho-associated protein kinase. The present invention is also directed to pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable carrier. The invention is additionally directed to a method of preventing or treating diseases or conditions associated... Agent:

20110144152 - Disubstituted alkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists: where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for... Agent: Theravance, Inc.

20110144151 - Novel process, salts, composition and use: The present invention provides a novel process for preparing pleuromutilin derivatives, novel salts of mutilin 14-(exo-8-methyl-8-azabicyclo[3.2.1]oct-3-ylsulfanyl)-acetate or solvates thereof, novel pharmaceutical compositions or formulations for topical administration comprising mutilin 14-(exo-8-methyl-8-azabicyclo[3.2.1]oct-3-ylsulfanyl)-acetate or a pharmaceutically acceptable salt or solvate thereof and their use in medical therapy, particularly antibacterial therapy.... Agent: Glaxo Group Limited

20110144153 - Amide compound: [Solving Means] The present inventors have conducted extensive studies on a compound having an EP4 receptor antagonistic activity, and confirmed that the amide compound of the present invention has an EP4 receptor antagonistic activity, thereby completing the present invention. The amide compound of the present invention has an EP4 receptor... Agent: Astellas Pharma Inc.

20110144155 - 8-hydroxyquinoline derivatives for the treatment of hematological malignancies: The application relates to compositions and methods for treating hematological malignancies and proliferative diseases, disorders and conditions involving increased D-cyclin expression. In particular, the application relates to compositions and methods for treating the hematological malignancies acute myeloid leukemia (AML), lymphoma and multiple myeloma (MM) using 5-nitrogen substituted hydroxy quinolones as... Agent:

20110144154 - Salts of 2-substituted quinolines: The invention relates to salts of 2-substituted quinolines, the manufacturing method for same, and use of the same for the production of drugs. Said salts are advantageous in that the same can be obtained in crystalline form, which facilitates their implementation in the manufacture of pharmaceutical compositions.... Agent:

20110144156 - A3 adenosine receptor allosteric modulators: Provided are 2,4-disubstituted quinoline derivatives that are A3 adenosine receptor modulators (A3RM), for use in the treatment of a condition which is treatable by adenosine, an A3 adenosine receptor (A3AR) agonist, or an A3 adenosine receptor antagonist. The 2,4-disubstituted quinoline derivatives can be used in the treatment of a condition... Agent: Can-fite Biopharma Ltd.

20110144157 - Pyrrole derivatives, preparation of same and therapeutic application thereof: o

20110144158 - Isoindole-imide compounds and compositions comprising and methods of using the same: This invention relates to isoindole-imide compounds, and pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.... Agent: Sepracor Inc.

20110144159 - Ether benzylidene piperidine aryl carboxamide compounds useful as faah inhibitors: The present invention relates to compounds of Formula (I) wherein Ar is optionally substituted phenyl or 6-membered heteroaryl moiety, or a benzisoxazole, pyrrolopyridine, or benzotriazole group; or a pharmaceutically acceptable salt thereof; processes for the preparation of the compounds; intermediates used in the preparation of the compounds; compositions containing the... Agent: Pfizer Inc

20110144160 - Antagonists of prostaglandin d2 receptors: Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions that include the compounds described herein, and methods of using such antagonists of PGD2 receptors, alone or in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.... Agent: Amira Pharmaceuticals, Inc.

20110144161 - 1-heterocyclylsulfonyl, 2-aminomethyl, 5- (hetero-) aryl substituted 1-h-pyrrole derivatives as acid secretion inhibitors: The present invention provides a compound having a superior acid secretion inhibitory effect and showing an antiulcer activity and the like. The present invention provides a compound represented by the formula (I) wherein R1 is a nitrogen-containing monocyclic heterocyclic group optionally condensed with a benzene ring or a heterocycle, the... Agent: Takeda Pharmaceutical Company Limited

20110144162 - Oxotetrahydrofuran-2-yl-benzimidazole derivative: The present invention relates to compounds, which are useful for treatment and/or prevention of diabetes mellitus, diabetes mellitus complications or obesity, since the compounds have glucokinase-activating effects, and are presented in Formula (I): wherein R1 represents a carbamoyl group; R2 represents a lower alkyl group; both of X1 and X2... Agent: Banyu Pharmaceutical Co., Ltd.

20110144163 - Thiolated paclitaxels for reaction with gold nanoparticles as drug delivery agents: Thioloated taxane derivatives are linked to colloidal metal particles such as gold nanoparticles for use as antitumor agents. The antitumor agents may be targeted to tumors.... Agent:

20110144164 - Pyridone derivatives as nk3 antagonists: The present invention relates to compounds useful in therapy, in particular in the treatment of psychosis, to compositions comprising said compounds, and to methods of treating diseases comprising the administration of said compounds.... Agent: H. Lundbeck A/s

20110144165 - Prodrug compounds useful as cannabinoid ligands: e

20110144166 - High concentration topical insecticides containing pyrethroids: A topical insecticide preparation is provided which can be safe to use and avoids many common deleterious side effects of conventional topical insecticides. The topical insecticide contains a combination of a first pyrethroid insecticide effective for killing fleas, a second pyrethroid insecticide effective for killing ticks, and an insect growth... Agent:

20110144167 - Prolyl hydroxylase inhibitors: t

20110144168 - Oxazolidine derivatives as nmda antagonists: The present invention provides therapeutically active oxazolidine derivatives and compositions as NMDA antagonists, which are useful in preventing and treating central nervous system disorders by inhibiting over-activation of NMDA receptors. In one aspect, the present invention provides methods of treating and/or preventing neurodegenerative diseases and neuropathological disorders, methods of providing... Agent: Biotechnology Research Corporation Limited

20110144169 - Inhibitors of cellular necrosis: The present invention relates to compounds and pharmaceutical preparations and their use in therapy for preventing or treating trauma, ischemia, stroke and degenerative diseases associated with cell death. Methods and compositions of the invention are particularly useful for treating neurological disorders associated with cellular necrosis.... Agent:

20110144170 - Fc receptor modulating compounds and compositions: The present invention provides compounds capable of binding to an Fc receptor and modulating Fc receptor activity comprising a core lipophilic group in the form of an Aryl zing substituted with a group rich in p-electrons. The invention further provides for a method of treating an autoimmune disease involving Fc... Agent:

20110144171 - Thiopene containing analogues of fluconazole as antifungal agents and process for their preparation: The present invention discloses novel compounds of the Formula (1), containing thiophene moieties and pharmaceutically acceptable salts thereof, methods for preparing these compounds, the use of these compounds in prevention and treatment of fungal infections, and pharmaceutical preparations containing these novel compounds.... Agent: Fdc Limited

20110144172 - Crystalline modifications of prothioconazole: There is disclosed a crystalline DMSO solvate of prothioconazole as well as amorphous prothioconazole. Methods for making these solid forms, microbicidal compositions comprising them and uses thereof are also disclosed.... Agent: Makhteshim Chemical Works Ltd.

20110144173 - Fungical control of moulds: e

20110144174 - Deuterium-enriched odansetron: The present application describes deuterium-enriched ondansetron, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Protia, LLC

20110144175 - Method for controlling degradation of agricultural chemical active ingredient: When Cyazofamid is formulated in accordance with a conventional formulation method, Cyazofamid is degraded in some cases. The problem to be solved by the present invention is to improve storage stability of the formulation by controlling degradation of Cyazofamid as an agricultural chemical active ingredient. The present invention provides a... Agent: Ishihara Sangyo Kaisha, Ltd.

20110144178 - 1 ,6-dihydro-2h-3-oxa-6-aza-as-indacene compounds: The invention provides new compounds of formula (I) wherein R1, R2, R3, R4, and X have different meanings. Preparative processes, pharmaceutical compositions, and uses thereof in the treatment or prevention of conditions mediated by melatonin receptors are also provided.... Agent: Ferrer Internacional, S.a.

20110144177 - Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents: wherein A is selected from the group consisting of an unsubstituted aryl, a substituted aryl, an unsubstituted heteroaryl and a substituted heteroaryl. The carbamoyl esters are employed in methods to treat an individual. The pharmacologically active agent obtained by hydrolysis of the carbamoyl esters can treat, for example, a nervous... Agent:

20110144176 - Macrolides and methods for producing same: This invention relates, in part, to macrolide compounds, actinomycete strains for producing them, and pharmaceutical compositions containing them.... Agent: Wyeth LLC

20110144179 - Substituted heterocyclic mercaptosulfonamide metalloprotease inhibitors: The present invention generally relates to substituted heterocyclic mercaptosulfonamide compounds, precursors, and derivatives as well as methods for the preparation of and pharmaceutical compositions comprising these compounds. These compounds are designed to be potent selective inhibitors of matrix metalloproteinases (MMPs), including, for example, gelatinases, collagenases, matrilysins, metalloelastase, stromelysin, and membrane-type... Agent:

20110144180 - Novel pyrrole inhibitors of s-nitrosoglutathione reductase as therapeutic agents: The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same.... Agent: N30 Pharmaceuticals, LLC

20110144181 - Pharmaceutical compositions of amorphous atorvasta and process for preparing same: Solid pharmaceutical compositions containing atorvastatin are disclosed. The compositions include a solid dispersion of amorphous atorvastatin and one or more optional pharmaceutically acceptable excipients. The solid dispersion is prepared by mixing crystalline atorvastatin with a melt-processible polymer and an optional stabilizer and an optional plasticizer at a temperature sufficiently high... Agent: Warner-lambert Company LLC

20110144188 - Salts of trimebutine and n-desmethyl trimebutine: Unique salts of trimebutine and N-monodesmethyl trimebutine, and their corresponding stereoisomers, having improved analgesic properties useful in the treatment of visceral pain are provided. The salts of the present invention are particularly useful in the treatment of conditions characterized by abdominal pain, such as inflammatory bowel disease (IBD) and irritable... Agent: Antibe Therapeutics Inc.

20110144189 - Guanylhydrazone compounds, compositions, methods of making and using: i

20110144190 - Method of preparing a supramolecular complex containing a therapeutic agent and a multi-dimensional polymer network: A method of preparing a supramolecular complex containing at least one therapeutic agent and a multi-dimensional polymer network is described. A supramolecular complex prepared by a method of the invention is described. A method of treatment by administering a therapeutically effective amount of a supramolecular complex of the invention is... Agent: California Institute Of Technology

20110144191 - Compositions comprising terpene compounds for treating negative sensory phenomena: Compositions comprising terpene compounds for the treatment of negative sensory phenomena (NSP). Negative sensory phenomena is characterized by a decreased ability to sense light touch, pin prick, vibration, temperature, pain and/or reduced proprioception. The terpene compounds are preferably aromatic terpene compounds such as geraniol and citronellol and analogs thereof. The... Agent:

20110144192 - Method for modulating or controlling sodium channel current by reactive oxygen species (ros) originating from mitochondria: Method for modulating or controlling sodium channel current of a cell includes inducing mitochondrial reactive oxygen species (ROS) production in the cell.... Agent: The Board Of Trustees Of The University Of Illinois

20110144194 - Chromenone derivatives useful for the treatment of neurodegenerative diseases: Compounds of general formula (I) and (II) in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14 and R15 have the meanings given in the specification, are useful in the treatment of neurodegenerative disease.... Agent:

20110144193 - Pharmaceutical composition comprising cinchonains ia and ib, process for preparing an epimeric mixture of cinchonains ia and ib, use and method for reverting/combating ventricular fibrillation: m

20110144195 - Methods for synthesizing glycinols, glyceollins i and ii, compositions of selected intermediates, and therapeutic uses thereof: Two distinct methods are disclosed and claimed for synthesizing glyceollin I plus glyceollin II as a mixture and as their pure forms. Stereochemical isomers and various synthetic intermediates are also synthesized and claimed for their novel compositions of matter. All compounds and their mixtures are claimed for use in formulations... Agent:

20110144196 - Treating various disorders with 7,8-dihydroxyflavone and derivatives thereof: Novel compounds and methods related to the activation of the TrkB receptor are provided. The methods include administering in vivo or in vitro a therapeutically effective amount of 7,8-dihydroxyflavone or derivative thereof. Specifically, methods and compounds for the treatment of disorders including neurologic disorders, neuropsychiatric disorders, and metabolic disorders (e.g.,... Agent: Emory University

20110144197 - Alcanoic acid amides substituted by saturated o-heterocycles: v

20110144198 - Breast cancer prognostics: The present invention provides new methods, uses and means for breast cancer prognostics. The provided method for establishing a prognosis for a mammalian subject having a breast cancer, comprises the steps of: obtaining a hormone receptor status of the subject; obtaining an HMGCR protein value of the subject; and correlating... Agent: Atlas Antibodies Ab

20110144199 - Methods for treating atrial fibrillation: The subject invention provides methods for reducing atrial fibrillation (AF) episode duration, methods for reducing stroke rate, methods for increasing time in normal sinus rhythm (NSR), methods for preventing atrial remodeling, and methods for reversing atrial remodeling, all comprising administering an amount of budiodarone effective to reduce AF episode duration.... Agent:

20110144200 - Combination of carotenoids and epi-lutein: The invention describes the preparation and use of carotenoid and epi-lutein compositions to treat various ocular diseases.... Agent:

20110144201 - Method for improving the tolerance of crops to chilling temperatures and/or frost: The present invention relates to the use of propamocarb and derivatives thereof for improving the tolerance of crops to chilling temperatures and/or frost.... Agent: Bayer Cropscience Ag

20110144202 - Concentrated oxaliplatin solution and its method of preparation: The present invention relates to a pharmaceutically stable and highly concentrated aqueous oxaliplatin solution. The present invention also concerns a method for preparing said solution.... Agent:

20110144203 - Use of cationic surfactants as sporicidal agents: Cationic surfactants derived from the condensation of fatty acids and esterified dibasic amino acids, such as from lauric acid and arginine, in particular the ethyl ester of the lauramide of the arginine monohydrochloride (LAE), may be used for the treatment of objects which are infected with spores. The spores may... Agent: Laboratorios Miret, S.a.

20110144204 - Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same: Buffer solutions for pharmaceutical preparations that have bactericidal activity preferentially against gram negative bacteria are provided. The buffers have a pH of greater than about 10 or less than about 4.5 with low buffer capacity. Methods of their use in reducing the occurrence of blood stream infections in a mammal... Agent: United Therapeutics Corporation

20110144205 - Blood glutathione as a biomarker for screening asymptomatic patients at risk for heart failure: The present invention relates to a method for screening an asymptomatic patient at risk for heart failure, said method comprising measuring the concentration of glutathione in a blood sample obtained from said patient.... Agent: Inserm (institut National De La Recherche Medicale)

20110144206 - Use of a cox-2 inhibitor for the treatment of a cox-2 dependent disorder in a patient not carrying hla alleles associated with hepatotoxicity: This disclosure relates to a method of determining the presence of at least one HLA allele, preferably selected from the group consisting of DQA1*0102, DRB1*1501, DQB1*0602 and DRB5*0101 to assess whether a patient is at risk for developing hepatotoxicity upon administration of the COX-2 inhibitor lumiracoxib. Also disclosed is the... Agent:

20110144207 - Aryl alkyl carboxylic acid salts, process for preparation and dosage forms: The invention particularly discloses a process for preparing aryl alkyl carboxylic acid salts by preparing aqueous alkali solution, adding aryl alkyl carboxylic acid to said alkali solution at a temperature ranging from 4° to 121° C. for obtaining a clear solution, preferably by heating and/or stirring and concentrating and cooling... Agent: Shasun Chemicals And Drugs Limited

20110144208 - Cosmetic compositions comprising at least one bis-urea derivative: e

20110144209 - Use of vasoconstrictors: There is disclosed the topical dermal use of vasocontrictor substances for regulating body temperature to treat cancer by inducing hyperthermia and treat, prevent or delay the onset of anesthetic induced hypothermia. Kits containing appropriate materials and instructions, and other embodiments, are also disclosed.... Agent:

20110144210 - Stable dosage forms of levomilnacipran: The present invention relates to stable dosage forms of levomilnacipran and pharmaceutically acceptable salts thereof. Processes for the preparation of these dosage forms and methods of using these dosage forms are also described.... Agent: Forest Laboratories Holdings Ltd.

20110144211 - Use of microcrystalline cellulose for interfering with the extraction of ephedrine: Use of microcrystalline cellulose and, optionally, a surfactant in an aqueous pharmaceutical composition in order to inhibit the extraction of ephedrine for the purpose of drug abuse.... Agent:

20110144212 - Key intermediate for the preparation of stilbenes, solid forms of pterostilbene, and methods for making the same: The present invention provides a scalable process for the preparation of stilbenes by (i) condensing 3,5-dialkylbenzyl phosphonates with 4′-O-tetrahydropyranyl benzaldehyde to get 3,5-alkyl-4′-O-tetrahydropyranyl Stilbene and (ii) deprotecting the obtained 3,5-Dialkyl-4′-O-tetrahydropyranylstilbene to yield stilbenes. The present invention also provides a novel intermediate 3,5-Dialkyl-4′-O-tetrahydropyranyl stilbene, which is a key intermediate for the... Agent: Aptuit Laurus Private Limited

20110144213 - Anhydrous depigmenting compositions comprising a solubilized phenolic compound: Novel anhydrous dermatological depigmenting compositions, especially for topical application, contain, as pharmaceutical active agent, a phenolic compound dissolved in a fatty phase therefor.... Agent:

20110144214 - Hydroalcoholic gel compositions for use with dispensers: A hydroalcoholic gel composition includes greater than about 40 weight percent of an alcohol, based upon the total weight of the alcoholic composition, a polyacrylate thickener, and an ester plug-preventing agent. The composition is suitable for use in dispensers, and exhibits reduced mis-directed output when the dispenser is actuated.... Agent:

20110144215 - Bruise amelioration composition and method of use: A bruise amelioration composition that can be applied for one hour to an affected site, such as a bruise, contusion or blister, in the form of a gel, liquid or adhesive bandage. The composition includes at least 40% by weight of glycerin and at least 2% by weight of primrose... Agent: Dr. Holmquist Healthcare, L.L.C.

20110144216 - Compositions and uses of cis-1,1,1,4,4,4-hexafluoro-2-butene: This invention relates to compositions, methods and systems having utility in numerous applications, and in particular, uses for compositions containing the compound cis-1,1,1,4,4,4-hexafluoro-2-butene (Z-HFO-1336mzzm), which has the following structure:... Agent: Honeywell International Inc.

20110144217 - Polymer with salt groups and antifouling coating composition comprising said polymer: A film-forming polymer with improved chemical stability in antifouling coating applications, said polymer bearing pendant to its backbone a salt of (i) a basic group with a first pKa of the conjugate acid of at least 4.0 and (ii) an organic acid with a first pKa of 2.0 or less;... Agent: Akzo Nobel Coatings International B.v.

20110144218 - Taste-modified consumable products and methods of preparation: A taste-modified consumable product, such as food product (including but not limited to fruit juice concentrates, fruit purées, and dairy products such as yogurt and ice cream), medical product, romance product, or entertainment product, comprising of a taste-modifying substance, such as extract from a miracle berry, and a method for... Agent:

  
06/09/2011 > patent applications in patent subcategories. invention type

20110136722 - Drug delivery carrier: The present disclosure relates to a method for the sustained release of a drug, comprising the steps of: (a) preparing a biocompatible polymer having a hydrophobic group conjugated to the biocompatible polymer; and (b) contacting the biocompatible polymer to the drug for adsorbing the drug to the hydrophobic group of... Agent: Pronexx Co., Ltd.

20110136723 - Novel reagents and method for conjugating biological molecules: A compound of the general formula X-[Q-W—(CH═CH)n—(CH2)2-L]m (I) in which X represents a polymer; Q represents a linking group; W represents an electron-withdrawing group; n represents 0 or an integer of from 1 to 4; L represents a leaving group; and m represent an integer of from 1 to 8.... Agent: Polytherics Limited

20110136724 - Analogues of glucose-dependent insulinotropic polypeptide: There is provided a novel series of analogues of glucose-dependent insulinotropic polypeptide compounds, pharmaceutical compositions containing said compounds, and the use of said compounds as GIP-receptor agonists or antagonists for treatment of GIP-receptor mediated conditions, such as non-insulin dependent diabetes mellitus and obesity.... Agent:

20110136725 - Analogues of glucose-dependent insulinotropic polypeptide (gip) modified at n-terminal: There is provided a novel series of analogues of glucose-dependent insulinotropic polypeptide compounds, pharmaceutical compositions containing said compounds, and the use of said compounds as GIP-receptor agonists or antagonists for treatment of GIP-receptor mediated conditions, such as non-insulin dependent diabetes mellitus and obesity.... Agent:

20110136726 - Novel antimicrobial agents: A novel class of antimicrobial polymeric agents which are designed to exert antimicrobial activity while being stable, non-toxic and avoiding development of resistance thereto and a process of preparing same are disclosed. Further disclosed are pharmaceutical compositions containing same and a method of treating medical conditions associated with pathological microorganisms,... Agent: Technion Research & Development Foundation Ltd.

20110136727 - Compositions and methods for rapid selection of pathogen binding agents: Isolated glycan binding peptide complex comprise two or more glycan binding peptides operatively coupled to each other. These are bacterial binding peptide conjugates (e.g., glycan binding peptides) to a multivalent polymer (e.g., a multivalent PEG molecule) or to the surface of particles that create multimeric constructs that inhibit growth and... Agent:

20110136728 - Methods of increasing bone formation using leptin-related peptides: The present invention relates to methods of increasing bone formation in patient suffering from a wasting disorder by orally or intranasally administering a pharmaceutically effective amount of a leptin peptide and a pharmaceutically acceptable carrier, wherein the leptin peptide increases serum osteocalcin levels.... Agent:

20110136729 - Occidiofungin, a unique antifungal glycopeptide produced by a strain of burkholderia contaminans: The present invention is directed to novel antifungal glycopeptide compounds and salts thereof produced by a strain of Burkholderia contaminans useful for preventing or treating fungal infection or disease in animals and plants and the bacterial strain that produces the compounds.... Agent:

20110136730 - \"method for screening compounds comprising the use of picornavirus protease 2a\": A method of screening compounds or molecules comprising the steps of: translating a sequence encoding the amino acid sequence comprising SEQ ID No. 29 in a translation system in the presence of a test compound or molecule; and analysing the translation product(s) for the presence of one or more of... Agent:

20110136731 - Protein having pesticidal activity, dna encoding the protein, and noxious organism-controlling agent that controls the insect pest, emerald ash borer (eab), agrilus planipennis: A noxious organism-controlling agent disclosed herein is effective to pests that have acquired a resistance to conventional Bacillus thuringiensis (Bt) agents and has activity on Coleoptera pests and specifically against the emerald ash borer (EAB), Agrilus planipennis Fairmaire (Coleoptera: Buprestidae). Also disclosed is a microbe Bacillus thuringiensis serovar galleriae SDS502... Agent:

20110136732 - Infant nutritional compositions for preventing obesity: The present invention relates to a method for preventing obesity later in life by administering a certain nutritional composition to an infant with the age between 0 and 36 months. The composition comprises linoleic acid and alpha-linolenic acid.... Agent: N.v. Nutricia

20110136733 - Analogues of glucose-dependent insulinotropic polypeptide: There is provided a novel series of analogues of glucose-dependent insulinotropic polypeptide compounds, pharmaceutical compositions containing said compounds, and the use of said compounds as GIP-receptor agonists or antagonists for treatment of GIP-receptor mediated conditions, such as non-insulin dependent diabetes mellitus and obesity.... Agent:

20110136734 - Methods of modulating inflammation in preterm infants using carotenoids: The present disclosure relates to preterm infant formulas comprising lutein, lycopene, and beta-carotene, and the use of the preterm infant formulas to modulate inflammation, such as skin inflammation, in preterm infants. Also disclosed are methods of modulating the level of C-reactive protein in a preterm infant using preterm infant formulas... Agent:

20110136735 - Cyclohexane derivatives and uses thereof: e

20110136736 - New insulin analogues of prolonged activity: New biosynthetic analogues of recombined human insulin of prolonged therapeutical activity, which can find place in prophylactic and treatment of diabetes.... Agent: Instytut Biotechnologii I Antybiotykow

20110136737 - Dpp-iv resistant gip hybrid polypeptides with selectable properties: The Present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction... Agent: Amylin Pharmaceuticals, Inc.

20110136738 - Alternatively transcribed genes associated with schizophrenia: Methods of identifying gene targets associated with schizophrenia or the symptoms thereof, as well as to specific nucleic acid molecules that have been discovered to be associated with schizophrenia are provided. Accordingly, the invention also relates to methods of modulating schizophrenia or the symptoms thereof, methods of diagnosing schizophrenia or... Agent: University College Dublin, National University Of Ireland, Dublin

20110136739 - Use of s1p receptor agonists in heart diseases: The invention relates to the use of sphingosine-1-phosphate receptor agonist in the treatment of heart diseases.... Agent:

20110136740 - Cystine knot peptides binding to alpha iib beta 3 integrins and methods of use: Disclosed are peptides having a cystine knot structural motif and comprising a sequence engineered for specificity against αIIbβ3 integrin, found on platelets, and a method of using the same in anti-thrombotic therapies. The present peptides utilize a cystine knot scaffold derived from modified agouti-related protein or agatoxin, An alternate library... Agent: The Board Of Trustees Of The Leland Stanford Junior University

20110136741 - Dicarba-analogues of octreotide: Analogues of octreotide, their preparation and use are described.... Agent:

20110136742 - Antidepressant prodrugs: The invention provides antidepressant prodrugs comprising an antidepressant conjugated to one or more amino acids. The invention also relates to pharmaceutical compositions comprising an antidepressant prodrug, and to methods of preparing and using the same.... Agent:

20110136743 - Survivin, a protein that inhibits cellular apoptosis, and its modulation: The present invention provides the amino acid of a protein that inhibits cellular apoptosis, herein termed the Survivin protein and nucleic acid molecules that encode Survivin. Based on this disclosure, the present invention provides isolated Survivin protein, isolated Survivin encoding nucleic acid molecules, methods of isolating other members of the... Agent: Yale University

20110136744 - Cyclosporin analog formulations: The present disclosure relates to formulations containing cyclosporin analogs that are structurally similar to cyclosporin A, in particular isomeric mixtures of cyclosporin analogs that are structurally similar to cyclosporin A. The formulations form stable microemulsion preconcentrates and may provide superior drug bioavailability and/or may reduce one or more adverse effects... Agent: Isotechnika Inc.

20110136745 - Method of selecting soybeans with enhanced bioactivity and compositions for reducing cancer cell viability: The invention provides a method that uses enzyme-treatment of whole soybeans or partially defatted soybeans to select soybeans with improved bioactivity or bioactivities. The invention further provides a soybean plant and seed with a non-transgenic mutation conferring enhanced bioactivity as an hydrolysate when compared to hydrolysate from other seeds, for... Agent: Monsanto Technology LLC.

20110136746 - Kallikrein-binding \"kunitz domain\" proteins and analogues thereof: This invention provides: novel protein homologous of a Kunitz domain, which are capable of binding kallikrein; polynucleotides that encode such novel proteins; and vectors and transformed host cells containing these polynucleotides.... Agent: Dyax Corp.

20110136747 - Use of tight junction antagonists to treat inflammatory bowl disease: The present invention provides materials and methods for the treatment of inflammatory bowel disease (e.g., Crohn's disease and ulcerative colitis). Materials of the invention may include compositions comprising one or more tight junction antagonists and optionally one or more therapeutic agents. Methods of the invention may comprise treating a subject... Agent: Alba Therapeutics Corporation

20110136748 - Novel glucopyranose derivatives, preparation thereof, and biological uses thereof: The invention relates to a novel ester, the 3,5-di-tertiobutyl-4-hydroxybenzoate of 3,4,5-trihydroxy-6-methoxytetrahydropyran-2-yl methyl defined by the following formula (I). The invention also relates to the method for preparing the compound of formula (I) and to the use of said compound (I) to prepare a drug for treating and/or preventing enveloped virus... Agent:

20110136749 - Compounds useful for treating neurodegenerative disorders: As described herein, the present invention provides compounds useful for treating or lessening the severity of a neurodegenerative disorder. The present invention also provides methods of treating or lessening the severity of such disorders wherein said method comprises administering to a patient a compound of the present invention, or composition... Agent: Satori Pharmaceuticals, Inc.

20110136750 - Compounds useful for treating neurodegenerative disorders: As described herein, the present invention provides compounds useful for treating or lessening the severity of a neurodegenerative disorder. The present invention also provides methods of treating or lessening the severity of such disorders wherein said method comprises administering to a patient a compound of the present invention, or composition... Agent: Satori Pharmaceuticals, Inc.

20110136751 - Use of polyphenols in the treatment of cancer: The present invention relates to polyphenol compounds, compositions thereof, and methods for treating or preventing cancer in a subject, the methods comprising co-administering to a subject an effective amount of two or more polyphenol compounds or a polyphenol composition thereof.... Agent: Green Molecular

20110136752 - Novel antibiotics: The invention relates generally to novel antibiotics and their analogs, to processes for the preparation of these novel antibiotics, to pharmaceutical compositions comprising the novel antibiotics; and to methods of using the novel antibiotics to treat or inhibit various disorders.... Agent: Novobiotic Pharmaceuticals LLC

20110136753 - Glycosylated indolecarbazoles, method for obtaining same and uses thereof: Glycosylated indolocarbazoles, method for obtaining same and uses thereof. This invention relates to rebeccamycin and staurosporine derivatives obtained by fermentation of recombinant bacterial strains. The invention also relates to the methods used to obtain the recombinant strains and the production of rebeccamycin and staurosporine derivatives. The invention also relates to... Agent: Entrechem S.l.

20110136754 - Novel triazole derivatives, their preparation and their application in therapeutics: y

20110136889 - Compositions and their uses directed to aceytl-coa carboxylases: Disclosed herein are compounds, compositions and methods for modulating the expression of ACC1 or ACC2 or both in a cell, tissue or animal. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders.... Agent: Isis Pharmaceuticals Inc.

20110136891 - Nucleic acid molecules and collections thereof, their application and identification: Provided is a method for characterising a sample comprising nucleic acid derived from a cell. The method comprises determining whether a sample comprises at least a minimal sequence of at least one new microRNA (miRNA) as disclosed herein or a mammalian ortholog thereof and characterizing the sample on the basis... Agent: Koninklijke Nederlandse Akademie Van Wetenschappen

20110136892 - Targeting tgf-beta as a therapy for alzheimer's disease: The invention includes compositions and methods for enhancing peripheral macrophage Aβ phagocytosis activity. The invention includes inhibiting a component of TGF-β signaling pathway in peripheral macrophages to promote central nervous system infiltration and beneficial cerebral Aβ clearance. Inhibition of TGF-β signaling in peripheral macrophages represents an advantageous anti-amyloid therapeutic approach... Agent: Yale University

20110136890 - Treatment of fibrotic conditions: Treatment of fibrosis and fibrotic diseases, disorders, and conditions, and associated methods, compositions, formulations and articles.... Agent:

20110136895 - Methods and compositions for modulating pd1: Disclosed herein are methods and compositions for modulating expression of a PD1 gene.... Agent: Sangamo Biosciences, Inc.

20110136893 - Oligonucleotide-, protein and/or peptide-polymer conjugates: A conjugate or compound comprising polyethyleneglycol and an oligonucleotide, wherein at least one polyethyleneglycol is linked to the 5′-end of the oligonucleotide and at least one polyethyleneglycol is linked to the 3′-end of the oligonucleotide, wherein the molecular weight of the polyethyleneglycol linked to the 5′- and 3′-end of the... Agent:

20110136894 - Shortened alk1 regulatory fragment: Regulatory elements for controlling expression of transgenes in angiogenic tissue are provided. One embodiment provides an isolated nucleic acid having at least 80%, 85%, 90%, 95%, 97%, 99% or 100% sequence identity to SEQ ID NO:1, or a fragment thereof that causes expression of a transgene in angiogenic tissue. Vectors... Agent: Medical College Of Georgia Research Institute, Inc.

20110136897 - Toll-like receptor 9 agonists for the treatment of anxiety-related disorders and inflammatory disorders: Uses of TLR-9 agonists are disclosed. The uses include treatment of anxiety-related disorders and inflammatory disorders. For treatment of inflammatory disorders the TLR-9 agonists are administered together with a therapeutically effective amount of a glucocorticoid.... Agent: Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.

20110136896 - Variant hcmv pp65, ie1, and ie2 polynucleotides and uses thereof: The present invention relates to compositions and methods to elicit or enhance cell-mediated immunity against HCMV infection by providing polynucleotides encoding variant HCMV pp65, IE1, and IE2 proteins, and fusion proteins thereof. The present invention also provides recombinant vectors including, but not limited to, adenovirus and plasmid vectors comprising said... Agent:

20110136755 - 2-propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity: e

20110136756 - Combination antitumor therapy: The present disclosure relates to methods of treating cancers that are responsive to antimetabolite or antimitotic anti-cancer agents. The methods involve the use of at least one anti-cancer agent selected from antimetabolite anti-cancer agents, antimitotic anti-cancer agents, and combinations thereof, and a superoxide dismutase mimetic to potentiate the therapeutic effect... Agent:

20110136757 - Hypersulfated disaccharide formulations: Hypersulfated disaccharides with utility in asthma or asthma related disorders are disclosed. The compounds are formulated with agents that enhance the oral delivery of the hypersulfated disaccharides. The delivery agents are selected from the group consisting of natural or synthetic polymers having ionic side chains as well as other compounds... Agent: Opko Health, Inc.

20110136758 - Carbohydrate compositions from basidiomycete fungi as biocidal agents active against pathogens: The invention provides biologically active compositions comprising oligosaccharides, and which are produced by growing a fungal culture, and are at least partially purified for use. The compositions of the invention have antibacterial, antifungal and nematicidal activity, and are thus useful to reduce the impact of such pathogens on growing plants,... Agent:

20110136759 - Moenomycin analogs, methods of synthesis, and uses thereof: The present invention provides novel moenomycin analogs as well as pharmaceutical compositions thereof, methods of synthesis, and methods of use in treating an infection by administering an inventive compound to a subject in need thereof. The moenomycin analogs may be prepared synthetically, biosynthetically, or semi-synthetically. The analogs are particularly useful... Agent:

20110136762 - Fungicidal pyridazines: e

20110136760 - Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases: The present invention is concerned with novel compounds useful in the treatment of hyperproliferative diseases and mammalian cancers, especially human cancers. The invention also pertains to methods of modulating kinase activities, pharmaceutical compositions, and methods of treating individuals, incorporating or using the compounds. The preferred compounds are active small molecules... Agent:

20110136761 - Vapour of a citrus essential oil blend and its antimicrobial properties: A vapour of a blend comprising the oil of orange and the oil of bergamot, a process for its preparation and its use as an antimicrobial. The vapour has been found to be particularly useful on food contaminated with microorganisms without affecting the sensory properties of the food.... Agent: The University Of Northampton

20110136763 - Trisubstituted boron-containing molecules: This invention largely relates to 3,4,6-trisubstituted benzoxaborole compounds, and their use for treating bacterial infections.... Agent: Glaxosmithkline LLC

20110136764 - Amino pyrimidine anticancer compounds: i

20110136766 - Aurora kinase inhibitors: Disclosed herein are Aurora kinase Inhibitors represented by Structural Formula (I): Values for the variables in Structural Formula (I) are defined herein.... Agent: Vitae Pharmaceuticals, Inc.

20110136765 - Pyrrolo[2,3-d]pyrimidine compounds: Described herein are pyrrolo[2,3-d]pyrimidine compounds, their use as Janus Kinase (JAK) inhibitors, pharmaceutical compositions containing these compounds, and methods for their preparation.... Agent: Pfizer Inc.

20110136767 - Processes for preparing piperazinium salts of kmup and use thereof: A series of monoquarternary piperazium salts including a structure of a formula I or II are provided. In formula I or II, R1, Ra, and RX are as defined in the specification. The monoquarternary piperazium salt of KMUP or piperazine disclosed in the present invention is characterized by being presented... Agent: Kaohsiung Medical University

20110136768 - Imatinib mesylate for the treatment of nephrogenic systemic fibrosis: Disclosed herein are methods of treatment and/or prevention of nephrogenic systemic fibrosis (NSF) in a subject in need thereof. The methods comprise administering an effective amount of imatinib mesylate to the subject, to thereby treat or prevent the nephrogenic systemic fibrosis. A corticosteroid and/or an antihistamine may also be administered.... Agent: The General Hospital Corporation

20110136769 - Method of treating men with testosterone supplement and 5alpha-reductase inhibitor: A method of treating Alzheimer's disease, Parkinson's disease, sexual dysfunction or erectile dysfunction in a man by administration of a 5alpha reductase inhibitor together with a testosterone supplement is described. The method is also concerned with the use of the 5alpha reductase inhibiting compound and the testosterone supplement together with... Agent: Merck Sharp & Dohme Corp.

20110136770 - Method for providing emergency contraception: m

20110136771 - Orally disintegrating solid dosage forms comprising progestin and methods of making and use thereof: The present invention is directed to non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising progestin and methods of making and using the dosage forms to treat conditions in females in need thereof.... Agent:

20110136772 - Sugar coatings and methods therefor: Compositions particularly useful as coatings for solid dosage forms of therapeutic agents are provided, as are solid dosage forms comprising such coatings, processes for preparing such solid dosage forms, and the products of those processes. The coating compositions generally provide excellent strength and resistance to cracking, even when applied to... Agent: Wyeth LLC

20110136773 - Pharmaceutical uses of lanosta-8,24-dien-3-ols: The invention generally refers to pharmaceutical uses of lanosta-8,24-dien-3-ols, a family of tetracyclic terpenols, as anti-inflammatory, anticancerigenous and analgesic agents via the inhibition of the disordered activation of serine-threonine protein kinases, particularly PKC.... Agent: Amazonia Fitomedicamentos Ltda

20110136774 - Anti-apoptotic benzodiazepine receptor ligand inhibitors: The present invention provides low molecular weight porphyrin compositions for inhibiting, preventing or delaying the binding of a ligand of a mitochondrial benzodiazepine receptor. The invention also provides pharmaceutical compositions comprising these porphyrin compositions and their use in the treatment of conditions involving the mitochondrial benzodiazepine receptor or interactions between... Agent:

20110136775 - Methods for treating injury associated with exposure to an alkylating species: Compounds may be administered to prevent or rescue organ injury following exposure to alkylating agents, such as sulfur mustards. The compounds may be substituted metalloporphyrins.... Agent: National Jewish Health

20110136776 - Copper(1)chloride complex of nicotinic acid and pharmaceutical compositions containing the same: Copper (I) chloride complex of nicotinic acid and pharmaceutical compositions containing the same. Such pharmaceutical composition are effective for the treatment of myopathy, myasthenia gravis, parkinsonism, Chronic Fatigue Syndrome, Male Infertility and post stroke muscle weakness, muscular dystrophy, skin burns, scars, alopecia, high blood lipids and obesity.... Agent:

20110136777 - Crystalline sodium salt of cephalosporin antibiotic: Polymorphs of Ceftiofur sodium as a crystalline product and a process for the preparation of polymorphs of crystalline Ceftiofur sodium of formula (I).... Agent: Orchid Chemicals And Pharmaceuticals Limited

20110136778 - Nitrogen-containing spirocyclic compounds and pharmaceutical uses thereof: l

20110136779 - Methods for stroke reduction in atrial fibrillation patients: The subject invention provides methods for reducing stroke rate, methods for preventing atrial remodeling, and methods for reversing atrial remodeling by administering a multiple ion channel blocker anti-arrhythmic to reduce atrial fibrillation (AF) episode duration and an anticoagulant (AC). According to some methods of the invention, the average AF episode... Agent:

20110136780 - Dihydropyrrolonaphtyridinone compounds as inhibitors of jak: where G1, R1, R2, R3, R4, R5, R6, and R7 are defined in the specification. Also disclosed are pharmaceutical compositions, kits and articles of manufacture which contain the compounds, methods and materials for making the compounds, and methods of using the compounds to treat diseases, disorders, and conditions involving the... Agent: Takeda Pharmaceutical Company Limited

20110136781 - Imidazotriazines and imidazopyrimidines as kinase inhibitors: The present invention is directed to imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.... Agent: Incyte Corporation

20110136783 - [6,6] and [6,7]-bicyclic gpr119 g protein-coupled receptor agonists: e

20110136782 - Nitrogen-containing heterocyclic derivative and fungicide for agricultural and horticultural use: The present invention provides a nitrogen-containing heterocyclic compound represented by formula (I) and salt thereof (wherein, R1 to R6 each independently represents a hydrogen atom, unsubstituted or substituted C1-20 alkyl group and the like, R1 and R2, R3 and R4, or R5 and R6 may together form an unsubstituted or... Agent: Nippon Soda Co., Ltd

20110136784 - Method of treating anxiety disorders: e

20110136786 - Method of treating mood disorders: Methods of treating mood disorders comprising administering an effective amount of 11-piperazin-1-yldibenzo[b,f][1,4]thiazepine or a pharmaceutically acceptable salt thereof and pharmaceutical compositions therefor.... Agent:

20110136785 - Method of treatment: t

20110136787 - Diphenyl azepane, diazepane and oxazepane derivatives and uses thereof:

20110136788 - Therapeutic agent for irritable bowel syndrome:

20110136789 - C-met protein kinase inhibitors: The present invention relates to compounds of formula I useful in the inhibition of c-Met protein kinase. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of proliferative disorders.... Agent: Vertex Pharmaceuticals Incorporated

20110136790 - Tricyclic heterocyclic derivatives and methods of use: The present invention relates to novel Tricyclic Heterocycle Derivatives, pharmaceutical compositions comprising the Tricyclic Heterocycle Derivatives and the use of these compounds for treating or preventing allergy, an allergy-induced airway response, congestion, a cardiovascular disease, an inflammatory disease, a gastrointestinal disorder, a neurological disorder, a metabolic disorder, obesity or an... Agent:

20110136791 - Combination of a nicotinic receptor partial agonist and of an acetylcholinesterase inhibitor, pharmaceutical composition containing same and use thereof in the treatment of cognitive disorders: The combination of an alpha-7 nicotinic receptor agonist and of an acetylcholinesterase inhibitor, pharmaceutical composition comprising the combination and the use thereof in the treatment of cognitive disorders.... Agent: Sanofi-aventis

20110136792 - Novel carboxylic acid analogs as glycogen synthase activators: e

20110136793 - Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs: Patients which are treated with stimulants (e.g., CNS stimulants, sympathomimetic amine, or anorectic/anorexigenic), such as patients being treated for attention deficit/hyperactivity disorder or obesity, often are atrisk in developing high blood pressure. Similarly, patients which are treated with analgesics such as non-steroidal anti-inflammatory drugs (NSAIDs) over an extended period of... Agent:

20110136794 - Novel pyrrole derivative having, as substituents, ureido group, aminocarbonly group and bicyclic group which may have substituent: The compound has an inhibitory activity on the production of interleukin-6, and is therefore useful as a preventive and/or therapeutic agent for a disease associated with interleukin-6, ocular inflammatory diseases and the like. In the formula, R1 represents a halogen atom, a hydrogen atom, a lower alkyl group which may... Agent:

20110136795 - Tricyclic alkylaminomethyloxazolidinone derivatives: e

20110136797 - Cyclopropyl amines as modulators of the histamine h3 receptor: Certain cyclopropyl amines are histamine H3 modulators useful in the treatment of histamine H3 receptor mediated diseases.... Agent:

20110136796 - Ido inhibitors: Presently provided are compounds according to the formula (I) or (II), and pharmaceutical compositions comprising the compounds, wherein R1, R4, and R5 are defined herein. Such compounds and compositions are useful for modulating an activity of indoleamine 2,3-dioxygenase; treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression; treating a medical conditions that benefit... Agent: Lankeanau Institute For Medical Research

20110136798 - Crystalline forms of a pyridine derivative: e

20110136799 - Proline derivatives:

20110136800 - Aryl-and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline: wherein the variables R1, R2, R3, R4, and m are defined as in claim 1, possessing valuable pharmacological activity. Particularly, the compounds are inhibitors of 11β-hydroxysteroid dehydrogenase (HSD) 1 and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this enzyme, such as... Agent: Boehringer Ingelheim International Gmbh Vitae Pharmaceuticals

20110136801 - Novel compounds: e

20110136802 - Ship1 modulators and methods related thereto: including stereoisomers and pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3, R4, R5, R6 and R7 are as defined herein. Such compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation.... Agent: Aquinox Pharmaceuticals Inc.

20110136803 - Triazolophthalazines: c

20110136804 - Nicotinic acetylcholine receptor ligands 101:

20110136805 - Bicyclic heterocycles, medicaments containing said compounds, use thereof, and method for production of same: the tautomers, the stereoisomers, the mixtures and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids which have valuable pharmacological properties, particularly an inhibitory effect on signal transduction mediated by tyrosine kinases, the use thereof for treating diseases, particularly tumoral diseases, as well as benign... Agent: Boehringer Ingelheim International Gmbh

20110136806 - Bicyclic heterocycles, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof: The invention relates to bicyclic heterocycles of general formula (I), in which Ra, Rb, Rc, Rd, Re and X are as defined in claim 1, the tautomers, stereoisomers, mixtures and salts thereof, in particular, the physiologically-acceptable salts thereof with inorganic and organic acids with useful pharmacological properties, in particular, an... Agent: Boehringer Ingelheim International Gmbh

20110136808 - 3',6-substituted indirubins and their biological applications: Indirubin derivatives of formula (I) wherein R represents -(A)n- R1 or —CO—N(R2,R3) with •A being C1-C5 alkylene group, optionally substituted by one or several A1 radical, A1 being an halogen Br, OH, OR4 or NH2, R4 being C1-C5 alkyl; —R1 being halogen, OH, N(R2, R3); R2 and R3, identical or... Agent:

20110136807 - Bicyclic compositions and methods for modulating a kinase cascade: The invention relates to compounds and methods for modulating one or more components of a kinase cascade.... Agent: Kinex Pharmaceuticals, LLC

20110136809 - Substituted pyrazolyl urea derivatives useful in the treatment of cancer: The present invention relates to compounds of formula (I), pharmaceutical compositions which contain them and methods for treating cancer using compounds of formula (I).... Agent: Bayer Pharmaceuticals Corporation

20110136810 - Antitumor agent, kit and method of treating cancer: Disclosed are an antitumor preparation comprising a combination of (1) a combination drug of tegafur/gimeracil/oteracil potassium, (2) at least one ingredient selected from the group consisting of folinic acid and pharmacologically acceptable salts thereof, and (3) cis-oxalate(1R,2R-diaminocyclohexane)platinum(II); a kit comprising a combination of pharmaceutical compositions for treating cancer in a... Agent: Taiho Pharmaceutical Co., Ltd.

20110136811 - Prokineticin 1 receptor: The present invention relates to methods of monitoring the biological activity of the PK1 receptor.... Agent:

20110136814 - Diazepine and diazocane compounds as mc4 agonists: The present invention relates to compounds of formula (I) wherein R1, R2, R3, R4, L and n are as defined in the specification. These compounds are useful as MC4 agonists.... Agent:

20110136812 - Solubilized topoisomerase poisons: A, B, W, Y, Z, and R1 have any of the meanings defined in the specification and their pharmaceutically acceptable salts. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I, and therapeutic... Agent: Rutgers, The State University Of New Jersey

20110136813 - Wnt protein signalling inhibitors: The present invention generally relates to protein signalling. In particular, compounds that inhibit the Wnt protein signalling pathway are disclosed. Such compounds may be used in the treatment of Wnt protein signalling-related diseases and conditions such as cancer, degenerative diseases, type II diabetes and osteopetrosis.... Agent:

20110136816 - Compounds that modulate intracellular calcium: Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of SOC channel... Agent: Calcimedica, Inc.

20110136815 - Solid oral film dosage forms and methods for making same: Improved pharmaceutical solid oral film dosage forms for the buccal and/or sublingual delivery of pharmaceutical, nutraceutical or cosmetic ingredients are endowed with instant hydration potential and complete dissolution potentially enabling the active ingredient to become immediately available for enhanced buccal and/or sublingual absorption and/or reduced absorption through the gastrointestinal route.... Agent:

20110136817 - Methods of identifying responders to dopamine agonist therapy: The present invention is directed to a method of identifying patients to be treated by dopamine agonist therapy comprising the step of analyzing a plasma or urine sample from said patient for concentrations of norepinephrine (NE), norepinephrine metabolites (NE metabolites), dopamine, dopamine metabolites, serotonin, serotonin metabolites, or fasting triglycerides, wherein... Agent:

20110136819 - 6-thioxopyridazine derivatives: Compounds of the formula I, in which R1, R2 and R3 have the meanings indicated in claim 1, are inhibitors of tyrosine kinases, in particular Met kinase, and can be employed, inter alia, for the treatment of tumours.... Agent: Merck Patent Gesellschaft Mit Beschr&#xc4 Nkter Haftung

20110136818 - Therapeutic compositions containing macitentan: The invention relates to a product containing the compound of formula (I) below or a pharmaceutically acceptable salt of this compound, in combination with at least one compound having prostacyclin receptor (IP) agonist properties, or a pharmaceutically acceptable salt thereof.... Agent:

20110136820 - Heterocyclic compounds as ccr2 antagonists: e

20110136821 - Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1: This invention relates to novel compounds of the Formulae I or II and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11 β-HSD 1 in mammals. Formula (I).... Agent: Vitae Pharmaceuticals Inc.

20110136822 - Certain crystalline hydrates, pharmaceutical compositions thereof and methods for preparation and use thereof: i

20110136823 - Compounds having a potentiating effect on the activity of ethionamide and uses thereof: The present invention relates to the use of compounds with a potentiating effect on the activity of antibiotics that are activatable via the EthA enzymatic pathway, for the preparation of a medicament for preventing and/or treating mycobacterial infections such as tuberculosis and leprosy, to pharmaceutical compositions comprising them in combination... Agent: Institut National De La Sante Et De La Recherche Medicale (inserm)

20110136824 - Urotensin ii receptor antagonists: The invention is directed to Urotensin II antagonists. More specifically, the present invention relates to certain novel compounds, methods for preparing compounds, compositions, intermediates and derivatives thereof and methods for treating Urotensin-II mediated disorders. Pharmaceutical and veterinary compositions and methods of treating cardiovascular disorders and various other disease states or... Agent:

20110136825 - Treatment of vasomotor symptoms: The invention relates to a method for the treatment of vasomotor symptoms comprising the administration of a therapeutically effective amount of flibanserin.... Agent: Boehringer Ingelheim International Gmbh

20110136826 - Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis: The present invention relates to a pharmaceutical combination for the treatment of diseases which involves cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis. The invention also relates to a method for the treatment of said diseases, comprising co-administration of effective amounts of specific active compounds and/or co-treatment with... Agent: Boehringer Ingelheim International Gmbh

20110136827 - Bis-acylated hydroxylamine derivatives: The invention provides certain bis-acylated hydroxylamine derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the invention provides methods of using such compounds or pharmaceutical compositions for treating, preventing, or delaying the onset and/or develop of a disease or... Agent:

20110136829 - 3-(n-heterocyclyl)-pyrrolidinyl-phenyl-oxazolidinones as antibacterial agents: The invention provides new oxazolidinone compounds of formula (I) wherein R, R1, R2 and R3 have different meanings. Preparative processes, pharmaceutical compositions, and uses thereof in the treatment of bacterial infections are also provided.... Agent: Ferrer Internacional, S.a.

20110136830 - Chromenone derivatives: e

20110136828 - Substituted n-oxide pyrazine derivatives:

20110136831 - N-2-(hetero)arylethylcarboxamide derivative, and pest-controlling agent comprising the same: wherein R1 and R2 are each independently a hydrogen atom etc., R3 and R4 are each independently a hydrogen atom etc., each Y is independently a halogen atom; a (C1-C6)alkyl group optionally substituted by halogen atom(s) etc., n is an integer of 1 to 5, A is a specific substituted... Agent:

20110136832 - Promoting cycling of apoe4 isoform: Cycling of ApoE4 isoform is promoted in a person in need thereof by contacting the person with an effective amount of a pharmaceutically-acceptable modulator of intracellular ApoE4 transport vesicle pH.... Agent: University Of Texas , Board Of Regents

20110136833 - Tetrahydropyridinyl and dihydropyrrolyl compounds and the use thereof: The invention relates to tetrahydropyridinyl and dihydropyrrolyl compounds of Formula (I): and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein X, Y, Z, R1, R2, m, and n are defined as set forth in the specification. The invention is also directed to the use of compounds of Formula (I) to... Agent: Shinogi & Co., Ltd.

20110136834 - Inhibitors of e1 activating enzymes: This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.... Agent: Millennium Pharmaceuticals, Inc.

20110136835 - Combination formulations of tranilast and allopurinol and methods related thereto: Disclosed is a pharmaceutical composition comprising tranilast or a pharmaceutically acceptable salt thereof and allopurinol or a pharmaceutically acceptable salt thereof, wherein the amount by weight of said allopurinol or pharmaceutically acceptable salt thereof in said composition is greater than the amount by weight of said tranilast or pharmaceutically acceptable... Agent: Nuon Therapeutics, Inc.

20110136836 - Methods for altering mrna splicing and treating familial dysautonomia and other mechanistically related disorders: This invention relates to methods for altering the splicing of mRNA in cells. In particular, this invention also relates to methods for increasing the ratio of wild type to misspliced forms of mRNA and corresponding encoded proteins in cells possessing a mutant gene encoding either the i) misspliced mRNA corresponding... Agent: The General Hospital Corporation

20110136837 - Mucoadhesive buccal tablets for the treatment of orofacial herpes: The present invention relates to the treatment or prevention of muco-cutaneous herpes simplex virus diseases using prolonged release mucoadhesive buccal tablets comprising an acyclic guanosine antiviral agent. These tablets are particularly suitable for the treatment or prevention of orofacial herpes.... Agent: Bioalliance Pharma

20110136838 - Chemical compounds: The compounds of the invention are inhibitors of PDK1 and can be useful in the treatment of disorders characterized by constitutively activated ACG kinases such as cancer and more specifically cancers of the breast, colon, and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of... Agent:

20110136839 - Combination of two analgesic chemicals: The present invention is a novel analgesic combination and its use. It is classified to he an invention in the field of medicine and technology. The purpose of this invention is to solve the problem that existing analgesics does not effectively attenuate pain or produces serious side-effects in clinic. The... Agent:

20110136840 - Anti-infective agents: The present invention relates to the use of molecules having a spacer unit, linker and recognition unit(s) for the treatment and prevention of various diseases, disorders and conditions. In particular, the present invention provides compounds useful in preventing or treating infectious diseases and diseases, disorders or conditions related thereto. Further,... Agent:

20110136842 - Substituted dihydroisoquinolinone and isoquinolinedione derivatives as calcium channel blockers: A series of disubstituted dihydroisoquinolinone and isoquinolinedione derivatives represented by Formula I, or pharmaceutically acceptable salts thereof are presented. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating... Agent:

20110136841 - Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase: s

20110136845 - (+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof: The present invention provides (+)-morphinans comprising Toll-like receptor 9 (TLR9) antagonist activity, as well as methods for using the (+)-morphinans to treat pain. Also provided are pharmaceutical combination compositions comprising a (+)-morphinan and an opioid agonist/monoamine reuptake inhibitor, as well as methods for using the combination compositions to treat pain.... Agent: Mallinckrodt Inc.

20110136844 - Methods for inhibiting dyrk1a to treat central nervous system diseases and disorders: Compositions and methods for treating, preventing and/or delaying the onset and/or the development of diseases and disorders of the central nervous system are disclosed. The present disclosure relates to indoloquinoline compounds that are capable of inhibiting at least one protein kinase, and to methods for preparing and uses of such... Agent: Medipropharma, Inc.

20110136843 - Novel combination of compounds to be used in the treatment of airway diseases, especially chronic obstructive pulmonary disease (copd) and asthma: The present invention relates to a combination of (a) a chemokine receptor 1 (CCR1) antagonist and (b) a muscarinic antagonist. The invention further relates to pharmaceutical compositions comprising said combination and to methods of treatment of airway diseases, such as chronic obstructive pulmonary disease (COPD) and asthma in mammals by... Agent:

20110136846 - Buprenorphine analogs: The present invention is directed to Buprenorphine Analog compounds of the Formula I, Formula II or Formula III shown below, wherein R1, R2, R8, R3, R3a, R3b, X, Z and Y are as defined herein, R1 H3CO (I) OCH3 OCH3 (III) Compounds of the Invention are useful for treating pain... Agent: Purdue Pharma L.p.

20110136847 - High concentration formulations of opioids and opioid derivatives: The present invention provides opioid formulations suitable for long-term delivery to a subject. The formulation of the invention comprises an opioid or opioid derivative (e.g., morphine, hydromorphone, fentanyl or a fentanyl congener), and an aqueous solvent comprising a low molecular weight carboxylic acid (e.g., C2-4, C2-7). The invention thus provides... Agent:

20110136848 - Morphinan derivatives for the treatment of drug overdose: The instant application relates to morphinan derivatives of Formula I with sustained effectiveness in treating drug toxicity and overdose:... Agent: Alkermes, Inc.

20110136849 - Process for reducing contaminating michael acceptor levels in oxycodone and other compositions: The present invention relates to processes for removal of Michael acceptors from certain compositions wherein the composition is treated with a thiol-containing compound under conditions sufficient to remove Michael acceptors and the resulting thiol-Michael adducts. Certain embodiments of the present invention enable quantification and/or removal of Michael acceptors and/or Michael... Agent:

20110136850 - Methods and compositions for topoisomerase i modulated tumor suppression: Disclosed herein are methods and compositions for determining the sensitivity or enhancing the sensitivity of cells to the effects of topoisomerase I inhibitors. Also disclosed are methods and compositions for inducing cell death, apoptosis and/or growth arrest which may be used for tumor suppression.... Agent:

20110136851 - Sucralose formulations to mask unpleasant tastes: The present invention is directed to a pharmaceutically acceptable taste masking liquid excipient base for administration of a relatively large amount of unpleasant tasting medicines. More particularly, the enhanced sweetness and taste masking effect are produced by the addition of sucralose to the excipient base with maintenance of a pH... Agent: Wyeth LLC

20110136852 - Rapamycin derivative or an impdh inhibitor for treating polycystic kidney disease: A method for treating polycystic kidney disease, comprising administering to a subject in need thereof a therapeutical effective amount of an inosine-5′-monophosphate dehydrogenase inhibitor or a rapamycin derivative.... Agent:

20110136853 - Ligand with a broad spectrum of pharmacological activity, a pharmaceutical composition, a medicinal agent and a method of treatment: m

20110136854 - Novel 9-aza-bicyclo[3.3.1]non-3-yloxy chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors: This invention relates to novel 9-aza-bicyclo[3.3.1]non-3-yloxy chromen-2-one derivatives useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.... Agent: Neurosearch A/s

20110136855 - Gemifloxacin process and polymorphs: The present invention provides a novel process for the preparation of gemifloxacin and its pharmaceutically acceptable acid addition salts in high yield. The present invention also relates to novel polymorphs of gemifloxacin free base and its hydrates to the processes for their preparation and to pharmaceutical compositions comprising them. The... Agent: Hetero Drugs Limited

20110136856 - Novel imidazo[1,5-a]pyridine derivatives, method for preparing same and pharmaceutical compositions containing same: The invention concerns compounds of formula I, a method for preparing said compounds, pharmaceutical compositions containing same and the theraprutic uses thereof.... Agent: Sanofi-aventis

20110136857 - Pyrrole[2,3-b]pyridine derivatives active as kinase inhibitors: Compounds which are pyrrolo[2,3-b]pyridine derivatives or pharmaceutically acceptable salts thereof, their preparation process and pharmaceutical compositions comprising them are disclosed; these compounds are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune... Agent: Pfizer Italia S.r.l.

20110136858 - Preferred combination therapy: Composition and use of a medicament comprising a fixed dose combination of droloxifene and clopidogrel, or the pharmaceutically acceptable salts thereof, for treating or preventing a disorder associated with the loss of normal adult tissue architecture.... Agent:

20110136859 - Compounds: m

20110136860 - Compounds: with the proviso that when o=0, then n is 1, 2 or 3 and when o=1, then n is 1 or 2 is provided. Pharmaceutical compositions comprising the compounds are also provided. These compounds are useful in the treatment of various disorders including arrhythmia.... Agent: Xention Ltd.

20110136863 - N-heterocyclic m1 receptor positive allosteric modulators: The present invention is directed to compounds of formula (I) (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical... Agent:

20110136862 - Novel tetramethyl substituted piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors: This invention relates to novel tetramethyl substituted pipehdine derivatives useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.... Agent: Neurosearch A/s

20110136861 - Quinolone inhibitors of lipoprotein-associated phospholipase a2: The present invention relates to new quinolone inhibitors of lipoprotein-associated phospholipase A2 activity, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Auspex Pharmaceuticals, Inc.

20110136864 - Tetrahydroquinoline indole derivatives and uses thereof: e

20110136865 - Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists: The present invention relates to the use of compounds and compositions of compounds having D4 and 5-HT2A antagonistic, partial agonistic or inverse agonistic activity for the treatment of the underlying dysregulation of the emotional functionality of mental disorders (i.e. affect instability-hypersensitivity-hyperaesthesia-dissociative phenomena-etc). The invention also relates to methods comprising administering... Agent:

20110136866 - Insecticidal phenyl- or pyridyl-piperdine compounds: A compound of formula (I): wherein A, p, R1, R3, R4, R5, R6, m, R7, n and R8 are as defined in claim 1. Furthermore, the present invention relates to intermediates used to prepare compounds of formula (I), to methods of using them to combat and control insect, acarine, nematode... Agent: Syngenta Crop Protection LLC

20110136868 - Agents for inhibiting osteoclastogenesis and/or osteoclast activation: Agents, which are both ceramide glucosyltransferase inhibitors and glucosidase inhibitors, may inhibit osteoclastogenesis and/or reduce osteoclast activation and, therefore, may be useful for osteolytic activity and bone loss in subjects with conditions, such as multiple myeloma.... Agent: University Of Oxford

20110136867 - Treatment of synucleinopathies: Methods and compositions useful in the treatment or prevention of synucleinopathies, such as Parkinson's Disease, Diffuse Lewy Body Disease, and Multiple System Atrophy, or other neurodegenerative diseases are provided. The treatment including administering to a subject a farnesyl transferase inhibitor compound.... Agent:

20110136869 - Compounds which selectively modulate the cb2 receptor: t

20110136870 - Gacyclidine formulations: Improved formulations of gacyclidine for direct administration to the inner or middle ear.... Agent: Neurosystec Corporation

20110136871 - 2-alkoxy-substituted dicyanopyridines and their use: The present application relates to novel 2-alkoxy-substituted dicyanopyridines, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prevention of cardiovascular disorders.... Agent: Bayer Schering Aktiengesellschaft

20110136872 - Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof: The present invention is based on the discovery that a marked increase in aqueous stability (and thereby shelf life) of prostanoid agonist prodrug compositions is achieved by incorporating into the compositions certain well-defined carboxylic acids, and thereafter adjusting the pH of the compositions from about 4.0 to about 8.0. As... Agent:

20110136873 - Inhibitors of cyclin dependent kinases and their use: wherein R1, R2, R3, R4, R5, R6, R7 and A have the meanings indicated in the claims. The invention also relates to processes for the preparation of the compounds of formula (Ia), to methods of inhibiting cyclin-dependent kinases and of inhibiting cell proliferation, to the use of the compounds of... Agent: Piramal Life Sciences Ltd.

20110136874 - Fungicidal n-(2-pyridylpropyl) carboxamide derivatives and their oxa, aza and thia analogues: e

20110136875 - Pyrrole inhibitors of s-nitrosoglutathione reductase: The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same.... Agent: N30 Pharmaceuticals, LLC

20110136876 - Altering pharmacokinetics of pirfenidone therapy: The invention relates to methods for reducing adverse events in patients receiving pirfenidone (5-methyl-1-phenyl-2-(1H)-pyridone) therapy.... Agent: Intermune, Inc.

20110136877 - 2-phenyl phenoxyacetic acids useful for treating inflammatory disorders: The present invention provides novel phenoxyacetic acids useful for the prevention and treatment of inflammatory disorders, including those affecting the respiratory system and skin. The compounds are of the general formula (I):... Agent: Ligand Pharmaceuticals Inc.

20110136878 - Amide derivative, pest control agent containing the amide derivative, and pest controlling method: A pest control agent containing a compound represented by the following Formula (1), wherein A represents a carbon atom, a nitrogen atom, or the like, K represents a non-metal atom group necessary for forming a cyclic linking group derived from a 5- or 6-membered aromatic ring, in combination with A... Agent: Mitsui Chemicals Agro., Inc.

20110136879 - Compound: p

20110136880 - Latrunculin-based macrolides and their uses: Latrunculin derivatives are disclosed, as are anti-invasive and cytotoxic uses for latrunculins and latrunculin derivatives, and semisyntheses of latrunculin derivatives. The latrunculins and latrunculin derivatives are useful, for example, in treating cancers.... Agent:

20110136881 - Novel pyrrole inhibitors of s-nitrosoglutathione reductase as therapeutic agents: The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same.... Agent: N30 Pharmaceuticals, LLC

20110136882 - Microbiocidal control in the processing of meat-producing four-legged animals: Methods of processing four-legged slaughter animals for consumption as meat and/or meat product(s) are described. The methods comprise I) contacting exterior surfaces of the live animal at least once with a microbiocidal solution formed from mixing together at least (i) water and (ii) at least one N,N′-bromochloro-5,5-dialkylhydantoin, such contacting occurring... Agent: Albemarle Corporation

20110136883 - Granulation of active pharmaceutical ingredients: The present invention discloses a dry formulation or granulation comprising, in admixture, more than 50 wt. % of active pharmaceutical ingredient and from 1 to 10 wt. % of each of any nonaqueous excipient selected from liquid substances. In a preferred embodiment no water or lower alcohol has been added... Agent: Lek Pharmaceuticals D.d.

20110136884 - Selective subtype alpha 2 adrenergic agents and methods for use thereof: The invention provides methods for treating disorders associated with selective subtype modulation of alpha 2 adrenergic receptors. In particular, the invention provides methods employing well-defined N-[1-(2 and/or 3-substituted-phenyl)-alkyl]-(4,5-dihydro-1H-imidazol-2-yl)-amines and pharmaceutical compositions thereof to treat disorders associated with selective subtype alpha 2 adrenergic receptor modulation, such as ocular disorders, pain and... Agent: Allergan, Inc.

20110136885 - Synergistic combination of analgesic compounds: e

20110136886 - Azabicyclo[3.2.0] hept-3-yl compounds, a process for their preparation and pharmaceutical compositions containing them:

20110136887 - Heterocyclic amide derivatives as ep4 receptor antagonists: The invention relates to compounds of Formula (I) (or pharmaceutically acceptable salts thereof) as defined herein, pharmaceutical compositions thereof, and their use in manufactures and methods for modulating biological processes including antagonism of Prostaglandin EP4 receptor as a therapeutic treatment.... Agent: Beta Pharma Canada Inc.

20110136888 - Substituted 1,3-diphenylpropane derivatives, preparations and uses thereof: The present invention involves substituted 1,3-diphenylpropane derivatives, pharmaceutical compositions comprising them and the therapeutic uses thereof, in particular in the fields of human and animal health.... Agent:

20110136898 - Treatment of retinal degeneration: The use of a compound of general formula (I): or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment or prevention of a disease or condition characterised by apoptosis or degeneration of mammalian cells, wherein: R1 is a alkoxy, alkyl, ether or ester group; R2... Agent: Consejo Superior De Investigaciones Cientificas

20110136899 - Combination of dronedarone with at least one diuretic, and therapeutic use thereof: The disclosure relates to a combination of dronedarone or a pharmaceutically salt thereof with at least one diuretic, and to the therapeutic use thereof.... Agent: Sanofi-aventis

20110136900 - Bruise amelioration composition and method of use: A bruise amelioration composition that can be applied for one hour to an affected site, such as a bruise, contusion or blister, in the form of a gel, liquid or adhesive bandage. The composition includes at least 40% by weight of glycerin and at least 2% by weight of primrose... Agent: Dr. Holmquist Healthcare, L.L.C.

20110136902 - 12-membered-ring macrolactam derivatives: There provided a 12-membered-ring macrolactam derivative having antitumor activity: A compound represented by Formula (1) or a salt thereof. In this Formula, R1 is a hydrogen atom, a C1-6 alkyl group, a C1-6 alkylcarbonyl group or a C6-14 arylcarbonyl group; R2 is a hydrogen atom or a C1-6 alkyl group;... Agent:

20110136901 - Derivatives of 4-nerolidylcatechol, pharmaceutical compositions comprising them and process for producing the same: The present invention discloses 4-nerolidylcatechol and its derivatives isolated from South American/Amazon plants (Pothomorphe species) and their potential use as therapeutical agent for treatment of malarial symptoms, including malarial patients resistant to traditional drugs. The present invention also discloses a method for producing 4-nerolidylcatechol and their derivatives.... Agent:

20110136903 - Soil amendment compositions and methods for using the same: Soil amendment compositions and methods for using the same are provided. The subject compositions are aqueous compositions consisting essentially of a carbon-skeleton energy component, a predisposing agent and a vitamin-cofactor component. The subject compositions find use in a variety of soil amendment applications, including: the control of soil born pests... Agent:

20110136904 - Prostaglandin derivatives: Prostaglandin nitroderivatives having improved pharmacological activity and enhanced tolerability are described. They can be employed for the treatment of glaucoma and ocular hypertension.... Agent: Nicox S.a.

20110136905 - Crystalline teglicar: The present invention relates to a new crystalline form of R-4-trimethylammonium-3-(tetradecylcarbamoyl)-amino butyrate (also named crystalline Form I of ST 1326 or teglicar), a process for its preparation and pharmaceutical compositions containing same.... Agent: Sigma-tau Industrie Farmaceutiche Riunite S.p.a.

20110136906 - Use of hydroxyoleic acid and related compounds in the manufacture of drugs: Use of hydroxyoleic acid and its analogous compounds in the manufacture of drugs. Describes the use of hydroxyoleic acid and its analogs of general formula I: COOH—CHR—(CH2)m—CH═CH—(CH2)n—CH3, in which m and n have, independently, a value of 0-15 and R can be any residue with molecular weight below 200 Da,... Agent: Universitat De Les Illes Balears

20110136907 - Perhydrolase providing improved peracid stability: An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a Thermotoga maritima acetyl xylan esterase gene was modified using error-prone PCR and site-directed mutagenesis to create an enzyme catalyst characterized by an increase in... Agent:

20110136908 - Perhydrolase providing improved peracid stability: An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a Thermotoga maritime acetyl xylan esterase gene was modified using error-prone PCR and site-directed mutagenesis to create an enzyme catalyst characterized by an increase in... Agent:

20110136909 - Method for suppressing excessive appetite: Agents for the inhibition, suppression, or prevention of overeating include glutamic acid and/or at least one of its salts, as is or in a carrier or base, and have superior safety at a low price and further have a favorable flavor and are suited for long-term use. Such agents will... Agent:

20110136910 - Method for stabilization of s-nitrosoglutathione and composition prepared by the same: The invention relates to pharmaceutical compositions having alkaline pH comprising S-nitrosoglutathione (GSNO) as active ingredient together with usual additives, optionally with one or more polysaccharide-type polymer(s). Another subject of the invention is a method for stabilizing a solution or non-solid composition containing GSNO wherein the pH of the solution or... Agent:

20110136911 - Treatment of sepsis and inhibition of mif by d-t4: Methods and compositions are disclosed for the use of dextrothyroxine (D-T4) to treat sepsis, inflammation, and conditions and diseases in which it is desirable to inhibit macrophage migration inhibitory factor (MIF).... Agent: The Feinstein Institute For Medical Research

20110136912 - Ophthalmic emulsion: The present invention is directed to an ophthalmic emulsion. The emulsion has a unique combination of ingredients that promotes the stability of small oil droplets within the emulsion. The emulsion also includes a mucoadhesive polymer that aid in delivering a lipid to the ocular surface.... Agent:

20110136913 - Assessing and treating breast cancer patients: This document provides methods and materials related to assessing and treating breast cancer patients. For example, methods and materials that involve assessing a breast cancer patient to determine whether the patient has (1) cancer cells that over express HER-2 polypeptides or comprise a HER-2 amplification and (2) at least an... Agent:

20110136914 - Substituted aryloxypropylamines with serotoninergic and/or norepinephrinergic activity: Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic... Agent: Auspex Pharmaceuticals, Inc.

20110136915 - Rapid dissolution formulation of a calcium receptor-active compound: The present invention relates to a pharmaceutical composition comprising a therapeutically effective amount of a calcium receptor-active compound and at least one pharmaceutically acceptable excipient, wherein the composition has a controlled dissolution profile. The present invention further relates to a method of manufacturing the pharmaceutical composition, as well as a... Agent: Amgen Inc.

20110136916 - 6-shogaol for using in a method for the treatment of leukemia: The present invention relates to the field of natural drugs, particularly to 6-shogaol for using in a method for the treatment of leukemia. The present invention provides a method for treating leukemia by applying a therapeutically effective dose of 6-shogaolt and this therapeutic method can be used for treating leukemia... Agent: China Pharmaceutical University

20110136917 - Tetrahydro-isoalpha acid compositions and methods for weight management: Compositions and methods to promote or maintain weight loss utilizing tetrahydro-isoalpha acid compounds are disclosed. Methods to increase synthesis of GLP-1 are disclosed.... Agent: Metaproteomics, LLC

20110136918 - Methods of treating infectious diseases: The present invention provides methods of treating a human or other mammal infected with a parasitic microorganism by administering an effective amount in unit dosage form of a C8-C16-alpha, beta-unsaturated aliphatic aldehyde, such as trans-2-dodecenal, to the human or other mammal. The parasitic microorganisms may include trypanosomes, bacteria, fungi and... Agent: Slippery Rock University Foundation, Inc.

20110136919 - Novel precipitated silicic acids for support applications: The present invention relates to novel precipitated silicic acids for use as support materials, manufacture thereof and use thereof.... Agent:

20110136920 - O/w emulsion containing a hydrophilic polymer and a semi-crystalline polymer: The invention relates to a composition for topical application, in the form of an O/W emulsion containing at least one crosslinked 2-acrylamido-2-methylpropane-sulfonic acid polymer comprising at least one hydrophobic unit, and at least one semi-crystalline polymer. The composition obtained has very good stability, and also good cosmetic properties. The present... Agent: L'oreal

20110136921 - Sustained release composition: A sustained release composition comprising spray dried particles of at least one polysaccharide gum and at least one polyhydric sugar alcohol, as well as methods of making the sustained released composition are provided. A sustained release pharmaceutical solid dosage form, and a method of making the solid dosage form by... Agent:

20110136922 - Activation induced deaminase (aid): The invention is directed to a cell comprising a nucleic acid encoding an Activation Induced Deaminase (AID) polypeptide, a fusion protein comprising an AID polypeptide, and methods of using a nucleic acid encoding an AID polypeptide.... Agent: Medical Research Council

  
06/02/2011 > patent applications in patent subcategories. invention type

20110130325 - Apoptosis-modulating protein therapy for proliferative disorders and nanoparticles containing the same: Protein containing nanoparticles and methods of use thereof for the treatment of proliferative disorders are disclosed.... Agent:

20110130324 - Methods for systematic control of protein stability: Methods and compositions to control the stability of proteins with special emphasis on antibodies and proteins with antibody-like structures, e.g., having an “immunoglobulin-like” fold, are described. Controlling the stability facilities different applications for a protein with the same function, but different stability.... Agent: Uchicago Argonne, LLC

20110130326 - Defensins for treatment of infective endocarditis: The present invention relates to methods for treating infective endocarditis, such as bacterial endocarditis, with defensin polypeptides.... Agent: Novozymes A/s

20110130328 - Flavivirus fusion inhibitors: The present invention provides an isolated peptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:36, as well as derivatives thereof comprising various N-terminal and C-terminal chemical moieties, substituted analogs thereof, and fragments thereof. The peptides of the invention are useful... Agent: The Rockefeller University

20110130327 - Multi-arm amines and uses thereof: Multi-arm amine compounds and compositions for enhancing intracellular, in vitro, and in vivo delivery of drug, active, and therapeutic substances including ribonucleic acids. This disclosure provides novel compounds and compositions for making and using delivery materials and carriers which increase the efficiency of delivery of biologically active and pharmacologically active... Agent: Marina Biotech, Inc.

20110130329 - Glp-1 fusion peptides, their production and use: The present invention provides fusion peptides having GLP-1 activity and enhanced stability in vivo, in particular resistancy to dipeptidyl peptidase IV. The fusion peptide comprises as component (I) N-terminally a GLP-1(7-35, 7-36 or 7-37) sequence and as component (II) C-terminally a peptide sequence of at least 9 amino acids or... Agent:

20110130330 - Topical drug delivery using phosphatidylcholine: The present invention relates to compositions and methods for transdermal drug delivery comprising formulating a phosphatidylcholine carrier composition containing the drug and applying the composition to the skin.... Agent:

20110130331 - Modified growth hormones: Provided are modified growth hormone polypeptides, nucleic acid molecules encoding modified growth hormone polypeptides and methods of generating modified growth hormone polypeptides. Also provided are methods of treatment using modified growth hormone polypeptides.... Agent: Hanall Pharmaceutical Co. Ltd.

20110130332 - Relaxin analogs: Human relaxin analogs, polypeptide compositions related thereto, as well as nucleotide compositions encoding the same, are provided.... Agent:

20110130333 - Therapeutic combination comprising a pulmonary surfactant and a steroid: Administration of a modified natural surfactant in combination with a corticosteroid is effective for the prevention of bronchopulmonary dysplasia (BPD) and lowers the markers of pulmonary oxidative stress.... Agent: Chiesi Farmaceutici S.p.a.

20110130334 - Methods and compositions for treatment of reperfusion injury and other cardiac conditions: The present invention discloses methods to prevent and treat cardiovascular disorders, hi certain aspects the methods are drawn to releasing endogenous calcitonin-gene related peptide from intrinsic cardiac adrenergic cells within the heart. In further aspects, a combination of a β2 adrenergic receptor agonist β2-AR agonist) and a vasodilator can be... Agent: The Board Of Regents Of The University Of Texas Sy

20110130335 - Therapeutic agent and test agent for disease with myocardial necrosis: Disclosed are a medicament for treating or preventing diseases with myocardial necrosis, which contains, as an active ingredient, a periostin variant (ΔbΔe) polypeptide or a modified form thereof or a polynucleotide encoding the same; and a diagnostic agent for diseases with myocardial necrosis containing a DNA encoding a periostin variant... Agent: Mitsubishichemical Medience Corporation

20110130336 - Method of treating ischemic injury using apoaequorin: Compositions containing apoaequorin and methods for their use in treating ischemic injury, particularly reduction in neuronal cell death following ischemic insult, are provided by the present invention.... Agent: Quincy Bioscience, LLC

20110130337 - Polymorphisms associated with parkinson's disease: The invention provides human polymorphisms that are associated with Parkinson's disease (PD). Also disclosed are compositions and methods for use in diagnostics, prognostics, prevention, treatment and/or study of PD.... Agent: 23andme, Inc.

20110130339 - Cosmetic composition for skin cell regeneration mimicking extracellular matrix: The present invention relates to a cosmetic composition which mimics the extracellular matrix to stimulate the regeneration of skin cells, and more particularly to a cosmetic composition which contains active ingredients consisting of low-molecular-weight materials, which easily permeate through the skin, at a composition ratio similar to that in the... Agent:

20110130338 - Use of serine protease inhibitors in the treatment of skin diseases: This invention relates to therapeutic compounds which are inhibitors of serine proteases, to pharmaceutical compositions thereof and to their use in the treatment of the human or animal body. More specifically, the present invention relates to a method for the treatment, diagnosis or prognosis of skin diseases comprising the administration... Agent: Institut National De La Sante Et De La Recherche Medicale (inserm)

20110130343 - Immunity-inducing agent and method for detection of cancer: An immunity-inducing agent comprising as an effective ingredient(s) at least one polypeptide selected from the following polypeptides, the polypeptide(s) having an immunity-inducing activity/activities, or as an effective ingredient(s) a recombinant vector(s) which comprise(s) a polynucleotide(s) encoding the polypeptide(s) and is/are capable of expressing the polypeptide(s) in vivo can be used... Agent: Toray Industries, Inc.

20110130341 - Method and kit for detection of cancer, and therapeutic agent for cancer: The object aims to comprehensively analyze miRNA that undergoes epigenetic silencing in cancer to identify miRNA associated with cancer, elucidate the role of the identified miRNA in cancer, and develop a novel method for detecting cancer and a novel therapeutic agent for cancer both of which relate to the miRNA.... Agent: Sapporo Medical University

20110130340 - Methods of identifying anti-cancer agents and uses thereof: The present invention provides methods of identifying and/or detecting anti-cancer agents. The present invention provides methods of identifying and/or detecting compounds that can activate PARP and/or induce necrosis. The present invention also provides for methods of treating cancer in an individual. The present invention also provides kits for identifying and/or... Agent:

20110130342 - Peptide homing to brain tumors: The present invention relates to a peptide, which specifically homes to the intracranial, early stage astrocytoma model that grows as islets and harbors co-opted tumor vessels in the brain. The peptide finds its use in targeted delivery of therapeutic substances to invasive brain cancer or metastatic brain lesions as such... Agent: Burnham Institute For Medical Research

20110130344 - Tight junction protein modulators and uses thereof: The invention provides tight junction protein modulators, compositions comprising the same, and uses thereof. In particular, the invention provides tight junction protein modulators that modulate the second extracellular loop of tight junction proteins, such as occludin or claudin.... Agent: The Regents Of The University Of Colorado, A Body Corporate

20110130345 - Alpha connexin c-terminal (act) peptides for treating age-related macular degeneration: Provided herein are compositions and methods for use in treating or preventing macular degeneration in a subject.... Agent:

20110130346 - Peptide conjugates for delvery of biologically active compounds: A construct comprising a cell delivery peptide covalently attached to a biologically active compound suitable for delivery of said biologically active compound into cells, wherein optionally the cells are cardiac muscle, skeletal muscle, smooth muscle or contractile cells.... Agent: Isis Innovation Limited

20110130347 - Identification of new splice-variants of g-protein coupled receptor ep3 and uses thereof: The present invention is directed to a polynucleotide sequence of the novel G-Protein Coupled Receptors EP3-11 OR EP3-12. The present invention provides polynucleotide sequences comprising the nucleic acid sequence SEQ ID NO: 20 or SEQ ID NO: 21 or nucleic acid sequences that hybridize to SEQ ID NO: 20 or... Agent: Bayer Schering Pharma Aktiengesellschaft

20110130348 - Kinetically efficient substrate for lipoic acid ligase: The invention provides methods for identifying and optimizing peptide substrates for enzymes such as lipoic acid ligase (Lp1A).... Agent: Massachusetts Institute Of Technology

20110130349 - Compounds and methods for treating toll-like receptor 2-related diseases and conditions: The present invention relates to compounds and methods useful in the prevention or treatment of diseases or conditions associated with Toll-like receptor 2 activation.... Agent:

20110130350 - Synthesis scheme for lacosamide: The present invention is concerned with an improved method of producing (R)-2-acetamido-N-benzyl-3-methoxypropionamide (lacosamide) comprising the 0-methylation of a compound of formula (I) to produce a compound of formula (II) in a single step reaction.... Agent: Ucb Pharma Gmbh

20110130351 - Glycolipid fraction from cyanobacteria for treatment of diseases of the oral cavity: The present invention relates to the preparation and use of a glycolipid fraction from Oscillatoria Planktothrix sp., for the treatment and/or prevention of bacterial gum diseases primarily caused by: Actinobacillum actinomycetemconcomitans, Porphyromonas gingivalis, Tannerella forsythia, Treponema denticola and even more preferably by Porphyromonas gingivalis. Said gum diseases, in particular gingivitis... Agent: Bluegreen Biotech Srl

20110130353 - Highly purified antiendotoxin compound: The invention provides compositions containing a highly purified antiendotoxin compound and methods of preparing and using such compositions.... Agent: Eisai R&d Management Co., Ltd.

20110130354 - Sulfated oligosaccharide derivatives: The invention relates to compounds which are polysulfated oligosaccharide derivatives having activity as inhibitors of heparan sulfate-binding proteins and inhibitors of the enzyme heparanase; methods for the preparation of the compounds; compositions comprising the compounds, and use of the compounds and compositions thereof for the antiangiogenic, antimetastatic, anti-inflammatory, antimicrobial, anticoagulant... Agent: Progen Pharmaceuticals Limited

20110130352 - The use of the effective fraction of alkaloids from mulberry twig in preparing hypoglycemic agents: The present invention relates to an effective fraction of alkaloids and the effective fraction is prepared from mulberry twig and its active ingredients are a composition of alkaloids. Determined by HPLC, the percentage of the total alkaloids are 50% or more by weight in the effective fraction and the percentage... Agent: Institute Of Materia Medica Chinese Academy Of Medical Sciences

20110130355 - Use of sophoricoside in the manufacture of medicaments: The present invention relates to the use of sophoricoside for the prevention and/or the treatment of articular cartilage degeneration or osteoarthritis in post-menopausal women. It is effective and has no side-effects on uterus, breasts and the like as animal-derived estrogen does. It is easy to be extracted and the source... Agent:

20110130356 - Morphine and morphine precursors: Methods and materials related to the use of morphine, morphine precursors (e.g., reticuline), and inhibitors of morphine synthesis or activity to treat diseases, to reduce inflammation, or to restore normal function are provided.... Agent:

20110130357 - Aminoglycosides: synthesis and use as antifungals: The present invention relates to novel aminoglycoside analogs having certain substituents at the 6 position of ring III which exhibit improved antifungal activity but possess minimal antibacterial properties. The compounds of the present invention are analogues of kanamycin B and kanamycin A. Also provided are methods of synthesizing and methods... Agent: Utah State University

20110130443 - Compositions and methods for inhibiting expression of factor v leiden mutant gene: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Factor V Leiden mutant gene (Factor V Leiden mutant gene), comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a... Agent:

20110130440 - Non-natural ribonucleotides, and methods of use thereof: One aspect of the present invention relates to modified nucleosides and oligonucleotides comprising such modified nucleosides. Another aspect of the invention relates to a method of inhibiting the expression of a gene in call, the method comprising (a) contacting an oligonucleotide of the invention with the cell; and (b) maintaining... Agent: Alnylam Pharmaceuticals, Inc.

20110130442 - Nucleic acid capable of controlling degranulation of mast cell: Provided are a mast cell degranulation control agent, a diagnostic agent or therapeutic agent for a disease resulting from mast cell degranulation control, a method of controlling mast cell degranulation, and a screening method for a mast cell degranulation control agent, all of which involve the use of a nucleic... Agent: Kyowa Hakko Kirin Co., Ltd.

20110130441 - Oligomeric compounds having at least one neutrally linked terminal bicyclic nucleosides: The present disclosure describes oligomeric compounds having at least one bicyclic nucleoside attached to the 3′ or 5′ termini by a neutral internucleoside linkage and methods of using the oligomeric compounds. In some embodiments, the oligomeric compounds provided herein hybridize to a portion of a target RNA resulting in loss... Agent: Isis Pharmaceuticals, Inc.

20110130444 - Methods and compositions for targeted delivery of gene therapeutic vectors: Embodiments of the present invention relate to methods and compositions for tissue- specific delivery of a gene therapeutic, transgenic nucleic acid in mammals. Methods and compositions of the invention include the steps of providing a nucleic acid comprising a transgene flanked by two terminal repeats and, within the same or... Agent:

20110130358 - Method for transdifferentiation of body tissues: The invention relates to methods for transdifferentiation of body tissues which can be used to generate specific cell types needed for regenerating organs or body parts, following cellular degeneration, injury or amputation. The present invention also describes the use of tissue transdifferentiation for treating cancer and autoimmune diseases.... Agent:

20110130359 - Methods for preventing or reducing neurotoxicity associated with administering dpd inhibitors in combination with 5-fu and 5-fu prodrugs: Methods for improved administration and dosing of DPD inhibitors in combination with 5-FU and/or 5-FU prodrugs are provided, comprising first administering to a patient in need thereof a DPD inhibitor that substantially eliminates activity of the enzyme in both nervous and non-nervous tissues within the patient and thereafter administering 5-FU... Agent: Adherex Technologies, Inc.

20110130360 - Preventing or reducing oxidative stress or oxidative cell injury: A water-insoluble cellulose derivative, such as ethyl cellulose is useful for preventing or reducing oxidative stress or oxidative cell injury in tissues of an animal and in particular for influencing the level Stearoyl-CoA Desaturase-1 (SCD1) gene expression or ATP synthase mitochondrial F1 complex assembly factor 1 (ATPAF1) gene expression in... Agent: United States Department Of Agriculture

20110130362 - A2b adenosine receptor antagonists: Disclosed are novel compounds that are A2B adenosine receptor antagonists, useful for treating various disease states, including asthma and diarrhea.... Agent: Gilead Sciences, Inc.

20110130361 - Silicon derivatives as histone deacetylase inhibitors: The present invention relates to a novel class of Silicon derivatives. The Silicon compounds can be used to treat cancer. The Silicon compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation... Agent:

20110130363 - Benzopyran and benzoxepin pi3k inhibitor compounds and methods of use: Benzopyran and benzoxepin compounds of Formulas I and II, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using... Agent: Genentech, Inc.

20110130364 - Pyrrolopyridine derivatives substituted with cyclic amino group: An object of the present invention is to provide an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastric diseases, drug dependence,... Agent: Taisho Pharmaceutical Co., Ltd.

20110130365 - Fluorinated heteroaryls: The present invention provides Formula (1A) XN O R 3 HN R 5 O R 4 R 2 R 1 (1A) 5 compounds that act as glucokinase activators; pharmaceutical compositions thereof; and methods of treating diseases, disorders, or conditions mediated by the glucokinase enzyme, where X, R 1, R 2,... Agent:

20110130366 - Fosaprepitant dimeglumine intermediate, neutral fosaprepitant, and amorphous fosaprepitant dimeglumine and processes for their preparations: The present invention generally relates to a process for the preparation of fosaprepitant dimeglumine intermediate and its use in the preparation of fosaprepitant dimeglumine; to a neutral form of fosaprepitant in a solid state and processes for the preparation thereof; and to a stable amorphous fosaprepitant dimeglumine, having a stability... Agent: Glenmark Generics Lmited

20110130367 - Combination therapy for treating proliferative diseases: The present invention relates generally to new chemical combinations and methods for their use in the treatment of proliferative diseases and in particular cancer.... Agent: Bionomics Limited

20110130368 - Derivatives of 4- or 5-aminosalicylic acid: The present invention provides new derivatives of 4- or 5-aminosalicylic acid, and a pharmaceutical composition containing these derivatives of 4- or 5-aminosalicylic acid as active ingredients, useful for the treatment of intestinal diseases such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) and for the prevention/treatment of colon... Agent: Antibe Therapeutics Inc.

20110130369 - Use of fts for the treatment of myocardial ischemia/reperfusion injury: Disclosed are methods for reducing the extent of myocardial ischemia/reperfusion injury, comprising administering to a human prior to reperfusion of the ischemic myocardium or pre-angioplasty, coronary artery bypass surgery, or thrombolytic therapy an effective amount of FTS, or various analogs thereof, or a pharmaceutically acceptable salt thereof. Methods of treating... Agent: Ramot At Tel-aviv University Ltd.

20110130370 - Pharmaceutical composition comprising a strontium salt, vitamin d and a cyclodextrin: A pharmaceutical composition comprising a strontium salt, vitamin D and a cyclodextrin.... Agent: Les Laboratories Servier

20110130371 - C-ring-substituted pregn-4-ene-21,17-carbolactones, and pharmaceutical preparations comprising the same: p

20110130372 - Composition comprising estrone and hydrocortisone for use in the topical treatment of baldness: The present invention relates to a composition comprising an association of active substances for use in the topical treatment of baldness, particularly of male pattern and female pattern androgenetic alopecia.... Agent:

20110130373 - Methods for administration and formulations for the treatment of regional adipose tissue: Provided herein are pharmaceutical formulations, methods, and systems for treating regional fat deposits and fat-related conditions and indications. Methods comprise administering a pharmaceutical formulation consisting essentially of a long-acting beta-2 adrenergic receptor agonist, for example, salmeterol, suitable for subcutaneous administration. Methods further comprise administering a pharmaceutical formulation that is suitable... Agent: Lithera, Inc.

20110130374 - Small pyrimidine derivatives and methods of use thereof: Provided are pyrimidine derivatives which are ubiquitination inhibitors that inhibit the ubiquitin ligase activity, particularly of POSH polypeptides, and are useful for the treatment of cancer, angiogenesis disorders, and inflammatory disorders.... Agent: Biosearch(2007) Ltd.

20110130376 - New no releasing steroids derivatives: o

20110130375 - New no-releasing steroids for the treatment of retina and macula lutea diseases:

20110130378 - Ezetimibe process and composition: The present invention describes a process for producing ezetimibe (EZT) from a protected compound, including a step of deprotecting the 4-(p-hydroxyphenyl) protection group by catalytic hydrogenation, wherein the catalyst is used in an amount of 0.7 wt.-% or lower, relative to the weight of the compound used for the deprotection... Agent: Lek Pharmaceuticals D.d.

20110130380 - Heteroaryl kinase inhibitors: e

20110130381 - Small molecule inhibitors of plasmodium falciparum dihydroorotate dehydrogenase: Inhibitors of dihydroorotate dehydrogenase (DHODH) for the Plasmodium enzyme have been identified and characterized. The inhibitors have high specificity, submicromolar efficacy against cultured parasite strains, exhibit drug-like properties, and are not overtly cytotoxic.... Agent:

20110130379 - Piperazine derivatives used as cav2.2 calcium channel modulators: The present invention relates to novel piperazine derivatives (I); to processes for their preparation; to pharmaceutical compositions containing the derivatives; and to the use of the derivatives in therapy to treat diseases for which blocking the Cav2.2 calcium channels is beneficial.... Agent: Convergence Pharmaceuticals Limited

20110130377 - Substituted aryloxazoles and their use: The present application relates to novel substituted aryloxazole derivatives, a method for the production thereof, the use thereof for the treatment and/or prophylaxis of diseases and the use thereof for the production of drugs for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prevention of cardiovascular and... Agent: Bayer Schering Pharma Aktiengesellschaft

20110130382 - Modulators of 5-ht receptors and methods of use thereof: e

20110130384 - Amide compound:

20110130385 - Bicyclic heterocylic derivatives and methods of use: The present invention relates to novel bicyclic heterocycle derivatives, pharmaceutical compositions comprising the bicyclic heterocycle derivatives and the use of these compounds for treating or preventing allergy, an allergy-induced airway response, congestion, a cardiovascular disease, an inflammatory disease, a gastrointestinal disorder, a neurological disorder, a metabolic disorder, obesity or an... Agent:

20110130383 - Use of ion channel modulators in the prophylaxis and treatment of inflammatory and immunological diseases: Use of compounds of general formula (1) and pharmacologically acceptable salts and prodrugs thereof: Formula (1) wherein A and B are CH2 or CH2CH2, R1 is hydrogen, alkyl, cycloalkyl, aryl, aralkyl or heteroaralkyl, R2, R3 and R4 are selected from hydrogen, alkyl, halogen, haloalkyl, alkoxy, alkoxycarbonyl, carboxyl, hydroxyl or cyano;... Agent: Lectus Therapeutics Limited

20110130386 - Dna-pk inhibitors: A compound of formula (I) wherein: R1 and R2 are independently selected from hydrogen, an optionally substituted C1-7 alkyl group, C3-20 heterocyclyl group, or C5-20 aryl group, or may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to... Agent:

20110130388 - Prophylactic or therapeutic agent for axial myopia: Since high myopia increases the risks of retinal detachment, myopic chorioretinal atrophy, myopic choroidal neovascularization, glaucoma, and cataract, establishment of prophylaxis against the progress of myopia is desired. However, at present, there is no effective prophylaxis or therapy for axial myopia, which is considered to cause high myopia. The present... Agent:

20110130387 - Sirtuin modulating compounds: Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases,... Agent: Sirtris Pharmaceuticals, Inc.

20110130389 - Fumarate salt of 4-bromophenyl 1,4-diazabicyclo[3.2.2]nonane-4-carboxylate, crystalline forms thereof, preparation thereof and therapeutic use thereof: Fumarate salt of 4-bromophenyl 1,4-diazabicyclo[3.2.2]nonane-4-carboxylate, crystalline forms thereof, methods of preparation thereof, and therapeutic use thereof.... Agent: Sanofi-aventis

20110130390 - Use of cox-2 inhibitors for the treatment of schizophrenia, delusional disorders, affective disorders, autism or tic disorders: The invention concerns the use of a COX-2 inhibitor for the treatment of psychiatric disorders such as schizophrenia, delusional disorders, affective disorders, autism or tic disorders, in particular chronic schizophrenic psychoses and schizoaffective psychoses, temporary acute psychotic disorders, depressive episodes, recurring depressive episodes, manic episodes and bipolar affective disorders. Moreover,... Agent:

20110130391 - Ureido substituted benzoic acid compounds and their use for nonsense suppression and the treatment of disease: The invention encompasses ureido substituted benzoic acid compounds, compositions comprising the compounds and methods for treating or preventing diseases associated with nonsense mutations of mRNA by administering these compounds or compositions.... Agent: Ptc Therapeutics, Inc.

20110130392 - Method of administering a methylene blue - curcumin analog for the treatment of alzheimer's disease: A method of administering a methylene blue-curcumin hybrid useful in treating or preventing Alzheimer's Disease.... Agent:

20110130393 - Inhibitors of janus kinases: The instant invention provides for compounds that inhibit the four known mammalian JAK kinases (JAK1, JAK2, JAK3 and TYK2). The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting the activity of JAK1, JAK2, JAK3 and TYK2 by administering the compound to a patient in need... Agent:

20110130394 - Pharmaceutical compounds: or salts, solvates, tautomers or N-oxides thereof; wherein X is O, CO, X1C(X2), C(X2)X1, X1C(X2)X1, S, SO, SO2, NRc, SO2NRc or NRcSO2; m is 0-2; n is 0-1; q is 0-2; A is C1-6 alkylene optionally interrupted by O; R1 is halogen, cyano, nitro, an optionally substituted acyclic C1-6 hydrocarbon... Agent: Sentinel Oncology Limited

20110130395 - P13k isoform selective inhibitors: 2-Morpholin-4-yl-9H-purine and 5-Morpholin-4-yl-3H-[1,2,3]triazolo[4,5-d]pyrimidine derivatives, especially those substituted by 6-heteroaryl, are unexpected PI3 kinase isoform selective inhibitors with good drug properties and are useful in treating disorders related to abnormal PI3K activities such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders.... Agent:

20110130396 - Imidazothiadiazole derivatives: M

20110130397 - Pyrrolinone compounds as inhibitors of bacterial peptidyl trna hydrolase and uses thereof: Provided herein are compounds that modulate the activity of a bacterial peptidyl tRNA hydrolase, including compositions and dosage forms comprising the compounds. Further provided herein are methods for preventing or inhibiting bacterial proliferation as well as methods for preventing, treating, and/or managing a bacterial infection using such compounds and compositions.... Agent:

20110130399 - Phthalazine derivatives with angiogenesis inhibiting activity: and to processes for the preparation thereof, the application thereof in a process for the treatment of the human or animal body, the use thereof alone or in combination with one or more other pharmaceutically active compounds for the treatment especially of a disease that responds to the inhibition of... Agent: Novartis Ag

20110130398 - Spiroindolinone pyrrolidines: d

20110130400 - Trpv4 antagonists: The present invention relates to diazabicyclo[2.2.1]hept-2-yl analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.... Agent:

20110130401 - New chemical compounds: e

20110130402 - Heteroaromatic glucokinase activators: The present invention describes 2,3-di-substituted N-heteroaromatic propionamides, wherein the substitution at the 3-position is an optionally substituted phenyl ring and the substitution at the 2-position is an alkyl or cycloalkyl group; pharmaceutical compositions comprising the same; and, methods of using the same. The propionamides are glucokinase activators which increase insulin... Agent: Novo Nordisk A/s

20110130403 - Pyrazolo [3, 4-b] pyridine derivatives as phosphodiesterase inhibitors: The present invention relates to phosphodiesterase (PDE) type 4, phosphodiesterase (PDE) type 7 and dual PDE type 4/PDE type 7 inhibitors. Compounds disclosed hereinf having the structure of Formula I: can be useful in the treatment, prevention, inhibition or suppression of CNS diseases, for example, multiple sclerosis; various pathological conditions... Agent: Ranbaxy Laboratories Limited

20110130404 - Quinoxalinedione derivatives: e

20110130405 - Substituted quinazolines as blood platelet lowering agents: This invention relates to the discovery of 3-and 5-substituted analogues of the selective platelet lowering agent anagrelide with reduced potential for cardiovascular side-effects which should lead to improved patient compliance and safety in the treatment of myeloproliferative diseases. More specifically, the present invention relates to certain imidazoquinazoline derivatives which have... Agent: Shire LLC

20110130406 - Pyrazolo-pyridines as tyrosine kinase inhibitors: Compounds of Formulas Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting receptor tyrosine kinases and for treating disorders mediated thereby. Methods of using compounds of Formula Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates and pharmaceutically acceptable salts... Agent: Genentech, Inc.

20110130407 - Isoquinolinone derivatives as nk3 antagonists: Isoquinolone derivatives of the general formula I are provided. The compounds are NK3 antagonists and useful for the treatment of e.g. psychosis and schizophrenia.... Agent: H. Lundbeck A/s

20110130408 - Piperazin-1-yl-trifluoromethyl-substituted-pyridines as fast dissociating dopamine 2 receptor antagonists: The present invention relates to piperazin-1-yl-trifluoromethyl-substituted-pyridines that are fast dissociating dopamine 2 receptor antagonists, processes for preparing these compounds, pharmaceutical compositions comprising these compounds as an active ingredient. The compounds find utility as medicines for treating or preventing central nervous system disorders, for example schizophrenia, by exerting an antipsychotic effect... Agent:

20110130409 - Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders: The present invention relates to certain substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives of Formula (Ia) and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists of the S1P1 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the... Agent: Arena Pharmaceuticals, Inc.

20110130411 - Process for preparing methyl carbamate and its purification for use as pharmaceutically active compound: e

20110130410 - Process for preparing methyl methylcarbamate and its purification for use as pharmaceutically active compound: and to a process for purifying the crude product of the compound of the formula (I) for use as pharmaceutically active compound, where, for purification, methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}methylcarbamate sulphinyldimethane (1:1), i.e. a compound of the formula (II), is isolated as intermediate or is generated as intermediate in this purification process, if... Agent: Bayer Schering Pharma Aktiengesellschaft

20110130412 - Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases: The invention relates to compounds of the general formula (I) which are inhibitors of purine nucleoside phosphorylases (PNPs) and/or nucleoside hydrolases (NHs). The invention also relates to the use of these compounds in the treatment of diseases and infections including cancer, bacterial infections, protozoal infections, and T-cell mediated disease and... Agent:

20110130413 - Substituted quinazolines: This invention relates to the discovery of prodrugs of substituted analogues of the selective platelet lowering agent anagrelide which have reduced potential for cardiovascular side-effects and which should therefore lead to improved patient compliance and safety in the treatment of myeloproliferative diseases. More specifically, the present invention relates to prodrugs... Agent: Shire LLC

20110130414 - Novel fused thiazolo and oxazolo pyrimidinones: The present invention relates to novel compounds, their pharmaceutically acceptable salts, and their isomers, stereoisomers, conformers, tautomers, polymorphs, hydrates and solvates. The present invention also encompasses pharmaceutically acceptable compositions of said compounds and process for preparing novel compounds. The invention further relates to the use of the above-mentioned compounds for... Agent: Torrent Pharmaceuticals Limited

20110130416 - Pharmaceutical composition for treating hypertension and metabolic syndrome and use thereof: The present invention provides a pharmaceutical composition comprising the following active ingredients: 1) amlodipine or a pharmaceutically acceptable salt thereof, 2) pioglitazone or a pharmaceutically acceptable salt thereof, and 3) rosuvastatin or a pharmaceutically acceptable salt thereof. The present invention also provides use of the pharmaceutical composition in preparing a... Agent: Lunan Pharmaceutical Group Coporation

20110130415 - Protein kinase c inhibitors and uses thereof: This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these... Agent:

20110130417 - New azacyclic derivatives: i

20110130418 - Substituted phenylenediamines as inhibitors of the interaction between mdm2 and p53: The present invention provides compounds of formula (I), their use as an inhibitor of a p53-MDM2 interaction as well as pharmaceutical compositions comprising said compounds of formula (I).... Agent:

20110130420 - Isoquinolinone derivatives as nk3 antagonists: Isoquinolone derivatives of the general formula Ik″ are provided. The compounds are NK3 antagonists and useful for the treatment of e.g. psychosis and schizophrenia.... Agent: H. Lundbeck A/s

20110130419 - Novel salt of isoquinoline compound and crystal thereof: The invention provides a salt of (R)-3-[2-(2-hydroxymethylpyrrolidin-1-yl)ethyl]-5-methyl-2H-isoquinolin-1-one and a crystal thereof. (R)-3-[2-(2-Hydroxymethylpyrrolidin-1-yl)ethyl]-5-methyl-2H-isoquinolin-1-one monophosphate is a compound which is chemically stable, has high solubility, and shows less weight change due to humidity as compared to a free form and monohydrochloride dihydrate, and is superior as a bulk drug for pharmaceutical products.... Agent: Mitsubishi Tanabe Pharma Corporation

20110130421 - Methods and compositions for the treatment of chronic renal hypertension: Methods and compositions for the treating chronic renal hypertension in a subject comprising administering a therapeutically effective amount of at least one nitroxide-containing composition to the subject, particularly 4-hydroxy-2,2,6,6-tetramethyl-1-piperidine-1-oxyl (Tempol).... Agent: Georgetown University

20110130422 - Biphenyl compounds useful as muscarinic receptor antagonists: wherein a, b, c, d, m, n, p, s, t, W, Ar1, R1, R2, R3, R4, R6, R7, and R8 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such... Agent: Theravance, Inc.

20110130423 - Compounds which have activity at m1 receptor and their uses in medicine: e

20110130424 - Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties: Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic... Agent: Auspex Pharmaceuticals, Inc.

20110130425 - Use of h3 histaminergic agonists for the treatment of addiction to drugs of abuse: The present invention relates to H3 histaminergic agonists, compositions thereof, and methods for treating or preventing addiction to drugs of abuse in a subject. The methods comprise administering to a subject in need thereof an effective amount of one or more H3 histaminergic agonists to prevent addiction, diminish the voluntary... Agent:

20110130426 - Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases: A compound of formula (I) or a pharmaceutically acceptable salt thereof; compositions comprising them, processes for preparing them and their use in medical therapy (for example modulating the glucocorticoid receptor in a warm blooded animal).... Agent: Astrazeneca Ab

20110130427 - Pesticidal composition: To improve the controlling effects of anthranilamide compounds against pests. A pesticidal composition comprising, as active ingredients, an anthranilamide compound or its salt, and a polyoxyalkylene phosphoric acid ester surfactant, and a method for controlling a pest by using such a composition, are provided. Further, a method for improving the... Agent: Ishihara Sangyo Kaisha, Ltd.

20110130428 - Sublingual compositions comprising (2s) - (4e) -n-methyl-5- (3- (5-isopropoxypyridin) yl)-4-penten-2-amine: The present invention relates to sublingual compositions comprising (2S)-(4E)-N-methyl-5-(3-(5-iso-propoxypyridin)yl)-4-penten-2-amine or pharmaceutically acceptable salts thereof, to the preparation of said compositions and the use of thereof in therapy.... Agent: Astrazeneca Ab

20110130429 - Pyridines for treating injured mammalian nerve tissue: Embodiments of the present disclosure provide a novel pyridine, pharmaceutical compositions comprising such pyridine, and the use of such compositions in treating injured mammalian nerve tissue, including but not limited to an injured spinal cord. In at least one embodiment of the method, the method comprises the step of administering... Agent: Purdue Research Foundation

20110130430 - Materials having embedded insecticides and additives: The present invention concerns polymeric material containing at least an embedded insecticidally active ingredient and an additive, which are released at room temperature. It similarly concerns materials produced from this polymer, for example in the form of self-supporting film/sheet, threads, wovens, fabrics, textiles, nets, curtains and pellets. The invention further... Agent: Bayer Cropscience Ag

20110130431 - Compounds which modulate the cb2 receptor: e

20110130432 - Heterocyclic carboxamides for use as thrombin inhibitors: This invention relates to novel pharmaceutically useful compounds of formula (I), in particular compounds that are competitive inhibitors of trypsin-like serine proteases, especially thrombin, their use as medicaments, pharmaceutical compositions containing them and synthetic routes to their production. Formula (I)... Agent: Astrazeneca Ab

20110130433 - Hepatitis c virus inhibitors: This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV... Agent: Bristol-myers Squibb Company

20110130434 - Modified release ramipril compositions and uses thereof: The invention relates to a modified release pharmaceutical composition comprising ramipril or pharmaceutically acceptable salts thereof and pharmaceutically acceptable excipient(s) wherein pharmaceutical composition is bioequivalent to conventional immediate release formulation of ramipril administered twice daily. The invention further relates to a modified release pharmaceutical composition comprising: an immediate release component... Agent: Panacea Biotec Ltd.

20110130435 - Time-released medication for applying to crustacean ovarian development: A time-released medication for applying to crustacean ovarian development comprises a covering oil and a serotonin-related reagent. The covering oil is coated with the serotonin-related reagent and provides a sustainable releasing effect for the serotonin-related reagent. The serotonin-related reagent is selected from a group of serotonin, a precursor of serotonin,... Agent:

20110130436 - Caspase inhibitors and uses thereof: where R1, R2, and R3 are as described herein, Ring A contains zero to two double bonds, each X is independently selected from nitrogen or carbon, at least one X in Ring A is a nitrogen, Ring A is optionally substituted as described, and may be fused to a saturated... Agent: Vertex Pharmaceuticals Incorporated

20110130437 - Salt forms of a 6-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene derivative, process for their manufacture and pharmaceutical compositions containing same: The present invention relates to salt forms of the compound 4-[(Z)-[[4-[(dimethylaminoJmethyllphenyllaminolCe-fluoro-1,2-dihydro2-oxo-3H-indol-3-ylidene)methyl]-benzenepropanoic acid which are suitable for pharmaceutical development and to a process for their manufacture.... Agent: Boehringer Ingelheim International Gmbh

20110130438 - Aniline analogs as glycogen synthase activators: e

20110130439 - Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents:

20110130446 - Injectable taxane pharmaceutical composition: New injectable taxane pharmaceutical composition. Stable composition with low percentage of ethanol and a lower ethanol/taxane ratio than that of the state-of-the-art taxane pharmaceutical compositions.... Agent: Gp Pharm, S.a.

20110130445 - Substituted 3-phenylpropionic acids and the use thereof: The present application relates to novel 3-phenylpropionic acid derivatives, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular disorders.... Agent: Bayer Schering Pharma Aktiengesellschaft

20110130449 - Assay for monitoring activity of jmjd6: The invention provides a method for assaying Jmjd6 activity.... Agent: Ludwig-maximilians-universitat Munchen Geschwister-scholl-platz 1

20110130448 - Functionalized phenolic esters and amides and polymers therefrom: The resultant functionalized phenolic compounds, used singly or in combinations, and their polymers have controllable degradation profiles, releasing the active component over a desired time range. The polymers are useful for biomaterials and biomedical devices, wherein said biologically active phenolic moiety is a residue of a phenolic compound.... Agent: Bezwada Biomedical LLC

20110130447 - Production of hop extracts having oestrogenic and antiproliferative bioactivity: A method for the production of a hop extract which is enriched in 8-prenylnaringenin with respect to 6-prenylnaringenin include the steps of subjecting a hop product to (1) an isomerisation reaction in the presence of water as a solvent and in the presence of an amount of a base and... Agent:

20110130451 - Method of treating dry eye disorders and uveitis: The topical use of 5,6,7-trihydroxyheptanoic acid and analogs are disclosed for the treatment of dry eye disorders and uveitis.... Agent: Alcon, Inc.

20110130450 - Pravastatin extraction: The present invention provides a method for the purification of pravastatin comprising extracting a solution comprising pravastatin in a water-immiscible solvent with water at a pH value ranging from 5.0 to 7.0.... Agent:

20110130452 - Store-operated calcium cellular assay: The present technology provides a cell based assay for identifying compounds that modulate store-operated ionic calcium levels using itpr mutant cell lines, such as itpr-ku cells, which have abnormal ionic calcium levels.... Agent: Intellectual Ventures Asia Private Limited

20110130453 - Aminoalkylphenyl antagonists of prostaglandin d2 receptors: Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the compounds described herein that are antagonists of PGD2 receptors. Also described herein are methods of using such antagonists of PGD2 receptors, alone and in combination with other compounds, for treating... Agent: Amira Pharmaceuticals, Inc.

20110130454 - Prodrugs of gamma-amino acid, alpha-2-delta ligands, pharmaceutical compositions and uses thereof: Prodrugs of alpha-2-delta ligands, pharmaceutical compositions of prodrugs of alpha-2-delta ligands, methods of making prodrugs of alpha-2-delta ligands, and methods of using prodrugs of alpha-2-delta ligands and pharmaceutical compositions of prodrugs of alpha-2-delta ligands to treat various diseases are disclosed.... Agent: Xenoport, Inc.

20110130455 - Nitrate esters and their use for the treatment of muscle and muscle related diseases: wherein n is an integer from 0 to 9, n′ is an integer from 0 to 9, and n″ is an integer from 0 to 9, and n+n′+n″≦9, and wherein at least one of R1, R2, and R3 is an ester nitrate selected from the group consisting of ONO2, CH2ONO2,... Agent: The Charlotte-mecklenburg Hospital Authority D/b/a Carolinas Medical Center

20110130456 - Hair growth regulating agent: A hair growth regulating agent containing, as an active ingredient, a compound represented by the following formula (I): [wherein R1 represents a substituted or unsubstituted, linear or branched C2 to C25 alkyl group; a group represented by the following formula (II): (wherein R1′ represents a substituted or unsubstituted, linear or... Agent: Kao Corporation

20110130457 - Wax-based emulsion for the treatment of dry eye conditions: Disclosed herein is a wax-based emulsion for the treatment of dry eye conditions by reducing the evaporation rate of saline and increasing the viscosity of the tear film. The composition of the present invention comprises an emulsion of wax dispersed in saline. One embodiment of the wax-based emulsion of the... Agent: University Of Louisville Research Foundation, Inc.

20110130459 - Composition for accelerated production of collagen: Here the inventors provide a composition for topical application to the skin of animal comprising stearidonic acid in combination with one or octadecatrienoic acids (CODTAs). Preferably the composition comprises echium oil as a source of the stearidonic acid, and a plant lipid as a source of octadecatrienoic acid, such as... Agent:

20110130458 - Krill oil process: The present invention relates to a process for preparing compositions of high concentrations of omega-3 fatty acids from krill. Furthermore, the invention relates to a composition comprising high concentrations of omega-3 fatty acids, and a lipid fraction from krill comprising high amounts of fatty acids with chain length C14 and... Agent: Pronova Biopharma Norge As

20110130460 - Increased creatine retention with soluble fibres: The present invention generally relates to increasing the efficiency of usage of an ingested biologically active substance by a body. In particular, the present invention relates to ways to improve the efficiency of utilization of ingested creatine in a body, in particular to increase the storage of creatine in the... Agent: Nestec S.a.

20110130461 - Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders: Dermatological disorders having an inflammatory or proliferative component are treated with pharmaceutical compositions containing on the order of 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously topically applicable gels, creams or lotions.... Agent: Galderma Research & Development

20110130462 - Aqueous organic acidic solution for sterilization and microbial growth inhibition: The present invention consists of a two acid core aqueous acidic solution with a pH value of less than one that is nonreactive to human skin, can be safely ingested, and is effective as both a disinfectant and a microbial growth inhibition agent. The solution consists of hydrochloric acid admixed... Agent:

20110130463 - Deuterium-enriched bupropion: The present application describes deuterium-enriched bupropion, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Protia, LLC

20110130464 - Combination agent for improving carcass performance in finishing pigs: A composition of ractopamine and astaxanthin, included as additives in a feed, for finishing hogs, improves carcass performance.... Agent: Igene Biotechnology, Inc.

20110130465 - Coatings for prevention of biofilms: This invention is directed to a method to reduce microbial fouling on a surface. The present invention provides antifouling coatings similar to the protein glues secreted by marine mussels for adhesion to underwater substrates.... Agent: Nerites Corporation

20110130466 - Use of rasagiline for the treatment of progressive supranuclear palsy: A method for the treatment of Progressive Supranuclear Palsy. Such method includes administering to a subject an amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof.... Agent:

20110130467 - Method for producing antimicrobial-containing solution: A method for producing an antimicrobial-containing solution includes mixing an alkaline aqueous solution which dissolves a phenol-based antimicrobial, and has a pH of 9 or higher and acid which has a pH 6 or lower.... Agent:

20110130469 - Compositions and methods relating to resveratrol: The present invention relates to compositions and methods comprising resveratrol and uses thereof. Some embodiments include compositions and methods with increased bioavailability of resveratrol. Certain embodiments include compositions comprising resveratrol and a solubilizer. Particular embodiments include transmucosal delivery of resveratrol from the composition.... Agent: Wilmore Labs L.l.c

20110130468 - Hydroxylated tolans and related compounds in the treatment of a cancer: Compounds of the hydroxytolan family kill tumor cells, inhibit tumor growth and development, and are thus useful in method for treating a tumor or cancer in subjects in need thereof. These compounds are also active in preventing or treating a variety of skin diseases and conditions. The most preferred hydroxytolan... Agent: Kent State University

20110130470 - Homoallyl alcohols useful as fragrances: m

20110130471 - Polyurethanes: where (a) the total number of carbon atoms in compounds (MA) is 4 to 18; (b) R1, R2 and R3 are independently hydrogen, or linear, branched or alicyclic, saturated or unsaturated alkyl; (c) optionally, R1 and R2, and/or R1 and R3, and/or R2 and R3 are linked together to form... Agent: CognisIPManagement Gmbh

20110130472 - Proteose peptone fraction: The present invention generally relates to compositions comprising the proteose peptone fraction (PPf). In particular, the present invention relates to a method for the production of an extract comprising a demineralised protein fraction depleted in β-lactoglobulin and enriched in the PPf and to uses of these extracts, e.g. in a... Agent: Nestec S.a.

20110130473 - Dilute filtration sterilization process for viscoelastic biopolymers: Manufactured hyaluronic acid products are used in numerous surgical applications including viscoelastic supplementation for the treatment of osteoarthritis, however, traditional sterilization techniques result in the breakdown of such high molecular weight viscoelastic biopolymers and are thus unsuitable. Disclosed are processes for obtaining concentrated sterile solutions of high molecular weight biopolymers... Agent: Bio-technology General (israel) Ltd.

Previous industry: Perfume compositions
Next industry: Colloid systems and wetting agents; subcombinations thereof; processes of


######

RSS FEED for 20141002: xml
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.

######

Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.



Results in 4.25396 seconds

PATENT INFO